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Abstract 
 
 
Protein biosynthesis has precisely controlled accuracy, and aminoacyl-tRNA 
synthetases (AARSs) play an important role in charging amino acids to their cognate 
tRNAs with high fidelity. In some cases the misactivation of non-natural amino acids by 
the wild-type or mutant AARS can be utilized to incorporate these non-natural amino 
acids into proteins in vivo.  Such technique has tremendous potentials in protein 
engineering and other applications.  Therefore, it is essential to understand the amino acid 
recognition mechanism displayed by AARSs.   
 
In this thesis, computational studies of the selection of natural and non-natural 
amino acids by AARSs at the binding stage have been conducted for methionyl-tRNA 
synthetase (Chapter 2), histidyl-tRNA synthetases (Chapter 3), and isoleucyl-tRNA 
synthetase (Chapter 4).  In these chapters, molecular docking and ligand perturbation are 
used to elucidate the binding discrimination showed by these AARSs.   
 
Because many non-natural amino acids carrying interesting physical and chemical 
properties on their side chains cannot be incorporated by using the wild-type AARSs, it is 
necessary to manipulate the activity of AARSs by making mutations in the binding site of 
amino acids.  To this end, we have developed a Clash Opportunity Progressive (COP) 
protein design tool to redesign the binding site of AARSs.  Chapter 5 describes the main 
steps in COP.  Chapters 6 to 8 present the application of COP to different AARSs.  In 
Chapter 6, COP has been applied to design mutant tyrosyl-tRNA synthetase (TyrRS) for 
 vii
recognizing Ome-Tyr, Naph-Ala, and p-keto-Tyr.  In Chapter 7, COP has been used to 
design mutant phenylalanyl-tRNA synthetase for p-keto-Phe. In Chapter 8, tryptophanyl-
tRNA synthetase is used as a template to design mutant AARS to recognize NBD-Ala, 
bpy-Ala, and DAN-Ala. 
 
 The appendices are some publications and manuscripts on various other projects.  
Appendix I is a molecular dynamics study of laboratory-evolved pNBE enzymes with 
different thermostability.  The findings presented here will help us to better understand 
the determinants in protein stability evolution.  Appendix II contains experimental work I 
have done in the Chan group.  Unfolding experiments revealed the existence of 
intermediates in the equilibration unfolding of RdPf.  In Appendix III, femtosecond time-
resolved spectroscopy was used to study the fluorescence resonance energy transfer and 
tryptophan solvation dynamics in RdPf.  
 viii
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1. The New Era of Computational Biochemistry  
 
 In the last twenty-five years the advances in the field of computational 
biochemistry have contributed tremendously to our understanding of complex 
biomolecular systems such as proteins, nucleic acids and bilayer membranes.  The very 
first molecular dynamics simulation of a protein, the bovine pancreatic trypsin inhibitor 
(BPTI), was published in 1977 (1).  Although the simulation is “crude” by today’s 
standards, it was important because it introduced an important conceptual change in our 
view of biomolecules.  The classic view of the structure of proteins and nucleic acids is 
static, because the protein crystal structures available at that time led to an image of 
“rigid” biomolecules with every atom fixed in place.  It is now recognized that the atoms 
of which the biopolymers are composed are in a state of constant motion at ordinary 
temperatures.  The X-ray crystal structure of a protein is merely the average atomic 
positions, and the atoms exhibit fluid-like motions about these averages.  This work 
marked the beginning of modern computational biochemistry, and numerous 
methodological advances in computational studies of biomolecules have followed since. 
 
 Molecular dynamics (MD) is the key in the advance of computational 
biochemistry.  There are other simulation methods, such as Langevin dynamics, Monte 
Carlo simulation and normal mode analysis.  New techniques are being developed that 
treat the bulk of a biomolecule classically while applying quantum mechanics to a subset 
 3
of atoms, typically in the active site.  In molecular dynamics, the motion of the system 
was described by Newtonian equations, and the trajectory is obtained by integrating a 
series of such equations.   
 
We all know that classical mechanics agrees well with quantum mechanics when 
∆E << kBT.  To understand why molecular dynamics can be applied to motions like bond 
stretches, which has quantized energy gap much higher than the thermal energy at room 
temperature, we can look at an example of the motion of an O−H bond.  The vibrational 
frequency of an O−H bond is about 100 ps-1.  It represents one of the highest frequency 
modes of vibration in a biomolecule and thus serves as a worst-case scenario for classical 
approximation in macromolecular simulations.  One of the physical quantities of great 
interest is the variance in the position of atoms at equilibrium, <(∆x)2>.  An oscillator 
model is usually used to describe the bond stretch motion.  Assume the equilibrium 
position is at x = 0, then <(∆x)2> = <x2>.  This mean-square fluctuation about the average 
position is related to the B factors of crystallography and is also measurable by neutron 
scattering (2) and by Mössbauer spectroscopy (3).  It is also one of the most important 
quantities in molecular dynamics simulations.  For a harmonic oscillator,  
    ,
2
1 2kxV =                                                                    (1) 
where V is the potential energy, k is spring constant.  Considering the equal partition of 
energy between kinetic energy and potential energy, we can get  
                            2
2
)2( fm
E
k
Ex π== ,                                          (2) 
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where E is the total energy and f is the vibrational frequency of the harmonic oscillator.  
Plug in the energy expressions of the harmonic oscillator from classical and quantum 
mechanics, assuming f = 100 ps-1, T = 300 K and m is the mass of a proton, we get <x2> = 
5×10-3 Å2 from quantum mechanics and 6×10-4 Å2 from classical mechanics.  The root-
mean-square deviation (rmsd) is only 0.07 Å, which is modest relative to crystallographic 
resolutions and the equilibrium length of the O−H bond.  Furthermore, when compared to 
motional amplitudes measured by neutron scattering, classical simulations predict too 
much motion (4).  Thus, the reduced motion resulting from the neglect of quantum effects 
is overshadowed by other approximations made in simulations, such as the neglect of 
electronic polarizability and the assumed pairwise additivity of van der Waals forces.  
The overestimate of protein motion by simulations is not yet understood.  To summarize, 
classical simulations are unable to analyze the details of bond stretching and angle 
bending correctly.  These motions are at frequencies too high for an accurate treatment 
using Newton’s law.  However, we have observed that the errors in motional amplitude 
are relatively small, and errors in energy tend to cancel out in appropriately designed 
calculations, as when ∆∆G’ s are calculated rather than ∆G’s. 
 
 It is worth mentioning that recent advances in techniques that combine quantum 
mechanics and classical molecular mechanics (QM/MM) now allow for an accurate and 
detailed understanding of processes involving bond breaking and bond making, and how 
enzymes catalyze those reactions.  In QM/MM approach the system is partitioned into a 
QM region and an MM region. The QM region typically includes the substrate and the 
side chains of residues believed to be involved in the reaction and any cofactors.  The 
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remainder of the protein and the solvents is included in the MM region.  The applications 
of QM/MM method include the reactions catalyzed by triosephosphate isomerase (5, 6),  
bovine protein tyrosine phosphate (7) and citrate synthetase (8). 
 
 To simulate the dynamics of a macromolecule, we generally need to specify three 
components: The topology of the molecule (also known as the connection records), the 
initial coordinates or the starting structure, and a force field.  There are currently more 
than ten force fields in use for biomolecule simulations, such as CHARMM (9), AMBER 
(10), OPLS (11), MMFF (12) and DREIDING (13). Some test studies on these force 
fields showed that they perform comparably well on proteins (14). These force fields 
were generally optimized using source data for small molecules from QM, electron 
diffraction, microware, IR and NMR spectroscopy, etc.  Because of the transferability of 
parameters, they perform equally well on biomolecules. 
 
 Clearly computational and theoretical studies of biological molecules have 
advanced significantly in recent years and will progress rapidly in the future.  These 
advances have been fueled by the ever-increasing number of available structures of 
proteins, nucleic acids, and carbohydrates. Computational biochemistry has many new 
applications in various areas.  Among these new applications are molecular docking, 3-D 
protein structure prediction, and protein design.  In this thesis, all these applications will 
be applied in various chapters.   
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2. Protein Engineering and Aminoacyl-tRNA Synthetases  
 
Biomolecules are polymers in principle.  Although many advances in synthetic 
polymer chemistry have been made over the last several decades to provide the polymer 
chemist with increasing control over the structure of macromolecules (15-18), none has 
provided the level of control afforded by in vivo methods, a level of control which is the 
basis of exquisite catalytic, informational, and signal transduction capabilities of proteins 
and nucleic acids.  The Tirrell laboratories at Caltech and others have been exploring the 
use of in vivo methods for producing artificial protein polymers whose sequence, 
stereochemistry, and molecular weight are exactly controlled.  Harnessing the control 
provided by in vivo methods in the synthesis of protein polymers should permit control of 
folding, functional group placement, and self-assembly at the angstrom length scale.  
Indeed, proteins produced by this method exhibit well-controlled chain-folded lamellar 
architectures (19, 20), unique smectic liquid-crystalline structures with precise layer 
spacings (21), and well-controlled, reversible gelation (22).  The demonstrated ability of 
these protein polymers to form unique macromolecular architectures will be of certain 
importance in expanding the role of proteins as materials with interesting liquid-
crystalline, crystalline, surface, electronic, and optical properties.  An important 
continuing objective, therefore, is to expand the chemical and physical properties that can 
be engineered into protein polymers in vivo, via the incorporation of non-natural amino 
acids. 
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The in vivo incorporation of non-natural amino acids is controlled in large 
measure by the aminoacyl-tRNA synthetases (AARSs), the class of enzymes that 
safeguards the fidelity of amino acid incorporation into proteins.  Translation is the 
process whereby genetic information, in the form of mRNA, is used to synthesize the 
corresponding sequence of amino acids found in proteins.  The identity of an amino acid 
inserted at a particular position during protein synthesis is determined by the pairing of a 
codon in mRNA with a particular aminoacyl-tRNA (Figure 1).  The overall fidelity of 
protein synthesis is dependent on the accuracy of two processes, condon-anticodon 
recognition and aminoacyl-tRNA synthesis.  The codon-anticodon recognition is rather 
straightforward because of the diversity of codons.  Aminoacyl-tRNAs are synthesized by 
the 3’-esterification of tRNAs with the appropriate amino acids.  For the majority of 
aminoacyl-tRNAs this is accomplished by direct aminoacylation of a particular tRNA 
with its cognate amino acid in a two-step reaction: 
 
 AA + ATP + AARS ⇔ AARS•AA-AMP + PPi                                  (3) 
 AARS•AA-AMP + tRNA ⇔ AARS + AA-tRNA + AMP,                 (4) 
 
where AA is an amino acid and AARS is the corresponding aminoacyl-tRNA synthetase. 
 
 It is necessary to clarify the naming conventions used here.  The specific AARSs 
are denoted by their three-letter amino acid designation, e.g., AlaRS for alanyl-tRNA 
synthetase.  Alanine tRNA or tRNAAla denotes uncharged tRNA specific for alanine; 
alanyl-tRNA or Ala-tRNA denotes tRNA aminoacylated with alanine. 
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Figure 1.  Role of aminoacyl-tRNA formation in the elongation phase of protein 
synthesis.  An uncharged tRNA is first aminoacylated with the cognate amino acid to 
generate an aminoacyl-tRNA, which then interacts with the elongation factor.  This 
allows delivery of the aminoacyl-tRNA to the ribosome A site, where its anticodon can 
interact with the cognate codon in mRNA.  The example shown illustrates how this leads 
to the translation of the codon GGU as tryptophan.  (Adapted from reference (23).) 
 
 The aminoacyl-tRNA synthetases have received much attention in recent years, 
and high resolution structures are now available for nearly every type of AARS (23).  
Many of these structures are complexes of AARS with various substrate ligands or 
inhibitors.  Detailed biochemical and genetic characterizations have also helped our 
understanding of the mechanisms in various stages of the aminoacylation reaction.  
Collectively, these studies have now provided information on the expression, structure 
and function of the aminoacyl-tRNA synthetases in almost every detail.  The exquisite 
specificity of these enzymes has been explained at a molecular level. 
 
 Concurrent with the surge in understanding of individual AARSs, the advent of 
whole-genome sequencing has provided a broader picture of the overall process of 
aminoacyl-tRNA synthesis.  Over 30 complete families of AARSs are now known (24), 
while only the Escherichia coli AARSs were complete in 1991 (25).  The availability of 
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so many sequences of AARS-encoding genes has led us to recognize the diversity of 
aminoacyl-tRNA synthesis mechanisms.  For many years, people thought there were 20 
AARSs (one for each amino acid) in each species.  However, the genomic sequence of 
the hyperthermophilic archaeon Methanococcus jannacshii only contains 16 of the 20 
known AARSs identified by homology technique (26).  Studies have shown that this 
apparent shortfall can be contributed to the existence of previously uncharacterized 
AARSs and of novel pathways for aminoacyl-tRNA synthesis, and such pathways are 
found in a wide variety of organisms (27). 
 
 Numerous studies have shown that all AARSs catalyze essentially the same 
reaction.  First, ATP and amino acid bind at the active site.  The respective positioning of 
the α-phosphate group of the ATP and the α-carboxylate group of the amino acid allows 
the latter to attack the former by an inline nucleophilic displacement mechanism (Figure 
2 a).  This leads to the formation of an enzyme-bound mixed anhydride (aminoacyl-
adenylate) and an inorganic pyrophosphate leaving group (Reaction 3 above).  In the 
second step of the reaction, the 2’- or 3’-hydroxyl of the terminal adenosine of tRNA 
nucleophilically attacks the α-carbonyl of the aminoacyl adenylate (Figure 2 b).  The 
final result is the 3’-esterification of the tRNA with the amino acid moiety and the 
generation of AMP as a leaving group (Reaction 4 above).  The product is then released 
from the enzyme. 
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 Figure 2.  The two steps of the aminoacylation reaction deduced from the crystal 
structure of yeast AspRS.  (a) Amino acid is activated by the forming of the aspartyl-
adenylate and the release of pyrophosphate.  The amino acid is shown in a postulated 
initial position.  (b) Amino acid is transferred to the ribose of the 3’-end adenosine of 
tRNA.  (Adapted from reference (23).) 
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 Despite the conserved mechanisms of catalysis, the aminoacyl-tRNA synthetases 
can be divided into two unrelated classes (I and II) based on their mutually exclusive 
sequence motifs that reflect distinct topologies (28).  In class I AARSs, the active site 
contains a Rossmann dinucleotide-binding domain, whereas this fold is absent from the 
active site of class II AARSs, which instead contains a novel antiparallel β-sheet fold.  
The difference results in the binding of ATP in different conformation in the active site.  
In class I AARSs, ATP assumes an extended conformation, while ATP is bent in class II 
AARSs.  Inside each class, AARSs can be further divided into subclasses (29).  Table 1 
lists the detailed classification of all AARSs. 
 
 Table 1.  The classification of aminoacyl-tRNA synthetases 
Class AARSs 
Class I  Motifs: ΦhΦGh, kmsKs 
     Subclass Iaa ArgRSb, CysRS, IleRS, LeuRS, MetRS, ValRS, LysRS Ib,c 
     Subclass Ib GlnRSb, GluRSb 
     Subclass Ic TrpRS, TyrRS 
Class II Motifs: (1)gΦxxΦxxpΦΦ (2)fRxe-h/rxxxFxxx(d/e) (3)gΦgΦgΦ(d/e)RΦΦΦΦΦ 
     Subclass IIa GlyRSd, HisRS, ProRS, ThrRS, SerRS 
     Subclass IIb AsnRS, AspRS, LysRS IIc 
     Subclass IIc AlaRS, GlyRSd, PheRS 
Φ: hydrophobic residue; Uppercase letter: strictly conserved; Lowercase letter: conserved 
but less strict; x: any residue 
aSubclasses and motifs are defined in reference (29) 
bArgRS, LysRS I, GlnRS, and GluRS require the presence of tRNA for amino acid 
activation (30, 31) 
cLysRS is found as both class I and class II AARS (31) 
dGlyRS exists in two unrelated forms (32) 
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 The other major difference between the two classes AARSs is in their binding of 
tRNA.  From the available AARS:tRNA complex structures, class I AARSs approach the 
acceptor stem of tRNA from the minor groove side with variable loop facing the solvent, 
whereas class II AARSs approach the major groove side of the acceptor stem and the 
variable loop faces the synthetase.  Whether this is true for all AARSs remains unclear, as 
there are only a handful of AARS:tRNA complex structures available.   
 
 An intrinsic requirement of aminoacyl-tRNA synthesis is that it should solely 
generate cognate aminoacyl-tRNA.  Although there are other mechanisms guarding 
against the infidelity, the accuracy of aminoacyl-tRNA synthesis mostly depends on the 
specificity of the AARSs.  The overall error of rate of aminoacyl-tRNA synthesis is about 
1 in 10,000 (33).  This fidelity is achieved in a number of ways:  First, the AARSs make 
an intricate series of contacts with both their amino acid and tRNA substrates, which go a 
long way in ensuring that only the correct substrates are selected from the large cellular 
pool of similar ligands.  In the case of cognate tRNA selection, the accuracy of the 
recognition is enhanced by the stabilization of the transition state for tRNA charging in 
cognate tRNA:AARS complexes and the existence if antideterminants in certain tRNAs 
that prevent interaction with non-cognate AARSs (34). 
 
 The discrimination of amino acids by AARSs is potentially more difficult, as 
some of the amino acids differ by only a methyl group.  Nevertheless, some amino acids 
such as tyrosine and histidine have sufficiently unique side chains to prevent other amino 
acids in competing for the binding site.  Others like valine and isoleucine do need extra 
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mechanism to assure the fidelity.  For example, while IleRS misactivates valine at a 
frequency of 1 in 150, the overall error rate is only 1 in 3000 because of the proofread 
mechanism in IleRS (35).  IleRS is able to proofread misactivated valine at two points in 
the aminoacylation reaction, both as a bound aminoacyl-adenylate (pre-transfer 
proofreading) and as a bound aminoacyl-tRNA (post-transfer proofreading).  Both 
reactions are dependent on the presence of tRNAIle, as summarized below: 
 
 IleRS + Val + ATP ⇔ IleRS•Val-AMP + PPi                                       (5) 
IleRS•Val-AMP +tRNAIle⇔ IleRS•Val-AMP•tRNAIle⇔ IleRS•Val-tRNAIle+AMP (6) 
      ↓ (7)   ↓ (8) 
      IleRS + Val + AMP + tRNAIle 
 
 Thus IleRS uses a double sieve selection in its amino acid recognition.  The first 
sieve guards against any amino acid large than isoleucine, while the second sieve 
hydrolyze any aminoacyl-tRNAIle that has an amino acid smaller than isoleucine.  Other 
AARSs, such as ValRS has a similar proofreading mechanism against threonine (36).  
The proofreading is a constant process, thus there is a significant energy cost in achieving 
accuracy in protein synthesis. 
 
 Because AARSs themselves are protein-based, the error in AARS itself can be 
propagated to affect the accuracy in the next generation protein synthesis.  Therefore, 
there must be an error threshold in aminoacyl-tRNA synthesis.  Above this threshold, the 
error propagation in protein synthesis will lead to an “Error Catastrophe” (37).  Various 
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models have shown that this “Error Catastrophe” could be a genetically programmed cell 
death mechanism (38).  So far these models have not been proved in experiments. 
 
 Because of the essential role of AARSs for cell activity, inhibition of a member of 
this family of enzymes is detrimental to the cell.  This led to the early realization that if 
inhibitors of AARSs could be found that differentiate between bacterial or fungal AARSs 
and their human homologs, such compounds might provide a means of developing 
antibacterial or anti fungal agents.  Over the years a number of natural products have 
been discovered that inhibit IleRS [furanomycin and pseudomonic acid], LeuRS 
[granaticin], PheRS [ochratoxin A], ProRS [cispentacin], ThrRS [borrilidin], and TrpRS 
[indolmycin] (see (23) for references).  Currently pseudomonic acid has been developed 
into an antibiotic, mupirocin (39).  The rapid rise of antibiotic-resistant pathogens has put 
considerable emphasis on the development of novel antibiotics, including search for 
potent AARS inhibitors.  The availability of complete set of AARS from many organisms 
offers the potential to develop new potent AARS inhibitors. 
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Abstract 
 
In vivo incorporation of amino acids in protein biosynthesis has a precisely 
controlled mechanism.  The accuracy of this process is controlled to a significant extent 
by a class of enzymes called the aminoacyl-tRNA synthetases.  Aminoacyl-tRNA 
synthetases achieve this control by a multi-step identification process that includes 
“physical” binding and “chemical” proofreading steps.  However, the degree to which 
each synthetase uses these specificity-enhancing steps to distinguish their cognate amino 
acid from the non-cognate ones vary considerably.  We have used HierDock 
computational protocol to elucidate this binding mechanism in methionyl-tRNA 
synthetase (MetRS) by first predicting the recognition site of Met in the apo form of 
methionyl-tRNA synthetase (apo-MetRS).  We have developed this generalized 
procedure, which can be used to search for ligand binding region in globular proteins 
with no prior information about the binding site.  We have further investigated the 
specificity of MetRS towards the binding of 19 other natural amino acids to both 
apo-MetRS and to the co-crystal structure of MetRS with Met bound to it (co-MetRS).  
We have established through our computed binding energies that the discrimination 
towards the non-cognate substrate increases in the second step of the physical binding 
process that is associated with a conformation change in the protein.   
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1. Introduction 
 
Specific recognition of amino acids by their corresponding tRNAs and 
aminoacyl-tRNA synthetases (AARSs) is critical for the faithful translation of the genetic 
code into protein sequence information.  The AARSs catalyze a two-step reaction in 
which amino acids are esterified to the 3΄ end of their cognate tRNA substrates (1).  In 
the first step, the amino acid and ATP are activated by the AARS to form an enzyme-
bound aminoacyl-adenylate complex.  In the second step, the activated amino acid is 
transferred to the 3΄-ribose of the conserved CCA-3΄ end of the cognate tRNA.  The 
fidelity of protein synthesis depends, in most part, on the accuracy of this aminoacylation 
reaction.  AARSs bind their cognate amino acid through a multi-step recognition process 
and correction mechanisms that include physical binding and a chemical proofreading 
(2).  The four major steps involved in the transfer of aminoacyl group to the tRNA are 
1. Binding of amino acid and ATP. 
2. Conformational change in the AARS induced by binding and formation of the 
aminoacyl-adenylate complex.   
3. Proofreading of misactivated non-cognate aminoacyl-adenylate complex. 
4. Transfer of aminoacyl to the tRNA and proofreading.  
 
The physical binding of the amino acid and ATP to AARSs is achieved in steps 1 
and 2, which is accompanied by a conformation change in the AARSs.  However, this 
binding event is necessary but not sufficient for the incorporation of the analog or the 
cognate amino acid during protein biosynthesis. Binding is followed by chemical 
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proofreading steps 3 and 4, which are termed as the pre-transfer and the post-transfer 
proofreading steps, respectively.  With every step, the AARS recognizes its cognate 
amino acid with increased specificity, while discriminating more efficiently against the 
non-cognate amino acids.  However, the degree to which each AARS uses the specificity 
enhancing steps varies considerably with regard to the 20 naturally occurring amino acids 
and the type of AARS. For example, tyrosyl-tRNA synthetase has the highest specificity 
in the first binding step whereas isoleucyl-tRNA synthetase, achieves maximum 
discrimination in the pre-transfer proofreading step (3-6).   
 
Many research groups have focused on the use of in vivo methods for 
incorporating the non-natural amino acid analogs into proteins.   It has been demonstrated 
that the wild-type translational apparatus can use non-natural amino acids with 
fluorinated, electroactive, unsaturated and other side chain functions (7-13).  However, 
the number of amino acids shown conclusively to exhibit translational activity in vivo is 
small, and the chemical functionality that has been accessed by this method remains 
modest.  Only those analogs that are able to successfully circumvent the multi-step filter 
mechanisms of the natural synthetases eventually get incorporated.  
 
With an increase in efforts of incorporating artificial amino acids in vivo, it has 
become vital to enhance our understanding of the molecular level mechanism at different 
steps that AARSs utilize to ensure high fidelity in translation.  A better understanding of 
this mechanism will also be very useful in allowing us to design mutants of AARS for 
incorporation of specific analogs and also in suggesting analogs that are more efficiently 
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incorporated (14-16).  In this study, we have implemented a computational procedure to 
gain insight into the binding mechanism of methionyl-tRNA synthetase (MetRS). 
Computational methods are becoming increasingly important to understand the molecular 
level mechanisms that are not feasible with experiments and also for faster virtual 
screening of analogs prior to synthesis.  
 
MetRS is a class I AARS, and undergoes a large conformational change upon 
substrate Met binding. It is a dimeric protein and the crystal structures of E. coli MetRS 
in its apo form and as a co-crystal with its native ligand, Met, have been solved to 1.85Å 
and 2.03Å resolution, respectively. [We refer to the apo form of MetRS protein structure 
as apo-MetRS(crystal) and the co-crystal structure of E. coli MetRS with Met as 
Met/MetRS(crystal). Note that the protein conformations in both these crystal structures 
are different especially in the binding site. The symbol MetRS always denotes the E. coli 
MetRS unless otherwise specified.]  Both in vivo incorporation of Met analogs into 
proteins and their in vitro measurements of the rate of incorporation have been studied 
extensively and it has been demonstrated that MetRS is one of the more permissive 
AARSs for the incorporation of a large number of analogs (8). We are interested in 
computationally determining the specificity of MetRS for the natural non-cognate amino 
acids and Met analogs in the steps of amino acid recognition and binding. A better 
understanding of its binding mechanism would be useful to streamline a virtual screening 
approach for the incorporation of non-natural amino acids.  
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We have used the HierDock computational protocol (17) to first predict the 
binding site of Met in MetRS in the apo-MetRS (crystal).  We scanned through the entire 
protein (except the anticodon recognition region) for predicting the preferential binding 
site for Met using no knowledge from the crystal structure of Met/MetRS (crystal). We 
refined the HierDock protocol and derived what we call as the “recognition site” which 
includes all the residues in the binding pocket of Met as seen in Met/MetRS (crystal), 
however, Met is oriented in this pocket with its side chain exposed to solvent.  Our results 
indicate that the first step to amino acid binding is the recognition of the zwitterions part 
of the ligand, which is referred to as the “recognition mode.”  We find that apo-MetRS is 
able to distinguish Met from the non-cognate natural amino acids but has cysteine and 
serine as competitors.  We also find that MetRS in the Met/MetRS (FF) protein structure 
has better discrimination for the twenty amino acids and once again Met has the best 
binding energy in this structure with Gln as a close competitor.  
 
The calculated binding energies of Met analogs are correlated with either the in 
vivo incorporation results or the in vitro measurements of rate of the aminoacyl- 
adenylate formation. We find that in Met/MetRS (FF) protein, the analog with high 
incorporation rates bind better than those that do not get incorporated.  In an attempt to 
incorporate novel Met analogs Kiick et al. reported that Homopropargylglycine (myag) 
replaces Met most efficiently utilizing the natural translation apparatus of E. coli while 
cis-crotglycine (ccg) shows almost no incorporation (18). Our calculated binding energies 
correlate well with the in vivo incorporation trends exhibited by these analogs and with 
the binding energies calculated by in vitro methods. 
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2.  Methods  
 
2.1 Preparation and Optimization of Structures 
Ligand Structures:  Both the neutral and the zwitterion forms were used for all the 
twenty natural amino acids as well as the five Met analogs. The ligand conformations 
were optimized in the extended conformation at the Hartree-Fock level of theory with a 
6-31G** basis set, including Poisson-Boltzmann continuum dielectric solvation using the 
Jaguar computational suite (19) (Schrödinger, Portland, OR). The Mulliken charges 
ascertained from this calculation were retained for the subsequent molecular mechanics 
simulations. The conformations of the five Met analogs are shown in Figure 4 a. 
 
Preparation and Optimization of Protein Structures: The 2.03Å E. coli apo-MetRS 
structure was obtained from PDB database  (pdb code: 1QQT) that included the fully 
active monomer α chain of a homodimer, crystal waters, and a zinc (II) ion (20).  
CHARMM22 charges with the nonpolar hydrogen charges summed onto the heavy atoms 
were assigned to the α chain according to the parameters set forth in the DREIDING 
force field (21).  The protein was neutralized by adding counterions (Na+ and Cl-) to the 
charged residues (Asp, Arg, Glu and Lys) and subject to a minimization of the potential 
energy by the conjugate gradient method using Surface Generalized Born continuum 
solvation method (22).   The RMS in coordinates (CRMS) of all atoms after minimization 
is 0.68Å and this structure is referred to as apo-MetRS(FF).  Using the same procedure 
the co-crystal structure of E. coli MetRS (pdb code: 1F4L; resolution 1.85Å) was 
minimized and the CRMS for all atoms of the minimized structure compared to the 
 24
crystal is 0.57Å (23).  We refer to this structure as Met/MetRS (FF).  The CRMS values 
for both structures are well within experimental error that demonstrates the proficiency of 
our FF used in present studies.  The crystal waters and other bound molecules were 
removed for docking to maximize the searchable surface of the protein. We have used 
SGB continuum solvation method for all structure optimizations and energy scoring in 
this study with an internal protein dielectric constant of 2.5 was employed for all 
calculations.  
 
2.2 HierDock Protocol 
     We use the HierDock procedure, which has been applied successfully to study the 
binding of odorants to membrane-bound olfactory receptors (17), for outer membrane 
protein A binding to sugars (15) and for Phe and its analogs binding to PheRS (24).  The 
HierDock ligand screening protocol follows a hierarchical strategy for examining 
conformations, binding sites and binding energies.  Such a hierarchical method has been 
shown to be necessary for docking algorithms (25).  The steps in HierDock involve using 
coarse-grain docking methods to generate several conformations of protein/ligand 
complexes followed by molecular dynamics (MD) simulations including continuum 
solvation methods performed on a subset of good conformations generated from the 
coarse-grain docking.  Methods combining docking and MD simulations have been tested 
(26) but the main drawback of these tests was that only one protein/ligand complex 
structure was kept from the coarse-grain docking methods for MD simulations.  This is 
risky considering that the coarse-grain methods do not have accurate scoring functions 
that include solvation.   
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Free energy perturbation methods are generally regarded to lead to accurate free 
energies of binding but are computationally intensive and not readily applicable to a wide 
variety of ligands (27). Our goal is to derive a fast hierarchical computational protocol 
that uses hierarchical conformation search methods along with different levels of scoring 
functions, which would allow screening of amino acid analogs for AARSs.  The three 
major steps in HierDock procedure in this paper are as follows: 
 
• First, a coarse-grain docking procedure to generate a set of conformations for 
ligand binding.  In this paper we used DOCK 4.0 (28, 29) to generate and score 
20000 configurations, of which 10% were ranked using the DOCK scoring 
function.  
• We then select the 20 best conformations for each ligand from DOCK and subject 
them to annealing molecular dynamics (MD) to further optimize the conformation 
in the local binding pocket, allowing the atoms of the ligand to move in the field 
of the protein.  In this step the system was heated and cooled from 50 K to 600 K 
in steps of 10 K (0.05 ps at each temperature) for one cycle.  At the end of 
annealing MD cycle, the best energy structure is retained. Annealing MD allows 
the ligand to readjust in the binding pocket to optimize its interaction with the 
protein.  This fine grain optimization was performed using MPSim (30) with 
DREIDING force field (21) and continuum solvation methods.  We use the 
Surface Generalized Born (SGB) continuum solvent method to obtain forces and 
energies resulting from the polarization of the solvent by the charges of the ligand 
and protein.  This allows us to calculate the change in the ligand structure due to 
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the solvent field and hence, obtain more realistic binding energies that take into 
account the solvation effects on the ligand/protein structure.  The annealing MD 
procedure generated 20 protein/ligand complexes for each ligand.   
• For the 20 structures generated by annealing MD simulations for each ligand, we 
minimized the potential energy (conjugate gradients) of the full ligand/protein 
complex in aqueous solution using SGB.  This step of protein/ligand-complex 
optimization is critical for obtaining energetically good conformations for the 
complex (cavity + ligand).  Then we calculated binding energies as the difference 
between the total energy of the ligand-protein complex in solvent 
(∆G(protein+ligand)) and the sum of the total energies of the protein (∆G 
(protein)) and the ligand separately in solvent (∆G(ligand)).  The energies of the 
protein and the ligand in solvent were calculated after independent energy 
minimization of the protein and the ligand separately in water. Solvation energies 
were calculated using Poisson-Boltzmann continuum solvation method available 
in the software Delphi.  The non-bond interaction energies were calculated 
exactly using all pair interactions. Thus the binding energy is given by 
              )()()( ligandGproteinGligandproteinGGcalc ∆−∆−+∆=∆∆        (1) 
Since the structure optimizations included solvation forces using the SGB 
continuum solvent approximation with the experimental dielectric constant, we 
consider that the calculated energies are free energies (31). This multi-step 
scanning procedure is based on docking via DOCK 4.0 coupled with fine-grain 
MM techniques. The coarse grain docked complex structures generated are scored 
with FF and differential solvation, which effectively filters the docked complexes 
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to isolate the top contenders. As demonstrated in our previous studies 
(unpublished result), Dock 4.0 structures vary erratically with rank, whereas 
filtering with MPSim optimization brings the best structures to the top of the rank 
list.  
 
2.3 Scanning the Entire apo-MetRS(FF) for Predicting Binding Site of Met  
For the case of apo-MetRS(FF) we wanted to test the HierDock procedure for 
scanning the entire protein for the favorable binding site of Met. However, it has not been 
tested for a case where the protein undergoes a large conformational change in the 
binding site after the ligand binding starting from apo-protein structure. The steps 
involved in the scanning procedure are as follows: 
 
1. Mapping of possible binding regions.  A probe of 1.4 Å radius was used to 
trace a 4 dots/Å negative image of the protein molecular surface, according to 
Connolly’s method (32). The resulting data was used to generate clusters of 
overlapping spheres with the SPHGEN program.  These spheres serve as the 
basis for the docking method. 
2. Definition of docking region.  The pockets of empty space of the receptor 
(apo-MetRS(FF)) surface represented by spheres were divided into 14 
possible 10 Å wide overlapping cubes, which covered the entire protein 
surface.  Each region was scanned to determine its suitability as a binding site.  
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The site that contains the greatest number of lowest energy docked 
conformations is designated as the putative binding region.  
3. Prediction of binding site.  Steps 1 to 3 of HierDock procedure were 
performed with Met as the ligand in all the 14 possible binding regions in the 
entire apo-MetRS(FF). The orientations of the ligand in the receptor were 
generated by DOCK 4.0, using flexible docking with torsional minimization 
of the ligand, a continuum dielectric of 1.0 and a distance cutoff of 10 Å for 
the evaluation of energy. 
4. Selection of the most probable binding site and best configurations. The best 
conformation from each region was determined using the buried surface area 
cutoff criteria for the ligand along with the binding energy. Such a buried 
surface area cutoff is required for filtering at the coarse grain level. An 
average of the most buried and the least buried conformer was calculated and 
all conformers whose buried surface area was lower than the average were 
eliminated from further analysis (33). The conformations that passed the 
buried surface area filter were sorted by binding energies calculated using 
equation (1) and the conformation with the best binding energy in every 
region were compared between regions. All the complex energies were 
calculated.  The region with the lowest energy binding energy calculated using 
equation (1) was selected as the preferential binding region. 
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2.4 Docking of Ligand Pool into the Binding Region and Calculating Relative Binding 
Energies   
Steps 1 to 3 of HierDock procedure were performed for all the ligands in the 
ligand pool in the putative binding region and the relative binding energies for the best 
ligand conformations were calculated using equation (1). The ligands (20 natural amino 
acids and analogs of Met) were ranked according to binding affinities to determine which 
ligands have the highest affinity for the binding site. The best energy conformation of 
Met in optimized apo-MetRS(FF) structure is the predicted structure of Met in apo-
MetRS(FF). We denote this predicted structure as Met/apo-MetRS(FF).  
 
2.5 Prediction of Binding Site for Met/MetRS(FF) Co-Crystal Structure  
For the case of Met/MetRS(FF) structure, the receptor was prepared by removing 
the Met from the Met/MetRS(FF) structure. The protein surface was mapped with 
spheres, as described above, and the binding regions were covered by a 12 Å × 12 Å × 12 
Å box centered in the center of mass of Met ligand.  Only this region was used in 
subsequent docking.  Steps 1 to 3 of HierDock procedure were performed using the same 
set of control parameters but only in the known binding region. The conformation with 
the best energy binding energy in this region calculated using equation (1), starting from 
the protein structure in Met/MetRS (FF) is the predicted co-crystal structure of 
Met/MetRS. We denote this predicted structure of Met in MetRS co-crystal structure as 
Met/MetRS (HierDock).  
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2.6 Docking of Ligand Pool into the Binding Site and Calculating Relative Binding 
Energies in Met/MetRS (HierDock)  
We performed steps 1 to 3 of HierDock procedure for all 20 natural amino acids 
and the Met analogs in the 12Å x 12Å x12Å binding region and the relative binding 
energies for the best ligand conformation for each ligand was calculated using equation 
(1). The ligands (20 natural amino acids and analogs of Met) can then be ranked 
according to binding affinities to determine which ligands have the highest affinity for 
the binding site. 
 
2.7 Binding Energy Calculation of the 20 Natural Amino Acids and Met Analogs in the  
Conformation that Activates the Protein  
HierDock protocol predicts the best energy conformation for each ligand (20 
natural amino acids and Met analogs) in the defined 12Å x 12Å x 12Å binding region in 
Met/MetRS(FF) structure. These predictions give rise to different preferred binding 
conformation for each ligand.  However, the orientation that Met adopts in the active site 
with all the necessary contacts required for the enzymatic activity is referred to as the 
“activation mode.”  To assess the relative binding energies of the 20 natural amino acids 
and their analogs in the activation mode perturbation calculations for all the ligands were 
performed as follows: 
 
• An amino acid rotamer library (34) was used to generate all the conformations of 
each amino acid in the binding site, and a similar library was generated for the 
five Met analogs.   
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• The best rotamer was chosen by matching each rotamer k in the binding site and 
evaluated with the following equation using the Dreiding force field: 
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where i and j sum over all atoms in the ligand and protein residue residues in the 
binding site, qi and qj are partial charges on atoms i and j, respectively.  rij is the 
distance between atoms i and j, and rm and De are van der Waals distance and well 
depth of atoms i and j, rHB and DHB are hydrogen bond distance and well depth, 
respectively.  θ is the hydrogen bond angle between atoms i, j and their bridging 
hydrogen atom.  The hydrogen bond term is only evaluated for hydrogen bond donor 
and acceptor atoms.  To avoid overpenalizing clash, the van der Waals radii were 
reduced to 90% of the standard values in the Dreiding force field.  
• After the best rotamer was chosen for each ligand, the total energy was   
minimized in the presence of protein, and the binding energy was then calculated 
using equation (1) for each of the twenty natural amino acids in the “activation 
mode” and compared.  
 
3. Results and Discussion 
 
3.1 Prediction of Binding Site of Met in apo-MetRS(FF) and Met/MetRS(FF) 
 Figure 1 shows the location of region 14 box in apo-MetRS(FF), which was 
determined to be the binding region by sifting through the 14 regions in apo-MetRS.  The 
best conformation of Met in this region shows Met to be making electrostatic interactions 
 32
with His301 and Asp52 (Figure 3 c), the two amino acids that have been shown to play a 
significant role in Met binding (35, 36).  His301 to Ala mutation results in loss of the 
affinity for Met and D52A mutation reduces the Kcat of the adenylation reaction by four 
folds indicating that it has a major role on the catalytic step in the formation of methionyl 
adenylate.  Tyr15, another key amino acid determined by mutation analysis and has been 
structurally observed in the co-crystal structure to form the binding pocket for Met (23, 
37), is located within 5 Å of the docked Met. The main component of the binding energy 
in our predicted binding orientation comes from the electrostatic interactions that Met 
makes with Asp52 and His301 followed by its van der Waals interactions in this binding 
region.   
 
Figure 1.  Sphere filled volume of MetRS representing the possible binding 
sites in the enzyme. The search volume was divided into 14 regions as indicated 
by the cubic boxes. The binding site was found in the box colored in red. 
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a) 
  
b) 
 
Figure 2. Binding energies of all 20 amino acids in the methionine binding 
site in Met/MetRS(FF) and apo-MetRS(FF).  (a) Shows binding energies of 
the 20 amino acids when docked in the predicted methionine binding site in 
apo-MetRS(FF), and (b) shows the binding energies generated from 
perturbation analysis at the same site. 
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c) 
 
d) 
 
Figure 2. Binding energies of all 20 amino acids in the methionine binding site in 
Met/MetRS(FF) and apo-MetRS(FF). (c) Reports the binding energies generated 
from docking all 20 amino acids in the crystallographic methionine binding site in 
Met/MetRS(FF). (d) Indicates binding energies calculated from perturbation 
analysis at the same site. 
 
 It was speculated, and subsequently, has been observed that the terminal methyl 
group makes contacts with Trp305 (23).  But in our model we find Met to be in exactly 
the opposite orientation.  The terminal methyl group is solvent exposed and is 10Å away 
from Trp305 which is considered to stabilize the enzyme-Met complex.  However, it is 
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suggested that Trp305 does not play a role in defining specificity.  Trp305 occupies the 
same position in the apo enzyme and the complex, and its role has been suggested to 
exclude water molecules from the binding site and correct positioning of Met.  In fact, it 
has been observed that an aromatic character of residue at this position seems to be 
enough to assure Met binding (36).    
 
 
Figure 3. (a) Binding site of methionine in apo-MetRS(FF) and 
Met/MetRS(FF). Amino acids lining the binding pocket are shown in purple 
for apo-MetRS(FF) and in green for Met/MetRS(FF). Methionine 
orientation from perturbation analysis in Met/MetRS(FF) in shown in red 
and its conformation from docking in apo-MetRS(FF) is colored blue. 
Residues closest to methionine that undergo the largest conformation 
changes are labeled.   
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Figure 3. (b) The Sδ of methionine makes two hydrogen bonds – one with 
the terminal oxygen of Tyr260 and the other with the backbone amide of 
Leu13 in the docked conformation in Met/MetRS(FF). The crystal structure 
orientation on methionine is shown in blue. The CRMS between the two 
conformations is 0.55 Å.   
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Figure 3. (c) The predicted binding site for methionine in apo-MetRS(FF). 
The conserved residues within 4 Å are labeled in gold and the conserved 
replacements are labeled in aqua. 
 
 The docked orientation in the apo enzyme occupies the identical position in the 
binding pocket as seen in the co-crystal structure (Figure 3 a). However the orientation of 
Met and the residues lining the binding pocket including parts of the protein backbone are 
very different in the two conformations of MetRS. Although Met seems to be making 
electrostatic contact with Asp52, one of the anchoring residues, the side chain of Met is 
not buried in the 7 Å pocket.  The reason for this is that we have used the unbounded 
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structure of the synthetase, which, on binding to the amino acids undergoes significant 
conformation change. The co-MetRS structure suggests that the large solvent exposed 
cavity become reduced in volume as it gets partially filled with Met and Tyr15, Trp253, 
Phe300, Trp229, Phe304 and Tyr251.  These residues are significantly displaced from 
their apo-enzyme orientation as they reorient to form a hydrophobic pocket for Met.  In 
our predicted binding mode of Met in the apo-enzyme, all these residues are within 5 Å 
of Met ligand.  We expect this to be the initial binding orientation of Met. 
 
 Another interesting observation that substantiates that the predicted orientation of 
Met could be the initial binding mode is that Met has one of the best binding energies of 
all 20 natural amino acids in this region (Figure 2 a).  The specificity of this site further 
confirms that we have been able to find the correct binding region.  Met has Ser and Cys 
as close competitors but they get eliminated as the protein undergoes conformation 
change.  In an attempt to force the side chain of Met to be buried in the pocket we did 
annealing dynamics of the entire complex with solvation and reduced vdW radii of the 
ligand atoms.  However, the orientation of Met did not change. 
 
 Also, a number of residues within 5 Å of Met in this region are conserved among 
a large number of organisms.  In a sequence alignment among 59 prokaryotes we find all 
the amino acids within 4 Å of Met in the predicted binding region are either strictly 
conserved or are conserved replacements.  Of the 12 residues within 4 Å of Met, 7 of 
them (Y15, D52, V252, W253, A256, Y260, H301) are strictly conserved and 5 (A12, 
L13, P14, P257, F300) are conserved replacements (Figure 3 c).  This is interesting 
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considering that there are only 21 positions in the entire alignment that are strictly 
conserved and we find a third of them in our predicted binding region without any prior 
knowledge of the binding site.  A binding search protocol for unliganded proteins 
followed by a sequence alignment analysis for the predicted binding region could provide 
more evidence on the accuracy of the predicted binding site and help in recognizing key 
amino acids lining binding pocket.  Generally, one would expect to see conserved 
residues or conservative replacements in substrate binding sites in proteins across various 
species.   
 
 We also docked Met in the binding region of the co-MetRS(FF).  This test was 
performed to check if we were able to predict the crystallographic binding orientation of 
Met in the binding pocket.  This test was important to validate the accuracy of our 
docking protocol and the force field. Our predicted structure had a CRMS deviation of 
0.55 Å from the crystal structure (Figure 3 b). 
 
3.2 Specificity for Met in 1QQT and 1FTM 
 We docked all 20 amino acids and calculated their binding energies in the 
predicted binding region in apo-MetRS(FF) and the crystallographic binding site in 
Met/MetRS(FF). We also did perturbation studies of the natural amino acids in these two 
structures. The perturbation studies were done to analyze the binding energies of the 
non-cognate amino acids if they oriented in a similar conformation in the binding site as 
Met.   
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Perturbation analysis:  
 In the case of apo-MetRS(FF) closest competitors for Met are Ser and Cys.  
However, as the enzyme undergoes conformation change, its ability to discriminate 
against these non-cognate residues increases significantly.  It has been noticed that for 
most synthetases there is no absolute specificity for the cognate substrate in the sense of a 
“lock and key” model.  For example, yeast IleRS is not able to distinguish between Trp 
and Ile in the first step of binding because of the higher hydrophobic interactions gained 
by the non-cognate substrate.  However, as the initial binding process is completed, the 
enzyme is able to discriminate against the non-cognate amino acids more easily (2, 4). 
 
 In Met/MetRS(FF), Met has the best binding energy, and it has an energy 
difference of more than 20 kcal/mol with its closest competitors, Asn and Arg (Figure 2 
d).  The closest competitors from the first binding step (Leu, Glu and Gln) are 
discriminated against with a very high efficiency as the structure of the protein changes.   
 
Docking analysis:  
 The docking study was done predominantly to recognize possible competitors of 
Met. It may be possible that a non-cognate amino acid binds at the Met binding pocket 
but does not make the critical interactions that methionine makes in this binding pocket.  
In such cases, the amino acid may not be able to react with ATP and charge the tRNA. In 
apo-MetRS(FF), Met has the best binding energy of –26.38 kcal/mol  with Leu, Gln and 
Glu as the closest competitors (Figure 2 a).  In Met/MetRS(FF) Met again has the best 
energy with Gln and Ser as the closest competitors. Gln, in its preferred binding site in 
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Met/MetRS(FF) has its zwitterions part and the χ1 torsional angle in the same orientation 
as Met at this site. Yet, its χ2 and χ3 angles are significantly different from that of Met.  
The Sδ of Met makes two hydrogen bonds—one with the terminal oxygen of Tyr260 and 
the other with the backbone amide of Leu13.   However, because of the difference in its 
binding mode, Gln is unable to make a hydrogen bond with Tyr260 and makes only a 
weak hydrogen bond with the backbone amide of Leu13 (O…H-N distance of 3.9 Å). 
 
 One more observation is that the order of binding of the amino acids is identical 
in the docking analysis in apo-MetRS(FF) and the perturbation study in Met/MetRS(FF) 
(Figures 2 a, 2 d). It indicates that when the enzyme undergoes structural change, if all 
the amino acids were to bind in the binding mode of Met in the co-crystal structure, their 
order of binding would remain the same as indicated by the apo enzyme. However, the 
magnitudes of binding energies, which indicate the level of discrimination, would be very 
different. 
 
3.3 Binding Energies of Met Analogs   
 
 To test the sensitivity of our simulation procedure, we wanted to test if we could 
get good correlation between the computed binding energies for the Met analogs with 
experimental binding energies.  We tested five Met analogs of which four get 
incorporated into proteins with reasonable efficiency and for which the experimental 
binding energies are available.  Ccg, which is a cis-form of tcg (Figure 4 a), has the 
lowest incorporation efficiency and hence, it was used as a negative control for which we 
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hoped to get the worst binding energy for this analog.  Binding energy calculations of the 
Met analogs were carried out in the conformation that activates the protein, i.e., by 
perturbation analysis. 
 
 
 
 
Figure 4.  (a) Structures of methionine and its analogs used in this study. L-
methionine (Met), homoallylglycine (mhag), homopropargylglycine (myag), 
norleucine (nleu), trans-crotglycine (tcg) and cis-crotglycine (ccg). 
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b) 
 
c)  
 
Figure 4. (b) Binding energies of the analogs in the binding site of 
Met/MetRS(FF) calculated using perturbation method. (c) Shows the 
correlation between the calculated binding energies and the experimentally 
observed ∆∆G with respect to methionine.  
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Figure 4. (d) Binding energies of analogs along with the natural amino acids in the 
binding site of apo-MetRS (FF).  
 
 In the case of 1QQT, the binding energies of the analogs are all in the top 50% but 
are interspersed with the non-cognate natural amino acids This indicates that in this 
conformation, MetRS has an inefficiently discrimination capability (Figure 4 d).  
However, in the co-crystal structure, there is a clear preference for binding the analogs.  
The analogs and Met have a binding energy range of  -63.4 to -79.1 kcal /mol (Figure 4 
b).  The closest competitor from the non-cognate set of natural amino acids has a binding 
energy of  -35.0 kcal/mol.  In this conformation, we also find a good correlation between 
experimentally observed binding energies and computed binding energies (Figure 4 c). 
As we had expected, ccg has the worst binding energy and gets incorporated with the 
lowest efficiency whereas myag has the best calculated binding energy and has been 
tested to be the best Met analog. This information could be useful for initial 
computational scanning of the analogs before experimental testing.  The binding energy 
of ccg in Met/MetRS(FF) could be used as a cutoff for  designing new analogs and the 
ones that rank above the cut off could be experimentally tested for binding.   
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 We analyzed the binding modes of ccg and tcg to understand what in particular 
about the cis-form of the ligand renders it to be an unfavorable ligand. We analyzed the 
non-bond energies of these ligands with all the residues lining the binding pocket and 
have tabulated our findings as pairwise interactions in Table 1. Ccg has a VDW clash 
with Ala12, the terminal hydroxyl group of Tyr260 and His301. At the same time, the cis 
orientation of terminal methyl group does not make the same favorable interactions with 
Ala 256 and Pro 267 as tcg (Figure 5). Since Tyr260 and His301 have an important role 
in the binding process as indicated by experiments, mutating them to smaller residues 
may be deleterious. On the other hand, it would be interesting to explore the effect of Ala 
to Gly mutation at position 12 on the incorporation of cis forms of various analogs. 
 
Table 1. Comparison of the interactions of ccg and tcg with residues in the binding site.  
These energies were calculated using Equation 2. 
  ccg   tcg  
Residue vdW Coulomb H-bond vdW Coulomb H-bond 
Asp52 
Leu13 
Tyr15 
Trp253 
Ile297 
Pro14 
His301 
Pro257 
Ile293 
Tyr260 
Ala256 
Val252 
Ala12 
0.438 
-1.255 
-2.173 
-3.779 
-2.097 
-0.973 
-0.102 
-0.670 
-0.273 
-0.227 
-0.941 
-0.233 
-0.084 
-21.47 
-6.045 
-7.773 
-1.934 
-0.454 
-1.467 
-1.189 
-0.122 
-0.145 
-0.116 
0.616 
-0.025 
0.673 
-10.246 
-9.898 
-0.677 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.364 
-1.762 
-3.282 
-3.779 
-0.967 
-1.931 
-1.216 
-1.486 
-1.110 
-1.780 
-1.414 
-0.227 
-0.144 
-21.427 
-6.142 
-6.162 
-1.879 
-1.585 
-0.526 
-1.074 
-0.080 
-0.232 
0.706 
0.601 
-0.047 
0.081 
-9.839 
-10.19 
-0.122 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
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Figure 5: The binding modes or tcg and ccg, shown in the binding pocket of 
Met/MetRS(FF), were predicted by perturbation analysis at this site. Ccg 
(orange) has VDW clashes with Ala12, His301 and Tyr 260 and at the same 
time, cis orientation of the terminal methyl group created a void near Ala 256 
and Pro 257. Tcg (pink) is shown to fill that void and also avoid the unfavorable 
VDW interactions. 
 
 MetRS has been observed to be extremely promiscuous and is able to incorporate 
substrates that are up to 340,000 folds poorer than Met.  This could be attributed to the 
conformational flexibility of the active site of MetRS that has not been modeled in our 
simulation.  The active site conformation could be different for different analogs.  
However, we have performed our perturbation studies only on the co-MetRS bound to the 
natural substrate.  The active site flexibility may be important in enabling MetRS to 
activate Met analogs with varying side chain functionalities.  One more consideration is 
that we are comparing our simulated binding energies to experimentally derived binding 
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energies that are further derived from ATP-PPi exchange studies.  ATP binding could 
have other structural effects on the enzyme that were not modeled in our simulations. 
However, it is interesting to note that we are able to get reasonably good correlation even 
with the limitations in the simulations. One can expect to gain more insights into the 
mechanism of this system with advancements in the simulation procedures.  
 
4. Conclusions 
 
We have studied the specificity of MetRS for Met in the first two steps of the 
binding process. We have demonstrated that its specificity increases in the second 
binding step where the enzyme undergoes a significant conformational change. We 
speculate that Met first anchors to residues Asp52 and His301 with its side chain and as 
the protein undergoes conformation change due to substrate binding (either the amino 
acid, ATP, or both), the cavity opens up and Met flips into the cavity.  Multi-step binding 
mechanisms where the ligand-protein complexes display “induced fit” have been 
illustrated in other proteins. This has been attributed to the presence of energy gradients, 
or funnels, near the binding sites—the binding process initiates from a higher energy 
conformer and terminates in lower energy conformation (38).  
 
When the structure to be docked is taken from the crystallized co-complex, 
predicting the fitted association is relatively straightforward as indicated by the docking 
study using Met/MetRS. Our study with the apo-MetRS illustrates that although 
determining the final bound conformation starting with the “free,” “unbound” state of the 
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enzyme is extremely difficult, a refined search method can be applied to predict the 
correct binding region for the ligand. The predictions can be used to indicate the 
important residues in the binding regions that can be further tested by mutations studies. 
Therefore, for those enzyme crystal structures that are not co-crystallized with their 
substrates a powerful docking protocol, like HierDock can prove to be very useful in 
recognizing the binding region, even in cases where the protein is very flexible.  If the 
molecules are relatively rigid and have smooth binding funnels with single or few 
minima, there is a higher likelihood that the docked conformation of the ligand in the 
“free,” “unbound” state is the correct bound conformation since the conformational 
diversity of the protein is limited (39).  But in the case of proteins that undergo 
significant conformation changes on associating with the ligand, it is unlikely that the 
predicted ligand plus protein complex would be the correct structure.  In the case of a 
flexible protein, like MetRS, that has a larger conformational diversity, achieving a 
correct prediction bound conformation is complicated since the bound conformation 
could be very different from the free, unbound structure.  However, the complex 
predicted with the apo enzyme should be regarded as an important “recognition mode” 
for the system, a key step in its multi-step binding process, since even at this stage of 
binding it could show some level of discrimination.  In apo-MetRS, both docking and 
perturbation analysis indicate that in this conformation the enzyme is able to eliminate 
more than 60% of the natural amino acids. One could imagine that if the final bound 
complex after the change in conformation was the only filtering mechanism for an 
enzyme, each amino acid would first have to bind at this site, followed by the structural 
change in the enzyme and then get eliminated. Such a process would be both time-
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consuming and energetically expensive for the enzyme. A first level of filter at the apo-
enzyme conformation certainly seems to be more efficient screening mechanism adopted 
by flexible enzymes. It would be interesting to see how the procedure for binding site 
search performs in other apo-enzyme systems. We have already tested it for the 
predicting the binding site of Phe in Thermus thermophillus PheRS by scanning the entire 
apo-crystal structure of PheRS and have been able to find the correct binding site 
(unpublished results). 
 
              Binding site dynamics in enzyme brings in the question of enzyme specificity. 
An interesting observation about protein plasticity is that proteins displaying higher 
selectivity are also more rigid while those that more flexible can bind to a large number 
of substrates. Considering the conformational flexibility in the MetRS, as indicated by the 
substantial structural change in the co-crystal, it is not surprising that it is one of the more 
permissive aminoacyl-tRNA synthetases. 
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Chapter 3 
 
Computational Simulations of Histidyl-tRNA 
Synthetases* 
 
                                                 
*  This chapter is adapted from a paper to be submitted to JMB. 
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Abstract 
 
Aminoacyl-tRNA synthetases play a very important role in the quality control of protein 
synthesis in vivo.  This function is achieved by the unique recognition of the cognate 
amino acid and tRNA, in some cases with the help of proofreading against similar amino 
acids.  Here we used the HierDock protocol to study the binding of 20 amino acids to two 
histidyl-tRNA synthetases from E. coli and T. thermophilus that have 3-D structures 
available.  Ligand perturbation was also conducted to compare the binding affinity in the 
reaction mode.  Both results show that histidyl-tRNA synthetases are able to differentiate 
their cognate ligand histidine from other amino acids in the binding stage.  The docked 
conformation of histidine agreed well with the ligand binding conformation in the crystal 
structures. 
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1. Introduction 
 
The selection of amino acids during protein biosynthesis is extremely precise.  
The recognition of the cognate amino acid takes place during the aminoacylation of 
tRNA, which is catalyzed by the aminoacyl-tRNA synthetases (AARSs).  This is a two-
step reaction, the amino acid first being activated by formation of aminoacyl adenylate 
and then transferred to the tRNA (1-3).  In most cases the amino acid binds to its AARS 
so strong that no competitor exists in the reaction.  However, there are cases that editing 
or proofreading mechanism is needed to guard against close competitors, such as the 
rejection of valine by isoleucyl-tRNA synthetases (4, 5).  In every case the preferential 
binding of the correct amino acid has been optimized during evolution.  The AARSs have 
binding sites that are unique to their respective amino acids.  The active site generally 
contains hydrophilic residues that stabilize the zwitterion termini of the bound amino 
acid, while other residues interact with the side chain, depending on the nature of the 
amino acid.  The specificity arises from the contacts of the side chain with the binding 
site conformation fitted for a given amino acid.  With the sufficient positioning of the 
amino acid carboxylate, the facilitated reaction with a bound ATP structure is made 
possible, giving the anticipated aminoacyl-adenylate product.   
 
Histidyl-tRNA synthetase (HisRS) belongs to the class II AARS (subgroup IIa) 
classified by their structural characteristics (6).  Its substrate, histidine is one of the two 
standard genetically coded amino acids with heterocyclic aromatic side chain.  The 
imidazole ring not only plays a role in stabilizing the structure of a protein by its aromatic 
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properties, but often has an important function in the catalytic centers of many enzymes, 
e.g., in acid-base catalysis, due to its unique pKa value of 6.00.  Enzymatic 
decarboxylation of histidine generates the biologically important compound histimine.  
HisRS was also found to be one of the antigens in autoimmune diseases such as 
rheumatic arthritis (7).  Hence structural study can help elucidate the epitopes that are 
responsible for recognition of HisRS by the autoimmune antibodies. 
 
In this paper, we used the HierDock protocol (8) to dock all the 20 natural amino 
acids into the binding site of two HisRS’s from E. coli (ecHisRS) and T. thermophilus 
(ttHisRS) that have three-dimensional structure available to date.  The result showed a 
good correlation with the fact that the binding site is optimized for histidine binding, and 
the best histidine conformations from docking are 0.47 Å  (ecHisRS) and 0.64 Å 
(ttHisRS) in rmsd from the ligands in the crystal structures.  To further simulate the 
binding mode that histidine adopts when it is activated with ATP, we perturbed the 
histidine ligand into other 19 amino acids.  The binding in this mode should allow us to 
compare the binding energies to the mischarging rate by HisRS.  The result showed far 
better binding to histidine than any other amino acids. 
 
2. Methods and Simulation Details 
 
2.1 Structure Preparation  
1HTT (resolution 2.6 Å) is a structure of the complex of ecHisRS and histidyl-
adenylate (9) and 1ADJ (resolution 2.7 Å) is a structure of ttHisRS complexed with 
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histidine (10). Both structures were downloaded from the Protein Data Bank.  In 1HTT, 
the adenylate was deleted from the structure to make the ligand as a histidine in order to 
compare with 1ADJ.  Hydrogens were added to the structures using Biograf (MSI, San 
Diego, CA), and the structures were minimized with DREIDING force field (11) and 
Surface Generalized Born (SGB) implicit solvation (12) using MPSim (13). Conjugate 
gradient minimization method was employed for 2000 steps with a termination criterion 
of less than 0.1 kcal/mol/Å in rms force.  The protein was described with CHARMM22 
(14) charges, and the ligand charge was the Mulliken charge derived from Quantum 
Mechanical calculation. 
 
 The amino acids were build in Biograf and optimized in Jaguar 4.0 (Schrödinger, 
Portland, OR) with basis set 6-31G** under Poisson-Boltzmann continuum dielectric 
solvent (15).  The electron density from molecular orbitals were fit into atom centers to 
obtain the Mulliken charges, which were used for the amino acids in force field 
calculations.  Because histidine has two possible protonation states at neutral pH, they 
were treated as two different ligands for docking.  The δ-protonated form is labeled as 
Hsd, and the ε-protonated form as Hse.  Depending on the local environment, both forms 
are commonly seen in natural proteins.  The third state, which is doubly protonated, is 
very rare at neutral pH.  Therefore, we did not consider it in docking. 
 
The binding energy for each ligand is given by 
              )()()( ligandproteinGligandGproteinGGcalc +∆−∆+∆=∆∆− .       (1) 
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Since the structure optimizations included solvation forces using the SGB continuum 
solvent approximation with the experimental dielectric constant, we consider that the 
calculated energies are free energies (16). 
 
2.2 HierDock Protocol 
The HierDock protocol has been shown to efficiently dock small ligands to 
proteins with or without the knowledge where the binding site is (8, 17).  It is based on 
DOCK 4.0 (18) and coupled with fine grain molecular mechanics technique.  It can be 
divided into three steps as follows: 
1. Mapping of possible binding regions.  A probe radius of 1.4 Å is used to trace 
a 4 dots/Å negative image of the protein molecular surface, according to 
Connolly’s method (19).  Clusters of overlapping spheres are generated from 
negative image with the SPHGEN program (18).  These spheres serve as the 
basis for the docking method. 
2. Definition of docking region.  The pockets of empty space of the receptor 
surface represented by spheres are divided into many 10 Å × 10 Å × 10 Å  
overlapping cubes, which cover the entire protein surface.  Each region is 
scanned to determine its suitability as a binding site.  The site that 
overwhelmingly contains the greatest number of lowest energy docked 
conformations is designated as the most probable binding region. 
3. Generation of docked conformations for the ligand-receptor complex.  The 
orientations of the ligand in the receptor are generated by DOCK 4.0, using 
flexible docking with torsional minimization of the ligand, a continuum 
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dielectric of 1.0 and a distance cutoff of 10 Å for the evaluation of energy.  
1000 conformations are generated and ranked according to the DOCK 4.0 
scoring function, and the top 100 structures are kept for further optimization. 
4. MPSim optimization of the complexes.  The top-ranking DOCK structures are 
then subjected to further optimization, using a more accurate full-atom 
forcefield with SGB solvation.  The first stage of gas phase optimization 
utilizes a fully flexible ligand with a fixed protein, followed by a single point 
energy calculation of the solvation using dielectric of 2.0.  A buried surface 
calculation for the ligands with a minimum threshold of 75% selects only 
those structures that are sufficiently buried within the protein. The 10 lowest 
energy conformations undergo further all-atom gas optimization with a single-
point solvation energy calculation to screen for the best binding candidate.  
5. Selection of the most probable binding site and best configurations.  The 
conformations with the lowest energy score are selected and assumed to 
demonstrate preferential binding to the region. 
6. Docking of ligand pool into the binding site.  Steps 3—5 are repeated for each 
member of the ligand pool to obtain relative binding affinities. 
7. Ranking of ligand affinities.  The relative binding energies for the best ligand 
conformations are defined as the difference between the ligand in protein 
versus in solution.  The amino acids can then be ranked according to binding 
affinities to determine which ligands have the highest affinity for the binding 
site. 
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Because the binding sites were well defined in both ecHisRS and ttHisRS, the 
binding site scanning step was skipped and only the region containing the histidine ligand 
in the crystal structure was used in further docking. 
 
2.3 Binding Energy Calculation of the 20 Natural Amino Acids in the Active 
Conformation by Ligand Perturbation  
HierDock protocol predicts the best energy conformation for each ligand (20 natural 
amino acids) in the defined binding region in HisRS structure. These predictions give rise 
to different preferred binding conformation for each ligand. But if the zwitterions part is 
positioned different from what is necessary for catalysis, the amino acid will not be 
charged to AMP even though it might bind to the protein.  So it is necessary to assess the 
relative binding energies of the twenty natural amino acids and their analogs in the 
activation mode. To generate the conformation of 20 natural amino acids in the activation 
mode we performed the following steps: 
• An amino acid rotamer library (20) was used to generate all the conformations of 
each amino acid in the binding site.  The best rotamer was chosen by matching 
each rotamer k in the binding site and evaluated with the following equation using 
the Dreiding force field: 
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where i and j sum over all atoms in the ligand and protein residue residues in the 
binding site, qi and qj are partial charges on atoms i and j, respectively.  rij is the 
distance between atoms i and j, and rm and De are van der Waals distance and well 
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depth of atoms i and j, rHB and DHB are hydrogen bond distance and well depth, 
respectively.  θ is the hydrogen bond angle between atoms i, j and their bridging 
hydrogen atom.  The hydrogen bond term is only evaluated for hydrogen bond donor 
and acceptor atoms.  To avoid over penalizing clash, the van der Waals radii were 
reduced to 90% of the standard values in the Dreiding force field.  
• After the best rotamer was chosen for each ligand, the total energy was   
minimized in the presence of protein, and the binding energy was then calculated 
using equation (1) for each of the twenty natural amino acids in the “activation 
mode” and compared.  
 
3. Results and Discussions 
 
3.1 Docking of Histidine Ligands    
The ecHisRS and ttHisRS proteins were minimized with SGB solvation using 
MPSim.  The rmsd between the crystal and minimized structures were 0.71 Å for 
ecHisRS and 0.64 Å for ttHisRS.  These values were well below the resolution of the 
crystal structures, which demonstrated that our choice with the DREIDING force field 
and CHARMM22 charges were suitable for describing proteins.  Similar results were 
obtained in other protein simulations using the same setup (17). 
 
 Two forms of histidine, δ-protonated Hsd and ε-protonated Hse, were tried to 
dock into the binding site of ecHisRS and ttHisRS.  It turned out that Hse was the form of 
choice in both cases.  The hydrogen bonding network analysis on the crystal structures 
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using WHATCHECK (21) gave the same result.  Figure 1 showed the interaction 
between Hse ligand and the protein in the binding sites for (a) ecHisRS and (b) ttHisRS.  
The rmsd for the docked Hse and the ligand in the crystal structures was 0.47 Å for 
ecHisRS and 0.28 Å for ttHisRS.  The calculated binding energy to ecHisRS was 81.6 
kcal/mol for the docked Hse, compared to 92.4 kcal/mol for the ligand in the crystal 
structure.  For ttHisRS, it was 73.5 kcal/mol for the docked Hse versus 69.6 kcal/mol for 
the crystal ligand.  Table 1 listed all the hydrogen bond interactions and the distances 
between the docked Hse and the protein in comparison with the crystal structure.   
 
 
 Figure 1. (a)  Interactions between the ligand Hse and ecHisRS in the binding site 
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Figure 1. (b) Interactions between the ligand Hse and ttHisRS in the binding site 
 
3.2 Docking of all other 19 natural amino acids  
Using the same HierDock protocol, all other 19 natural amino acids were docked 
into the histidine binding sites of ecHisRS and ttHisRS.  Figure 2 showed the binding 
energies of these docked amino acids along with Hse and Hsd.  These results suggest that 
both ecHisRS and ttHisRS have a binding site optimal for Hse binding, because none of 
the natural amino acids has a binding energy close to Hse.  This is consistent with our 
current understanding of HisRS’s.  None of the HisRS’s known to date has shown any 
editing mechanism.    
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Table 1.  The hydrogen bond interactions between the Hse ligand and HisRS from 
docking comparing to crystal structures. The distances in ( ) for the crystal structures are 
from the structures minimized with force field. 
Ligand Atom Protein Atom 
(ecHisRS) 
Distance in docked 
structure (Å) 
Distance in crystal 
structure (Å) 
Nδ Tyr32 Oη 2.87 2.70 (2.89) 
Nε Glu131 Oε1 3.13 2.78 (3.31) 
N Glu83 Oε1 2.72 2.95 (2.64) 
N Tyr263 Oη 2.92 3.32 (3.09) 
N Water  O 3.16 2.62 (3.64) 
O Arg113 Nη2 3.15 3.84 (3.45) 
O Gln127 Nε2 2.88 3.43 (2.93) 
OXT Arg259 Nη2 2.83 3.16 (2.87) 
Ligand Atom Protein Atom 
(ttHisRS) 
Distance in docked 
structure (Å) 
Distance in crystal 
structure (Å) 
Nδ Tyr264 Oη 2.89 2.57 (2.91) 
Nε Glu130 Oε1 2.82 2.68 (2.82) 
N Thr83 Oγ1 2.91 2.63 (2.91) 
N Tyr263 Oη 3.69 2.67 (3.68) 
N Asn Oδ1 3.11 2.98 (3.00) 
O Arg112 Nη2 4.12* 4.82 (3.96)* 
O Gln126 Nε2 2.78 3.91 (2.90) 
OXT Arg259 Nη2 2.89 3.65 (2.87) 
 * Water mediated hydrogen bond 
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a) 
 
b) 
 
Figure 2.  Binding free energies of all 20 docked amino acids to (a) ecHisRS and (b) 
ttHisRS. 
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a) 
 
b) 
 
Figure 3.  Binding free energies of all 20 amino acids to (a) ecHisRS and (b) 
ttHisRS by perturbing the crystal Hse ligand. 
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3.3 Perturbation of Hse in the binding site   
Because only the binding mode that places the zwitterions of the other 19 amino 
acids the same position as histidine binding can lead to misactivation, it is useful to look 
at the competitive binding of all amino acids in that binding mode.  This binding can be 
simulated with amino acid perturbation in the binding site, in which the zwitterions are 
fixed, and the side chain is mutated into other resides.  Figure 3 showed the binding 
energies of all 20 amino acids to (a) ecHisRS and (b) ttHisRS from perturbation.  In the 
case of ecHisRS, there is no real competition from other amino acids, while Asn and Thr 
stand out from the rest.  For ttHisRS, Asn seems to be a strong competitor.  Figure 4 
shows the overlaid Asn and Hse in the activation binding mode.  The COO- moiety of 
Asn is slightly further (0.4 Å) into the binding site than Hse.  Because the aminoacylation 
reaction requires the COO- moiety positioned exactly, Asn will be less effective in 
misactivation. 
 
 
 
Figure 4.  Comparison between Hse and Asn in the activation binding mode.  
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4. Conclusions 
 
We have used the HierDock protocol to successfully predict the binding site and 
binding modes of histidine in ecHisRS and ttHisRS.  The rmsd of between the docked 
Hse ligand and the crystal structure Hse ligand is 0.47 Å  for ecHisRS and 0.64 Å for 
ttHisRS.  Other 19 natural amino acids have also been docked into the binding site of 
HisRS’s, and the result shows that Hse binds to HisRS significantly tighter than any other 
natural occurring amino acids in both ecHisRS and ttHisRS.   
 
Ligand perturbation from Hse has also been performed to calculate the binding 
energies of 20 amino acids in the activation mode for aminoacylation.  These results also 
show that there is almost no competition from other amino acids in binding to HisRS’s.  
These results are consistent with our current understanding that HisRS’s use ligand 
binding as the sole mechanism in amino acid selection. 
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and Fluorinated Analogs by Isoleucyl-tRNA Synthetase 
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Abstract 
 
Protein biosynthesis has an unmatched accuracy and aminoacyl-tRNA synthetases 
are responsible for the recognition fidelity to large extent.  It has been demonstrated in 
lab that some non-natural amino acids can be incorporated using the wild-type apparatus 
of in vivo protein synthesis.  Recently, two tri-fluorinated isoleucines were tested using 
the wild-type tRNAIle:IleRS apparatus to make proteins containing fluorinated non-
natural amino acids.  But only one tri-fluorinated isoleucine was incorporated 
successfully. 
 
 In this paper, we simulated the binding of isoleucine and three fluorinated 
isoleucine analogs to isoleucyl-tRNA synthetase under surface generalized Born 
continuum electrostatic solvent.  We found that while all three analogs have van der 
Waals clash with the binding site, the clash is less severe for the γ-tri-fluorinated Ile.  The 
result showed that the δ1-tri-fluorinated Ile analog binds IleRS 7.4 kcal/mol less than Ile, 
while the γ2-tri-fluorinated Ile analog binds 1.8 kcal/mol less than Ile.  This is consistent 
with the experimental result.  A third analog, the hexa-flurinated Ile, which has not been 
experimentally tested, showed slightly better binding affinity than the γ2-tri-fluorinated 
Ile.  We performed a component analysis to show that the γ2-methyl binding region in 
IleRS is slightly bigger and more adaptive to bigger binding group than the δ1-methyl 
binding region.  Furthermore, it facilitates a bigger binding region for the δ1-methyl 
group. Solvation is another factor against the binding of the δ1-tri-fluorinated Ile analog.  
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The δ1-methyl binding region is more polar than the γ2-methyl binding region.  As a 
result, the more hydrophobic CF3 group goes to the γ2-methyl binding region easier than 
the δ-methyl binding region. 
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1. Introduction 
 
Protein biosynthesis is a precisely controlled mechanism.  It has been known for a 
long time that aminoacyl-tRNA synthetases (AARSs) are responsible for the accurate 
recognition of cognate amino acid-tRNA pairs.  There is also a recognition process for 
codon-anticodon match up in the ribosome, but the mechanism is rather straightforward.  
On the other hand, AARSs achieve the selection by a multiple step process, including the 
binding selection and pre- and post-transfer “proofreading” mechanisms (1).  There are 
up to four steps involved in the selection (2): 
 
(1) Binding of amino acid and ATP 
(2) Conformational change in the AARS induced by binding and formation of 
aminoacyl-adenylate complex. 
(3) Proofreading of misactivated non-cognate aminoacyl adenylate complex 
(4) Transfer of aminoacyl to the 3’ end of the tRNA and proofreading 
However, not every AARS use all four steps for amino acid selection. 
 
 Isoleucyl-tRNA synthetase (IleRS) is one of the first AARSs that have been 
known to have a proofreading or editing mechanism in guarding against misactivation of 
non-cognate amino acids (3).  The term “double sieving” illustrates the way that IleRS 
selects isoleucine (Ile) over other natural amino acids (4).  In the binding step 1 IleRS 
rejects any amino acid that has a larger side chain than Ile.  In the proofreading step 3 
IleRS hydrolyzes any aminoacyl adenylate complex with a side chain smaller than Ile, 
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such as Val, Ala, etc. (5).  The proofreading requires the presence of tRNAIle in the 
binding site in order to transfer the intermediate product to the proofreading site (6). 
 
 Protein biosynthesis has many advantages over the traditional polymer synthesis, 
such as well-defined chain length, sequence and fold.  There have been a lot of efforts 
trying to use in vivo protein synthesis to make proteins containing non-natural amino 
acids (7-20).  Recently the Tirrell lab at Caltech tried to incorporate two tri-fluorinated Ile 
analogs to protein in vivo using IleRS.  By analyzing the products they found that only 
one of the analogs was incorporated while the other was not.  Because the proofreading 
mechanism is to hydrolyze aminoacyl adenylate that has a smaller side chain than Ile, it is 
not expected to hydrolyze any fluorinated aminoacyl adenylate formed due to the bulkier 
size of the CF3 group than CH3.  There is much evidence that showed that once a non-
natural amino acid is charged into an tRNA, it almost certainly will be put into a protein 
in the ribosome (21).  Therefore, the initial binding step seems to be the only step to 
govern the selection here. 
 
 Computer simulation offers a great opportunity in understanding the selection of 
ligand binding in the molecular level.  The crystal structure of E. coli IleRS co-
crystallized with Ile in the binding site has been solved at a resolution of 2.7 Å (Cusack, 
personal communications).  This can be used as a starting structure in simulation and the 
analogs can be perturbed from Ile easily.  Molecular dynamics simulations can provide a 
good binding free energy change when the change in ligands is small.  Also models based 
on continuum electrostatics can often provide semi-quantitative binding free energies 
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(22).  Another important advantage computer simulations offer is that the overall binding 
free energy can be easily decomposed into different components.  This can be valuable 
information when manipulating the activity of AARSs by mutation or protein engineering 
as well as understanding the selection mechanism (23). 
 
 In this paper, we present the results of simulating the binding of Ile and three 
fluorinated Ile analogs to IleRS using the surface generalized Born (SGB) continuum 
electrostatic solvation model (24).  SGB is a good approximation to the Poisson-
Boltzmann (PB) continuum solvation model, and is significantly faster than PB.  The 
result showed that the δ1-tri-fluorinated Ile analog (Idf) binds IleRS 0.3 kcal/mol less than 
Ile, while the γ2-tri-fluorinated Ile analog (Igf) binds 4.5 kcal/mol less than Ile.  This is 
consistent with the experimental result that Idf was incorporated, while Igf was not.  We 
performed a component analysis to show that the δ1-methyl binding region in IleRS is 
slightly bigger and more adaptive to bigger binding group than the γ2-methyl binding 
region.  Val, known to be misactivated by IleRS and subsequently edited out by the 
proofreading mechanism, and hexa-fluorinated Ile analog (Ihf) have also been simulated. 
 
2. Methods and Simulation Details 
 
 The crystal structure of IleRS from E. coli co-crystallized with Ile in the binding 
site was obtained from Prof. Cusack.  Hydrogens were added to the structure using 
Biograf (Molecular Simulations, San Diego, CA).  The structure was first annealed with 
heavy atoms fixed to optimize the hydrogen bonds of the structure.  The structure was 
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then minimized using conjugate gradient method for 2000 steps under SGB continuum 
solvation using MPSim (25).  Cell multiple method (26) was used to calculate the 
nonbond interactions.  Dreiding force field (27) was used in energy expression.  Protein 
was described with CHARMM22 (28) charges.  The charges for Ile and Ile analogs were 
Mulliken charges by fitting the molecular orbitals to atom centers in quantum mechanics.  
Jaguar 4.0 (Schrödinger, Portland, OR) was used to run the calculation with 6-31G** 
basis set under Poisson-Boltzmann continuum dielectric solvent (29).  The optimized 
IleRS-Ile complex showed a rmsd of 0.30 Å from the original crystal structure.   
 
 The Ile ligand was taken out and mutated into three fluorinated Ile analogs 
(Figure 1).  An annealing dynamics was performed on each analog to find the best 
conformation of the side chain in the binding site of IleRS.  The free energy of each 
ligand complexed with IleRS was calculated by minimizing the complex under SGB 
continuum electrostatic solvent.  A dielectric constant of 2 for protein, and 78.2 for 
solvent was used in the simulations.  The probe radius of solvent was 1.4 Å.  The free 
energy of the ligand and IleRS alone were also calculated this way, and the binding free 
energy was calculated using 
)()()( ligandproteinGligandGproteinGGbinding +∆−∆+∆=∆∆− .  (1) 
 
Generally the free energy calculated this way omits the entropy contributions 
from translations and rotations, so they can only be compared relative to different ligands 
(22, 30).  Nonetheless, the differential value between these binding free energies can be 
compared to experimental values. 
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 Figure 1.  Structure of Ile and three fluorinated analogs used in this simulation. 
 
 A component analysis was performed as previously described (23).  It is the same 
technique in principle as in reference (22).  The following equation was used to calculate 
the interaction energy between the ligand and residue k in the binding site: 
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where i and j sum over all atoms in the ligand and protein residue k in the binding site, qi 
and qj are partial charges on atoms i and j, respectively.  rij is the distance between atoms 
i and j, and rm and De are van der Waals distance and well depth of atoms i and j, rHB and 
DHB are hydrogen bond distance and well depth, respectively.  θ is the hydrogen bond 
angle between atoms i, j and their bridging hydrogen atom.  The hydrogen bond term is 
only evaluated for hydrogen bond donor and acceptor atoms.   
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3. Results and Discussions 
 
 The binding free energies of Ile, Val, and three fluorinated Ile analogs (Idf, Igf, 
and Ihf, see Figure 1) to IleRS were calculated under SGB continuum electrostatic 
solvent.  The contributions from each free energy component (valence, vdW, coulomb, 
hydrogen bond and solvation) were also calculated using Equation 1.  These results were 
plotted in Figure 2.  Please note that the nonbond (NB) energy is the sum of vdW and 
Coulomb energy. 
 
 It is apparent from Figure 2 b that there are three major differences in binding free 
energy components: Coulomb, vdW and solvation energies.  In the case of Idf, vdW and 
Coulomb interactions play different roles.  Coulomb energy favors the binding of Idf, 
while vdW disfavors it.  These two interactions cancel out, as a result there is no net 
contribution from NB energy.  Other energies seem to cancel out as well for Idf.  
Therefore, the total binding energy of Idf is almost the same as Ile.  For Igf, both 
Coulomb and vdW interactions disfavor Igf, leading to a NB energy of 13 kcal/mol worse 
than Ile.  Although solvation favors Igf binding, it is not enough to offset the NB energy.  
As a result, Igf is the worst binding ligand among the five ligands we studied here.   
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a) 
 
b) 
 
Figure 2.  (a) The binding energies of Ile, Val, and three fluorinated Ile analogs 
to IleRS decomposed into components.  (b) Same as in (a), but relative to Ile. 
 
A third hexa-fluorinated Ile analog Ihf, which has not been tested experimentally 
due to difficulty in synthesis, shows a binding energy between Idf and Igf.  Although the 
vdW energy strongly disfavors Ihf, the Coulomb energy only slightly disfavors it.  The 
valence part in the binding, which is the response to the vdW clash in the binding site, 
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favors Ihf binding by 4 kcal/mol compared to Ile.  As expected, Ihf is more hydrophobic 
than Ile, leading to a favorable solvation contribution than Ile by 5.5 kcal/mol.  Ihf is a 
case we are trying to predict, and it is useful to compare it with Val.  It has been known 
that Val binds IleRS 200 times weaker than Ile, and it translates into 3 kcal/mol binding 
energy difference between Ile and Val (31).  This is in agreement with our result here.  
But Val is also known to be misactivated by IleRS, and Ihf shows 1 kcal/mol better than 
Val, therefore we predict that Ihf WILL be incorporated by IleRS in vivo.   
 
A component analysis was also performed using Equation 2 to compare the 
contributions from each individual residue in the binding site (Figure 3a-d).  Figure 3 a 
shows the vdW contributions from each residue with 5 Å of Ile in binding each ligand 
compared to Ile.  Residues G45 and Q554 show strong clash with Idf, but other residues 
such as P46, P47, E550 and W558 actually compensates part of the clash by having 
favorable interaction with Idf.  Please note that these interactions are with the ligand 
directly and it does not consider the propagation of the clash into protein-protein 
interaction, thus they don’t add up to the value in Figure 2 b.  But they should be 
proportional to each other.  For Igf, the clashes are with different residues, because the 
CF3 is on different binding region from Idf.  There are four residues that show severe 
clash with Igf, and they are P46, W518, S521, and W558.  G45, D85 and Q554 have 
favorable vdW interaction with Igf.  It is an interesting observation that most of the clash 
and favorable interaction residues are complimentary between Idf and Igf (Figure 3 a).  
For most residues, the vdW interaction with Ihf is just the addition of Igf and Idf.  For 
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Val, the unfavorable vdW is from not making some of the contacts with protein due to 
the lack of a CH2 group compared to Ile. 
a) 
 
b) 
 
Figure 3. The component analysis for each residue in the binding site with ligands 
compared to Ile. (a) vdW interaction. (b) Coulomb interaction. 
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For Coulomb interactions with Idf, E550 strongly disfavors Idf by almost 4 
kcal/mol compared to Ile, but it is compensated by favorable interactions with P46, K64, 
D85 and Q554.  The net contribution from Coulomb interaction is favorable for Idf 
binding.  This is consistent with the conclusion we drew from Figure 2 b.  For Igf, there 
is no dominating Coulomb interaction from a single residues, but it seems that there are 
more residues with unfavorable interactions (K64, D85, R391, S521, Q554 and W558) 
than residues with favorable interactions (P46 and E550 only).  Again, the Coulomb 
energies for Ihf can be obtained by the addition of Idf and Igf.  And the complementary 
rule holds for most residues except P46, which has favorable interactions for both Idf and 
Igf.  As a result of the addition, Ihf is strongly favored by the Coulomb interaction with 
P46.  This can be explained by the fact that P46 is located close to the Cβ atom of the 
ligands.  The electron withdrawing effect of CF3 leaves the Cβ with more positive charges 
in all three cases, and is favored by the oxygen atom of the main chain carbonyl group of 
P46.  For Val, there is very little change in the Coulomb interactions compared to Ile. 
 
 The hydrogen bonding interactions show very little change in all four ligands 
compared to Ile (Figure 3 c).  This implies that the zwitterions of all different ligands 
position equally well, and the interactions with protein are strong (Figure 2 a).  It also 
eases the concern that the binding mode might be different for some of the ligands, 
therefore these ligands might not be activated even though they have a good binding 
energy with protein. 
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c)
 
 d) 
 
Figure 3. The component analysis for each residue in the binding site with ligands 
compared to Ile. (c) Hydrogen bond (HB) interactions.  (d) Nonbond (NB) interactions.  
Here NB interactions include vdW, Coulomb and HB interactions. 
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Figure 3(d) show the total nonbond interactions as a whole for each residue in the 
binding site of IleRS with all ligands compared to Ile.  The purpose is to find which 
residues are important in differentiating the binding of each ligands.  And this 
information is very useful when it comes to design of an optimal mutant IleRS for non-
cognate ligand binding.  Coulomb energies dominate the nonbond interactions for most 
important residues in the binding site.  This is true for E44, K64, D85, R391, and E550, 
as they are all charged residues.  Other important residues, such as G45, P46, V517, 
W518, S521, Q554, and W558 have comparable contributions from both vdW and 
Coulomb energies.  Comparing between Idf and Igf, P46, P47, K64, D85, S521, and 
W558 are the residues favoring Idf over Igf in binding to IleRS, while E44, G45, and 
E550 are the residues favoring Igf.  The overall effect is that there are more residues 
favoring Idf binding and larger favorable energy interactions for Idf than Igf.  As a result, 
Idf can be incorporated into proteins using IleRS in vivo, and Igf cannot.  Again, for Ihf, 
four residues P46, T48, K64, and D85 favor Ihf binding, and E44, R391, W518, S521, 
E550, and W558 disfavor Ihf.  The overall effect for Ihf is that it is much less favored 
than Ile and Idf, but slightly more favorable than Val, and more favorable than Igf.  Using 
Val as a reference, which is known to be able to bind to IleRS, Ihf seems to be able to 
bind to IleRS as well. 
 
4. Conclusions 
 
 We have simulated the binding of Ile, Val, and three fluorinated Ile analogs to 
IleRS.  Component analysis was performed on each system to elucidate the contributions 
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from each residue in the binding site.  The overall binding order is Ile > Idf > Ihf > Val > 
Igf.  Using Val as a reference, both Idf and Ihf are better binders, and Igf is a worse 
binder than Val.  Component analysis shows that Coulomb, VdW, and solvation energies 
are the main energy components in the difference.  And Coulomb interaction seems to 
dominate the overall energy interactions with some charged residues in the binding site. 
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Chapter 5 
The COP Protein Design Tool*  
                                                 
* This chapter is adapted from the provisional patent application “The COP Protein 
Design Tool,” filed at Caltech on April 12, 2002. 
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1. Introduction 
 
Proteins are synthesized with precise control over sequence, leading to the vast 
range of specific structures and functional properties observed in nature.  Even so the 
monomer pool for proteins is limited to the 20 natural amino acids.  Increasing the 
monomer pool by incorporating new amino acid analogs would allow development of 
fascinating new bioderived polymers exhibiting novel but well-controlled architectures 
(1, 2).  This could lead to many interesting applications including incorporating a 
fluorescence probe to elucidate specifics of protein structure and function (3) and 
incorporating selenium-substituted serine to facilitate crystallization processes in proteins 
(4).  
 
The in vivo incorporation of amino acid analogs into proteins is controlled in large 
measure by aminoacyl-tRNA synthetases (AARSs), the class of enzymes that safeguards 
the fidelity of amino acid incorporation into proteins.  It has been demonstrated that the 
wild-type translational apparatus can be used to incorporate some amino acid analogs into 
protein (5-11).  However, the number of amino acid analogs incorporated in proteins in 
vivo is small, and the functionalities of these analogs have been limited.  To expand the 
range of amino acid analogs that can be incorporated in vivo, it is desirable to manipulate 
the activity of the AARSs (12, 13).  There has been steady progress in developing the 
twenty-first AARS-suppressor tRNA pairs in vivo (14, 15).  The biggest success is the 
design of a novel orthogonal tRNA and tyrosyl-tRNA synthetase (TyrRS) [from 
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Methanococcus jannaschii tyrosyl tRNA synthetase (hereafter denoted as M.jann-
TyrRS)] that incorporates O-methyl L-tyrosine (OMe-Tyr) site-specifically in protein in 
response to an amber nonsense codon (16). Such procedures have tremendous potential to 
expand the genetic codes in living cells, but the current combinatorial experiments, which 
considered 520 mutation trials on five residues expected to be at the binding site of the 
tyrosine ligand, can become cumbersome.   
 
In this chapter, we describe the Clash Opportunity Progressive (COP) design that 
can computationally design a mutant protein that would preferentially bind an analog 
ligand over the natural ligand occurring in the wild type protein binding.  The method has 
been applied to design a series of mutant tyrosyl-tRNA synthetase (TyrRS), 
phenylalanyl-tRNA synthetase (PheRS), and tryptophanyl-tRNA synthetase (TrpRS) for 
various non-natural amino acids. Chapters 6, 7 and 8 will present these results. 
 
2. Methods  
 
The Clash Opportunity Progressive (COP) procedure is a structure-based rational 
redesign of a binding site.  Given a protein structure with its binding site for the wild-type 
ligand, the redesigned protein or mutant will specifically bind an analog of the wild-type 
ligand.  This procedure is useful in predicting which mutations in the binding site are 
essential for preferential binding to a specific ligand.  We demonstrate the design strategy 
by designing AARS mutants that activate a specific amino acid analog preferentially 
compared to all natural amino acids.  Our design goal is for the mutant protein to 
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preferentially bind the target amino acid analog versus the wild type ligand (and any 
other natural amino acid). To do this we calculate the differential binding energy of the 
desired analog against any other potential competitor ligand that might bind selectively to 
the mutant. For example, in redesigning TyrRS, we calculate the differential binding 
energy of the analog against Tyr and Phe.  For cases in which the analog is much larger 
than Tyr, we might consider Trp as a potential competitor for the redesigned mutant 
AARS.  The COP design procedure for designing mutant AARS comprises the 
progressive sequence of steps (Figure 1): 
 
 
 
Figure 1.  The flowchart of COP.  Each step is color-coded. 
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Step 0: Conformation determination.  
We first determine the favorable conformations of the analog.  These can be 
generated the various rotamers of the ligand over a grid of dihedral angles and calculated 
their energies in solution using QM (alternatively, this can be carried out using a force 
field with molecular mechanics).   
 
In building the analogs, we want to preserve the binding site as much as possible, 
which means the zwitterions for non-natural amino acids will always be conserved.  Only 
binding site for the side chain is redesigned.  This is important because the AARS binds 
not only the amino acid, but also ATP and the cognate tRNA (17).  These binding events 
need to be in the exact position in order for the AARS to catalyze the reaction (18).   
Sometimes the analog is much bigger than the wild-type ligand, which is true for many 
non-natural amino acids with interesting properties, we might need to find an optimal 
orientation for the side chain of the analogs.  In Chapter 8, we will describe how to 
generate such conformations for the analogs.  
 
Step 1: Clash identification.   
The low energy rotamers from Step 0 are then docked into the binding site.  To do 
this the natural amino acid in the binding pocket is replaced with the energetically 
favorable rotamers of the analog while keeping the backbone of the ligand fixed (in order 
that the reaction center for the formation of the aminoacyl–AMP complex would be 
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retained for the analog).  Then the analog rotamer is matched onto the binding site and 
the non-bond energy contributions (Ek) are calculated for each residue k in the binding 
pocket. These calculations can use any reliable force field or can use quantum mechanics.  
In our illustrations, we use Equation 1 [the functional forms for these Coulomb, van der 
Waals, and hydrogen bond non-bond interactions are from the DREIDING force field 
(19)]:  
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where i and j sum over all atoms in the ligand and protein residue k, of interest, qi and qj 
are partial charges on atoms i and j, respectively. rij is the distance between atoms i and j, 
and rm and De are van der Waals distance and well depth of atoms i and j, rHB and DHB are 
hydrogen bond distance and well depth, respectively.  θ is the hydrogen bond angle 
between atoms i, j and their bridging hydrogen atom.  Please note that the hydrogen bond 
term is only evaluated for hydrogen bond pair atoms.  When there is no bridging 
hydrogen atom for i and j, the hydrogen bond term is turned off. In principle any 
functional form from any forcefield can be used for this component analysis.  
 
Those residues in the wild-type protein having bad clashes with the analog are 
marked for mutation.  Because the protein backbone is fixed in Step 2, we require that the 
analog rotamer should not clash with the backbone of the protein.  Analog rotamers 
having a severe clash with the protein backbone are discarded.  Table 3 in Chapter 6 
shows an example of the bad clashes of the analog in the wild-type protein.  
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 Step 2.  Relieving clashes with point mutations.  
Those residues having bad clashes with the analog are mutated sequentially to all 
the other 19 amino acids.  These point mutations use conformations that can be generated 
over a grid of dihedral angles or by using side chain rotamer libraries (20).  The backbone 
of the protein is held fixed in this stage.  After each point mutation the side chain alone is 
optimized while keeping the rest of the protein fixed.  This optimization can be by energy 
minimization (used in our example) and can be using Molecular Dynamics or Monte 
Carlo techniques.  This optimization is important because the initial side chain placement 
may not be optimal, leading to local bad contacts that might give misleading indications 
of the viability of this specific conformation.  Then we calculate the contribution from 
this mutated side chain to the binding energy of both the analog and the wild-type amino 
acid using, for example, Equation 2.  Also the clashes of this mutated residue with 
neighboring residues in the protein are calculated.  The best mutations are selected using 
a scoring energy function consisting of a weighted sum of the differential non-bond 
interaction energy of the mutated residue with the ligand and the analog, and the non-
bond interaction energy of the mutated residue with the rest of the residues in the protein.  
We find that weights of 0.75 to 1.0 for ligand-protein interaction, and 0.0 to 0.25 for 
protein-protein interactions are useful.  Since the energy cost of desolvating an amino 
acid to place it in the binding pocket of a protein can be important in some systems, we 
also add desolvation penalty to the energy of the mutated residue.  The desolvation 
penalty can be calculated using any of a variety of methods (including SGB (21), AVGB 
(Zamanakos et al., unpublished result), Poisson-Boltzmann (22) solvation method). Here 
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we calculate the differential binding energies for all twenty possible amino acid 
mutations, as shown in Table 4 in Chapter 6.  This procedure is repeated for all the 
residues showing a clash in the binding pocket of the analog (Step 1).  The mutation 
candidates for further consideration are selected based on the scoring energy between the 
analog and the natural ligand. Here we consider both mutations that favor binding of the 
analog ligand and ones that disfavor the natural ligand.  Based on this differential scoring 
we select a subset of amino acids for each residue that will be used later for simultaneous 
combinatorial mutations at each clash site (from Step 1).  
 
Step 3.  Stabilizing point mutations (opportunities).  
After identifying candidate mutation for relieving clashes, we look for 
opportunities for mutations in the binding pocket that would stabilize the analog ligand or 
disrupt the bonding with the natural ligand.  Thus we consider residues near the ligand (in 
our example we used a cutoff of 6 Å) and look for residues that might take advantage, for 
example, of hydrogen bond donor or acceptor atoms that are different between the analog 
and the natural ligand.  Another strategy for doing this is to calculate the void space in the 
binding pocket after making the clash mutations and consider any residue close to a large 
void as a candidate for a stabilizing point mutation.  These opportunity mutations are 
selected with the same procedure as for clash mutations.  It is important to include the 
original choice for the opportunity mutations to compare the effect of opportunity part in 
the final mutants generated by combined mutations in Step 4. 
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Step 4.  Combined mutations.  
Steps 2 and 3 lead to a subset of mutation candidates that are expected to either 
relieve clashes or provide stabilization opportunities to the binding of the analog in 
preference to the wild type ligand.  In Step 4 we generate simultaneous mutations from 
each of the chosen subsets of mutations.  For example, if the clash analysis (Step 2) leads 
to 3 residues with 2, 3 and 4 candidates and the opportunity analysis leads to one residue 
with 5 possible mutation candidates (say for making hydrogen bonds with the analog), 
then we would consider 2 × 3 × 4 × 5=120 possible protein mutants.  In Step 4 we 
generate the best possible rotamer combination for each of these 120 mutant proteins 
(here we optimize the side chains, for example, using conjugate gradient minimization).  
Then after selecting optimum side chains for all 120 cases, the structure of the whole 
mutant protein is optimized both with the natural ligand and with the analog.  This 
optimization can be by energy minimization (used in our example) and can be using 
Molecular Dynamics or Monte Carlo techniques.  Before doing the optimization we first 
re-examine the residues near any of the mutated residues to determine the optimum side 
chain conformation.  Finally the differential binding energy of the analog to the natural 
amino acid in the mutant is calculated.  These calculations can use any reliable force field 
or can use quantum mechanics.  In our illustrations we use Equation 2 with DREIDING 
force field and including SGB solvation. 
  )()()( ligandproteinGligandGproteinGG +∆−∆+∆=∆∆−                      (2) 
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Step 5.  Relaxation of the free mutant protein without the ligand.  
In Step 4 we considered mutations and side chain conformations that enhance 
binding of the protein to the analog.  However, it is possible that some mutations would 
disrupt the folding of the free protein when the ligand is not present.  Thus for the best 
mutants selected from Step 4, we re-optimize the side chains without the ligand in the 
binding site.  This allows the side chain of each mutation to go into the part of the 
binding site normally occupied by the ligand.  In this step we first reselect the side chain 
conformation from the side chain library and then optimize the structure of the full 
protein using the including solvation (for example, SGB continuum solvent procedure).  
In these calculations we might include explicit water in the active site to better represent 
the stability of the active site without ligand.  Once the mutant structure is optimized 
without ligand, the ligand is then matched on to the binding site and the potential energy 
of the resulting structure is minimized using for example SGB solvation.  This is done for 
both the analog and the natural ligand (and any other ligands that might bind to the 
mutated site).  For the analog ligand this will generally lead to a weaker binding energy 
than Step 4, because we now include the penalty paid to push the side chains away from 
the binding site as the ligand binds.  However, the natural ligand may have a stronger 
binding energy for Step 5.  Thus the differential binding energy in Step 5 will generally 
be smaller than in Step 4.  We denote this differential binding energy as the “relaxed 
protein binding energy,” since the mutants were optimized with no ligand in the binding 
pocket.  The binding energy is defined the same as in Equation 2.  
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Step 6.  Mutant Selection.  
From Steps 4 and 5 we select candidate mutants with good binding energies to the 
analog both for the relaxed protein (Step 5) and from Step 4 and which have high 
differential binding energies to the natural amino acid.  While redesigning AARS for 
binding to a specific analog, it is important that the mutant AARS activates only the 
analog and not any other natural amino acid.  Thus the best candidate mutants are tested 
further for binding to other natural amino acids.  To do this we dock likely natural amino 
acid competitors into both the relaxed and optimized binding sites, using the procedures 
described in Step 1.  The binding energy is calculated for each ligand/mutant pair.  The 
mutants are finally ranked by the difference in binding energies between the analog and 
its competitors.  The better binding energy is taken either from the relaxed or the 
optimized mutant cases. 
 
There is a possibility that the designed mutant protein might not be able to fold 
correctly. For example, if there is charged residue placed in the protein core without 
favorable local stabilizing interactions, it is a strong destabilizing force.  In order to detect 
such cases in post design, we use a consensus method to evaluate the interactions for each 
residue involved in the design.  The consensus is from all the AARS structures our group 
has worked on in the last couple of years.  These AARSs include TyrRS (PDB: 2ts1, 
3ts1, 4ts1), PheRS (PDB: 1b70), SerRS (PDB: 1ses, 1set, 1sry, 1fyf), ArgRS (PDB: 
1bs2), MetRS( PDB: 1f4l), HisRS (PDB: 1adj, 1hht).  Table 1 lists the energies for each 
amino acid from the consensus: 
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Table 1.  Interactions energies of each amino acid in crystal structures of AARSs.  These 
values are used to decide if an amino acid is in an unfavorable position. 
Residue 
Average Energy 
(kcal/mol) 
Standard Deviation 
(kcal/mol) 
Ala -1.893 3.654 
Arg -108.953 40.459 
Asn -28.324 9.948 
Asp -48.155 14.464 
Cys -4.297 3.145 
Gln -23.980 7.071 
Glu -44.910 11.809 
Gly -2.857 3.652 
His -6.088 6.505 
Ile 3.522 5.380 
Leu 1.613 5.037 
Lys -43.560 10.184 
Met -2.067 4.624 
Phe 6.536 6.326 
Pro 8.183 6.653 
Ser -6.136 5.444 
Thr -6.364 5.733 
Trp 16.568 7.371 
Tyr 0.960 5.725 
Val 1.578 4.564 
 
 
In a case where a residue has lower interaction energy with its neighboring 
residues, a warning message will be given with a stability score of the residue.  The score 
is defined by the energy difference divided by the standard deviation.  A score higher 
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than 2 generally means the residue is in a very unfavorable position, i.e., it is not making 
enough interactions with other residues to stabilize the fold. 
 
Steps 1 to 6 are repeated for other low energy rotamers of the analog from Step 0. 
3. Advantages and Improvements over Existing Methods 
 
Existing computational protein design methods focus mainly on design of protein 
core, i.e., the packing effect of various protein side chains combinatorially. Such methods 
use different algorithms to tackle the combinatorial nature of side chain packing, such as 
dead-end-elimination, branch-and-bound, Monte Carlo and genetic algorithms. Some 
methods were also extended to include surface residues. Nonetheless, these methods 
almost exclusively design for a certain protein fold, i.e., replacing many residues to 
achieve better protein stability while maintaining the original fold. Since these methods 
are focused on design of a whole protein, computational efficiency required very crude 
energy evaluators.  In addition, these existing design methods have one or more of the 
following drawbacks: 
 
1. Partial force field, which cannot describe proteins accurately. 
2. Energy function is not complete. 
3. Solvation is often empirical, if present at all. 
4. Backbone fixed all the time. 
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On the other hand, the purpose of the COP method is to make the minimum 
number of rational structure based mutations (we understand that 5 is practicallly a 
maximum) in a protein so that the protein binds preferentially to the desired ligand 
compared to the native ligand. The COP method uses the principle minimum change 
design, which focuses on mutation of residues in the binding site.  There may be 
circumstances in which it is appropriate to modify residues outside of the active site. This 
simplifies the problem greatly, because the number of residues involved is typically much 
less than the number of residues involved in a protein core design.  In addition, the 
residues required to do mutation are often distant, hence no combinatorial side chain 
placement problem exists.  Other advantages in the COP design methods include the 
following: 
 
• COP can use any force field valid for both protein and ligand (particularly 
valuable here are generic force fields such as DREIDING or UFF that are 
valid for a large part of the periodic table) and it can use quantum mechanics 
for the region of the active site.  
 
• COP uses a complete nonbond energy function such as in Equation 1.  This 
function includes (Coulomb) electrostatic interactions (which may be describe 
as point charges as in Equation 1 or maybe described as distributed charges as 
in Qeq (23) or ReaxFF (24)), nonelectrostatic nonbond interaction (referred to 
as van der Waals) which may be described by a 6-12 Lennard-Jones potential 
(or Morse form or exponential six), and an explicit hydrogen bond potential 
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(which may be described by a radial potential (e.g., 10-12 Lennard-Jones) and 
may use a three-body cosine angle term as in Equation 1. 
 
 
• Solvation is explicitly included in the COP design procedure.  Continuum 
implicit solvation methods such as SGB or AVGB can be used to describe the 
role of solvation in the structure and energies of protein and ligand in water 
(or other) solvent. This greatly decreases the computation effort over the use 
of explicit solvent. However, explicit solvent molecules can be included in the 
evaluation of the best cases for final selection in the design. 
 
• The protein backbone can be allowed to move (distort in response to the 
mutations, solvent, and ligand) at any part of the algorithm. COP allows the 
protein backbone to be fully movable in any part of the optimization. The 
designed protein can be better optimized with backbone flexibility. 
 
• COP design adds the functionality of recognizing a new analog ligand to a 
mutant AARS, and it selects against any natural amino acids.  This ensures 
that the designed AARS binds the analog amino acid exclusively, therefore 
can be used as an orthogonal tRNA-synthetase tRNA pair that corresponds to 
the twenty-first amino acid (25).  
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4. Possible variations and modifications 
 
The basic COP design methodology can be modified in many ways that are 
various manifestations of the same idea. 
  
• Force field used. 
Although the DREIDING force field is chosen in this procedure, other force 
fields, such as AMBER(26), CHARMM (27), OPLS (28), etc., can also be used to 
calculate clashes and binding energies.  The functional forms of the nonbond energy in 
Equation 1 can have different forms:  The dielectric constant in the Coulomb term can be 
distance dependent.  The charges for both protein and ligand can be varied.  This includes 
charges from experiment, or charge based on various models (such as but not limited to 
QEq, Del Re, Gasteiger).  The van der Waals term can have different forms, such as a 
Morse potential instead of a Leonard-Jones potential.  The Leonard-Jones potential can 
be made 6-10 or even softer to allow closer contact.  Finally the hydrogen bond term can 
have several different variations.  Here we use three-body form, but two-body or four-
body form is common, too.  In some force fields, hydrogen bond is treated implicitly as 
part of the Coulomb term.   
 
• Solvation methods. 
Solvation is an important factor in determining biomolecular stability and binding 
properties.  As an integrated part in the COP design, implicit solvent is used to minimize 
the structures and calculate binding energies.  This implicit solvent model includes, but 
not limited to, Surface Generalized Born (SGB) model, Solvent Accessible Surface Area 
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(SASA)/ Analytical Volume Generalized Born (AVGB), and Poisson Boltzmann (PB) 
model.  In addition, explicit solvent can be easily added to the calculation of binding 
energy here. What is important is that the solvation model must be accurate enough to 
account for the solvation effect in the ligand binding to the protein. 
 
• Methods of binding energy calculation. 
It is always important to get the correct relative binding energies for different 
ligands.  Here we can use minimization in the Potential of Mean Force (PMF) from 
implicit continuum solvent model to calculate binding (free) energies.  Alternatively we 
can use the average dynamic free energy instead of free energy from a single 
conformation.  Other methods can be used to calculate binding free energies, but they 
may require significantly longer computation time.  These methods include Free Energy 
Perturbation (FEP) (29), and methods based on thermodynamic cycles.  For the case of 
amino acids binding to AARS, we found that the binding energy with PMF is very close 
to experimental numbers when the average dynamic free energy is used. 
 
• Input protein/ligand structures.  
The COP design program requires a protein and a ligand structure as input.  
Generally speaking, the protein structure should be in high quality from either X-ray or 
NMR study.  However, protein structures of high quality from theoretical modeling can 
also be used.  Indeed for the example used here of M. Jannaschii, the protein structure 
was obtained computationally by combining the STRUCTFAST structure alignment 
predicting with molecular dynamics using a force field.  In some cases a homologous 
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protein can be used in the design, and mutations can be translated back into the protein of 
interest according to the sequence alignment between the two proteins.  The structures of 
the ligand can be obtained from crystallographic databases or can be predicted using 
quantum mechanics or a force field.  The binding site can be determined from crystal 
structure containing a ligand bound to the target protein, or if no ligand is present in the 
protein structure it can be modeled using various docking techniques.  An example of 
such docking techniques is HierDock (30), which has been used extensively to predict 
and verify the binding of amino acids to AARS. 
 
• Protein side chain modeling. 
There are several side chain modeling methods that can be incorporated into the 
COP procedure.  These side chain modeling methods include scwrl (20), scap(31), and 
methods based on branch-and-bound, dead-end-elimination algorithms.   
 
• Different type of protein function design. 
COP is a generic method that can be applied to any protein for recognizing a 
desired ligand.  The ligand type can be any molecule that is a binding target to a protein 
and has some sort of anchoring point as the reaction center.  More generally, the binding 
can be between two proteins.  With one of the proteins changes in mutation, COP can be 
applied to design a complimentary counterpart for binding. 
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5. Features Believed to Be New 
 
The new feature in this invention is that we use a full force field in the design 
with hydrogen bond capability and solvation effects.  In addition, we allow protein fully 
movable in the stage of binding calculation.  This algorithm has been designed to make 
few mutations to recognize a desired ligand. Hence the energy function is more accurate 
and also biased towards recognizing the new ligand compared to its competitors. The 
conformational search of side chain rotamers can be exhaustive along with an all-atom 
energy function that allows COP to be unique.  
 
6. The Graphical User Interface for COP 
 
To make COP user-friendlier, we have written a graphic user interface (GUI) for 
COP using Glade, a GTK-based free user interface builder.   Figure 2 shows the screen 
snapshot when COP is started using the graphical interface. 
 
 
Figure 2.  The graphical interface of COP. 
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 Clicking a button brings out a popup window with the corresponding information. 
For example, clicking the “About…” button will open a window showing the version and 
copyright information of COP.  The help window is designed to let user know the 
conventions used in the COP program.  The four buttons in the bottom right of the 
window are for carrying four functions in COP, with each corresponding to a different 
program.  “Calculate Clash” will run the clash identification to find mutation residues and 
their mutation targets to relieve clash.  “HB Builder” uses a rotamer library to build 
possible hydrogen bond donor or acceptor residues in the binding site to stabilize new 
polar atoms in the analog ligand, if there is any.  “Combi Mutation” carries out the 
combined mutation step in COP, and calculates the binding energies of each ligand 
including competing natural amino acids to generated mutants.  A list of top candidates 
will be given at the end.  Finally the “Stability Check” step will eliminate any mutant that 
potentially cannot fold correctly. 
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Chapter 6 
 
Application of COP to Design Mutant Tyrosyl-tRNA 
Synthetases from Methanococcus jannacshii* 
                                                 
* Part of this chapter has been published in PNAS, 99, 6579-84 
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1. Introduction 
 
Proteins are synthesized with precise control over sequence, leading to the vast 
range of specific structures and functional properties observed in nature.  Even so the 
monomer pool for proteins is limited to the 20 natural amino acids.  Increasing the 
monomer pool by incorporating new amino acid analogs would allow development of 
fascinating new bioderived polymers exhibiting novel but well-controlled architectures 
(1, 2).  This could lead to many interesting applications ranging from incorporating a 
fluorescence probe to elucidate specifics of protein structure and function (3), to 
incorporating selenium-substituted serine to facilitate crystallization processes in proteins 
(4).  
 
The in vivo incorporation of amino acid analogs into proteins is controlled in large 
measure by aminoacyl-tRNA synthetases (AARSs), the class of enzymes that safeguards 
the fidelity of amino acid incorporation into proteins.  It has been demonstrated that the 
wild-type translational apparatus can be used to incorporate some amino acid analogs into 
protein (5-11).  However, the number of amino acid analogs incorporated in proteins in 
vivo is small, and the functionalities of these analogs have been limited.  To expand the 
range of amino acid analogs that can be incorporated in vivo, it is desirable to manipulate 
the activity of the AARSs (12, 13).  There has been steady progress in developing the 
twenty-first AARS-suppressor tRNA pairs in vivo (12, 13).  The biggest success is the 
design of a novel orthogonal tRNA and tyrosyl-tRNA synthetase (TyrRS) from 
Methanococcus jannacshii tyrosyl-tRNA synthetase (mj-TyrRS) that incorporates O-
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methyl L-tyrosine (OMe-Tyr) site-specifically in protein in response to an amber 
nonsense codon (14).  A few other non-natural amino acids were incorporated by the 
same group using the same apparatus since then.  Such procedures have tremendous 
potential to expand the genetic codes in living cells, but the current combinatorial 
experiments, which considered 520 mutation trials on five residues expected to be at the 
binding site of the tyrosine ligand, can become cumbersome.  In this chapter we 
summarize the result of using the Clash-Opportunity Progressive Design algorithm 
(denoted as COP) to redesign the binding site of mj-TyrRS for the preferential binding of 
OMe-Tyr, Naphthyl-Ala and p-keto-Phe over natural amino acids.  The design for OMe-
Tyr leads to three mutants, of which the best mutant [Y32Q, D158A] is expected to bind 
OMe-Tyr strongly while discriminating against Tyr.  This mutant is similar to the one 
[Y32Q, D158A, E107T, L162P] designed by Wang et al using combinatorial 
experiments.  We predict that the new mutant will have much greater activity while 
retaining significant discrimination between OMe-Tyr and Tyr.   
 
Since there is no crystal structure available for mj-TyrRS, we predicted the three- 
dimensional structure for wild-type mj-TyrRS, based on a combination of the 
STRUCTFAST sequence alignment and structure prediction algorithm with molecular 
dynamics (MD) including continuum solvent forces.  [To select the 5 residues to modify 
in their experiments, Wang et al. (14) used a sequence alignment between mj-TyrRS and 
Bacillus stearothermophillus tyrosyl-tRNA synthetase (bs-TyrRS).]  To validate the 
predicted structure for mj-TyrRS, we use MD plus continuum solvent energies to 
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demonstrate that tyrosine (Tyr) is the preferred ligand over the 19 other natural amino 
acids.  
 
2. Methods 
 
2.1 Structure Prediction for TyrRS from Methanococcus jannacshii 
 Because the crystal structure of TyrRS from Methanococcus jannacshii was not 
available, we predicted the structure using STRUCTFAST homology technique.  There 
are three TyrRS crystal structures in the Protein Data Bank.  They are all from Bacilus 
stearothermophilus, with different ligands in the structures.  Structure 2ts1 has no ligand 
(15), 3ts1 with Tyr-AMP bound (15), and 4ts1 has a Tyr in the binding site (16).  By 
using the sequence of the wild-type mj-TyrRS from Genbank (accession number: 
Q57834), the three-dimensional structure of the main chain of mj-TyrRS was predicted 
with STRUCTFAST homology modeling technique (Debe & Goddard, unpublished 
result).  The structure of 4ts1 was used as the template in the prediction.  The sequence 
identity between the two sequences is 32.1%.  The main chain atoms of the initial 
predicted mf-TyrRS structure agree with the corresponding residues of 4ts1 structure to 
0.64 Å in root mean square difference (rmsd) in coordinates after aligning the two 
structures using DALI (17).   
 
 To place the Tyr ligand in the predicted structure, we matched the side chain 
conformation of the five strictly conserved residues (Tyr32, Tyr151, Gln155, Asp158 and 
Gln173) in the binding site of mj-TyrRS with those conformations from the 4ts1 crystal 
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structure.  The rest of the side chains for the predicted mj-TyrRS structure were added by 
using side chain modeling program SCWRL version 2.7 (18, 19) while keeping the 
conformations in the binding site fixed.  Here we used the backbone-dependent side chain 
rotamer library with SCWRL to optimize the side chain conformations.  The potential 
energy of the resulting structure was then minimized using conjugate gradient method 
with MPSIM (20), which allowed all the side chains to move but kept the main chain 
fixed.  In MPSIM the Cell Multiple Method (CMM) (21) was used to rapidly yet 
accurately calculate the nonbond interactions.  The protein was described with the 
DREIDING force field (22) with CHARMM22 (23) charges. 
 
 For the Tyr ligand and other amino acids in the simulation, we used Mulliken 
charges derived from the molecular orbitals in quantum mechanics (QM).  The QM 
calculations were done at the HF level with the 6-31G** basis set.  The geometry of the 
molecules was optimized under forces from Poisson Boltzmann continuum solvation (24) 
inside of QM package Jaguar 4.0 (Schrodinger, Portland, OR). 
 
 After optimizing the side chain conformations in the protein, the potential energy 
of the whole protein was minimized, with all atoms movable but with distance constraint 
on the hydrogen bonds between the phenolic OH group of the Tyr ligand and the Tyr32 
and Asp158 side chains.  This minimized structure was then used as a starting structure 
for annealing molecular dynamics (MD), where all constraints were relaxed.  Each cycle 
of annealing MD involved heating the system from 50 to 600 K and cooling from 600 to 
50 K in steps of 20 K for 0.5 ps.  These annealing MD calculations included solvent 
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forces from the Surface Generalized Born (SGB) continuum solvation method (25) with a 
dielectric constant of 80 for bulk solvent, 2 for protein and a solvent probe radius of 1.4 
Å.  The final structure, shown in Figure 1, was used to predict the binding of all 20 
natural amino acids and to design mutant TyrRS for non-natural amino acids. 
 
 
Figure 1.  Comparison of predicted mj-TyrRS structure (in blue) and the crystal structure 
for B. stearothermophilus TyrRS (4ts1) (in yellow).  The Tyr ligand is shown as a ball 
model. 
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2.2   Docking All 20 Natural Amino Acids to the Predicted mj-TyrRS 
 To validate our predicted mj-TyrRS structure, we docked all 20 natural amino 
acids to the Tyr binding site of the TyrRS.  To guard against misactivation noncognate 
amino acids, AARSs must be able to charge the correct amino acid to its corresponding 
tRNA.  The activation step consists of the bound amino acid forming the aminoacyl 
adenylate complex and subsequent transferring the aminoacyl group to the 3’-end of the 
bound tRNA.  While there are extra proofreading mechanisms to ensure the fidelity for 
some AARSs, many AARSs recognize their substrate with very high specificity.  And 
TyrRS is one of them (26, 27).  It has been also shown that PheRS, another AARS 
recognizing their substrates with high specificity, has calculated bonding energies 
correlating well with the translational activity measured in vivo (28). 
 
 In order to get a binding conformation for other amino acids, the Tyr ligand 
obtained in mj-TyrRS structure optimization was used to build 19 other amino acids.  To 
preserve the reaction center for activating the amino acids, the contact between the 
zwitterions of the amino acid and the appropriate residues in the binding site was fixed.  
SCWRL was used to mutate the side chain into 19 other amino acids.  Each of the 
resulting amino acids was minimized in the binding site of the protein using conjugate 
gradient method. 
  
 The binding energy of each amino acid is calculated as 
 -∆∆Gbinding =  ∆G(protein) + ∆G(ligand) - ∆G(protein+ligand),      (1) 
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where ∆G(protein+ligand) is the free energy for the protein-ligand complex, while 
∆G(protein) and ∆G(ligand) are the free energy for the protein and ligand alone, 
respectively.  The structure optimization was always done with SGB continuum 
solvation.  Such continuum solvation model is optimized with the potential mean force 
(PMF) from bulk solvent, the total energies are very close to the free energy of the 
system (29).  This is true especially for tight bound complexes. 
 
 2.3 Mutant mj-TyrRS Design for Recognizing Non-Natural Amino Acids  
 The clash opportunity progressive (COP) design algorithm (30) was used to 
design mutant mj-TyrRS for recognizing non-natural amino acids.  The non-natural 
amino acids used in this chapter are listed in Figure 2.   
 
 
Figure 2.  Non-natural amino acids used in mutant mj-TyrRS design in this 
chapter. 
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In determining the low-energy rotamers for each non-natural amino acid, several 
rotamers over a grid were generated and the geometry was then minimized in QM using 
Jaguar 4.0.  Only the ones with low energy were used for subsequent COP design.  The 
Mulliken charges were also obtained from these calculations and used for these amino 
acids in the design. 
 
These low-energy conformation structures are then built in Biograf using the Tyr 
structure as a starting structure.  The atoms that are identical in the non-natural amino 
acids are left as where they are.  This means the zwitterions of the non-natural amino 
acids are always in the same position as in the Tyr ligand.  These structures were used as 
input to the COP along with the Tyr ligand and mj-TyrRS structure.  COP requires that 
the new atoms in the non-natural amino acids be labeled as HETATM in order to cut the 
binding site.  The cutoff distance was 6 Å for the binding site.  Residues outside the 
cutoff distance are not included in the clash calculation, but are included in the binding 
energy calculation. 
 
The following equation is used in calculating the nonbond interaction energies 
between the ligand and residues k in the binding site: 
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where i and j sum over all atoms in the ligand and protein residue k, of interest, qi and qj 
are partial charges on atoms i and j, respectively. rij is the distance between atoms i and j, 
and rm and De are van der Waals distance and well depth of atoms i and j, rHB and DHB are 
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hydrogen bond distance and well depth, respectively.  θ is the hydrogen bond angle 
between atoms i, j and their bridging hydrogen atom.  Please note that the hydrogen bond 
term is only evaluated for hydrogen bond pair atoms.  When there is no bridging 
hydrogen atom for i and j, the hydrogen bond term is turned off.  
 
3. Results and Discussions 
 
3.1  Assessment of the Quality of the Predicted mj-TyrRS Structure 
Figure 1 shows the predicted structure of mj-TyrRS superimposed with the crystal 
structure of the B. stearothermophilus TyrRS (4ts1).  The general folds are very similar 
between the two structures.  The main chain structure, predicted by STRUCTFAST 
homology technique, led to an initial rmsd of 0.64 Å for all aligned main chain atoms 
between the two structures before minimization.  After full minimization, the main chain 
rmsd increases to 1.75 Å for the 139 structurally aligned residues.   However, the 
conserved five residues (Tyr32, Tyr151, Gln155, Asp158, and Gln173) in the binding site 
have a rmsd of 0.62 Å for all heavy atoms.  The structural alignment was done using 
DALI (17). 
 
The main difference between the two structures is that mj-TyrRS lacks the α-
helical domain present in 4ts1 (residue 246−317), which is consistent with the 
observation that mj-TyrRS has only a minimalist tRNA anticodon loop-binding domain 
(31). 
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For mj-TyrRS, the tyrosine ligand binds in the deep cleft formed by several α-
helices and β-strands in the α/β domain.  The phenolic hydroxyl group of the Tyr ligand 
makes hydrogen bonds with Tyr32-Oη and Asp158-Oδ1, both with a hydrogen bond 
distance of 2.87 Å.  The amino group of the Tyr ligand make three hydrogen bonds with 
Tyr151-Oη, Gln155-Oε1, and Gln173-Oε1.  Table 1 lists all the hydrogen bonds and their 
distances that the Tyr ligand makes in the binding site.  Comparison of these distances 
(see Table 1) shows that these hydrogen bonds made by Tyr ligand are very similar. 
 
 Table 1.  Hydrogen bonds in the binding site of the predicted mj-TyrRS structure, 
compared with the hydrogen bonds in B. stearothermophilus TyrRS (bs-TyrRS) crystal 
structure (PDB ID 4ts1). 
 mj-TyrRS bs-TyrRS (4ts1) 
ligand atoms protein atom HB distance (Å) protein atom HB distance (Å) * 
Oη Tyr32 Oη 2.80 Tyr34 Oη 2.93 (2.87)  
Oη Asp158 Oδ1 3.02 Asp176 Oδ1 2.27 (2.83) 
N Gln75 Oε1 3.14 Asp78 Oδ1 2.91 (2.87) 
N Tyr151 Oη 2.83 Tyr169 Oη  2.78 (2.94) 
N Gln173 Oε1 3.12 Gln173 Oε1 3.13 (3.28) 
OXT Gln75 Nε2 5.56** Lys82 Nε 4.83 (4.97)** 
 
* The values quoted here are from the crystal structure for bs-TyrRS (pdb code: 4ts1).  
The values in parentheses are after minimization using the DREIDING FF. 
** Water mediated hydrogen bonds (HB) 
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3.2  Docking of the Natural Amino Acids to mj-TyrRS 
 As described in the methods section, all 20 natural amino acids were docked into 
the binding site of Tyr in mj-TyrRS.  The binding conformation was first minimized with 
protein fixed and followed by relaxing the binding site residues.  The final optimization 
was done without any constraint on the protein.  All structure optimizations were done 
with implicit SGB continuum solvent.  Table 2 shows the binding energies of these 
amino acids to mj-TyrRS.  As expected, the wild-type ligand Tyr has a much higher 
binding energy than any other natural amino acids.  The closest binding competitors are 
Ala, Asn and His, but all bind at least 16 kcal/mol less favorably than Tyr. 
 
 Table 2.  Binding energies (including solvation) for the 20 natural amino acids 
docked to the binding site of the predicted structure for mj-TyrRS 
Amino Acid Binding Energy 
(kcal/mol) 
Amino Acid Binding Energy 
(kcal/mol) 
Tyr 43.8 Val 16.2 
Ala 27.2 Ile 14.1 
Asn 27.2 Leu 12.0 
His 27.1 Gln 9.7 
Thr 26.8 Arg 2.3 
Phe 26.6 Pro 1.3 
Ser 25.6 Glu -3.5 
Gly 24.1 Met -13.8 
Cys 22.9 Trp -20.6 
Asp 16.4 Lys -56.9 
 
 Although there are several steps involved in the selection specificity in AARSs, 
TyrRS has been known for a long time to be able to differentiate its cognate amino acid 
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in the initial binding stage (26).  Hence the binding profile validates our predicted mj-
TyrRS structure. 
 
3.3  Design of Mutant mj-TyrRS for OMe-Tyr 
 
Starting with the predicted mj-TyrRS structure, we used the COP algorithm to 
design mutant mj-TyrRS for selective binding of OMe-Tyr.  
 
OMe-Tyr has two equally favorable rotamers with the carbon of the methyl group 
in the same plane as the aromatic ring.  Both rotamers were matched in the binding site of 
Tyr in wild-type mj-TyrRS, keeping the zwitterions fixed in the structure. Component 
analysis of the energy contributions of each residue in the binding site to the binding of 
OMe-Tyr using Equation 2.  The binding site is defined as the entire residue for all atoms 
within 6 Å cutoff distance of the ligand.  Twenty-six residues are found in the binding 
site.  The nonbond interaction energies between OMe-Tyr and these residues in the 
binding site are summarized in Table 3.  Because rotamer 2 clashed with protein 
backbone at position Gly34 and rotamer 1 did not, we considered only rotamer 1 further. 
 
From Table 3, we can see that Asp158 has a very severe clash with OMe-Tyr, and 
hence this residue was selected for mutation to relieve the clash.  In addition, Tyr32 has a 
strong contribution to Tyr binding over OMe-Tyr, and it represented an opportunity to 
mutate to some other residue to disfavor Tyr. 
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Table 3.  Interaction energies of OMe-Tyr ligand (both rotamers) and of Tyr ligand with 
the predicted wild-type structure of mj-TyrRS.  The interactions are shown for all ligands 
with any atom within 6Å of the Tyr (referred to as the binding site) 
Residue OMe-Tyr 
(rotamer 1)
OMe-Tyr 
(rotamer 2)
Tyr Difference#
Gln 155 -11.15 -10.65 -10.66 -0.48
Met 154 -0.93 -0.60 -0.60 -0.32
Ala 67 -1.69 -1.43 -1.42 -0.27
Gln 109 -0.99 -0.91 -0.91 -0.08
Leu 66 -0.21 -0.13 -0.13 -0.08
Asn 157 0.13 0.20 0.20 -0.08
Val 156 -0.24 -0.17 -0.17 -0.07
Phe 108 -0.16 -0.10 -0.10 -0.06
Leu 65 -1.28 265.94* -1.23 -0.05
His 160 -0.25 -0.21 -0.21 -0.04
Gly 105 -0.08 -0.03 -0.03 -0.04
Phe 35 -1.52 -1.50 -1.49 -0.04
Pro 152 -0.32 -0.28 -0.28 -0.04
Ile 159 -0.05 -0.02 -0.02 -0.03
Ile 33 -0.23 -0.21 -0.20 -0.03
His 70 -2.89 -2.87 -2.88 -0.01
Tyr 161 -0.08 -0.06 -0.07 -0.01
His 177 -0.38 -0.39 -0.37 -0.01
Leu 69 0.02 0.02 0.02 0.00
Gly 34 -2.04 302.84** -2.06 0.02
Gln 173 -11.15 -11.20 -11.17 0.03
Asp 68 -0.94 -0.98 -0.97 0.03
Tyr 151 -9.44 -9.52 -9.66 0.21
Glu 36 -1.14 -1.27 -1.36 0.22
Tyr 32 -13.45 12745.3* -15.69 2.25
Asp 158    2450.97* -0.80 -15.44 2466.41
 
# Difference between OMe-Tyr rotamer 1 and Tyr 
*Large van der Waals energy showing steric clashes of protein side chain with 
OMe-Tyr ligand. 
**Steric clash with main chain 
 
We considered all 20 amino acids as possible mutations for both Asp158 and 
Tyr32, and selected a subset of them that favor the binding of OMe-Tyr over Tyr for 
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further consideration.  Table 4 shows those subsets: for Tyr32 Glu, Asp, Gln, Phe and 
Met; for Asp158: Ala. 
 
Table 4.  Binding scores of the best 6 mutations for Tyr32 and Asp158 in mj-
TyrRS. Scores (in kcal/mol) are nonbond interaction energies of the mutated residue with 
the OMe-Tyr or Tyr.  Based on these results, we selected the 5 mutations with negative 
difference for Tyr32, and one case for Asp158. 
  
Tyr32 Tyr OMe-Tyr difference Asp158 Tyr OMe-Tyr difference
Glu 0.13 -0.28 -0.41 Ala -0.41 -0.92 -0.51
Asp -0.14 -0.37 -0.23 Gly -0.26 -0.08 0.18
Gln -0.10 -0.28 -0.18 Ser -0.52 2.68 3.20
Met -0.32 -0.37 -0.05 Cys -0.99 4.88 5.87
Phe -0.45 -0.49 -0.04 Asp -1.70 4.36 6.06
Ser -0.08 -0.07 0.01 Asn -0.64 10.54 11.18
 
 
In stage 2, we generate all mutants by combining the mutations from each site we 
identified in the previous stage.  SCWRL was used to make these mutants.  With 5 
choices for Tyr32 and one choice for Asp158, a total number of 5 mutants were 
generated.  These side chains were optimized separately for the OMe-Tyr and Tyr in the 
binding site.  We then carried out energy minimization of the mutant structures.  First 
only the mutated residues were allowed to move, followed by full minimization with all 
atoms movable.  The binding energies for both Tyr and OMe-Tyr were then calculated 
for all mutants generated.  The results are shown in the top half of Table 5. 
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Table 5.  Binding energies of OMe-Tyr and Tyr to the wild-type mj-TyrRS and 
designed mutants.   
Y32 D158 E107 L162 OMe-Tyr 
(kcal/mol) 
Tyr 
(kcal/mol) 
differential 
(OMe-Tyr – Tyr) 
Y D E L -12.34 43.83 -56.17* 
E A   37.11 37.64 -0.54 
D A   43.85 38.24 5.60** 
Q A   48.93 42.30 6.62** 
F A   39.06 39.81 -0.76 
M A   44.17 39.00 5.16** 
E A T P 27.48 34.98 -7.51 
D A T P 31.65 25.58 6.06 
Q A T P 27.06 17.72 9.33*** 
F A T P 31.54 34.06 -2.53 
M A T P 27.20 28.69 -1.50 
The first row is for the wild type, which binds Tyr well but not OMe-
Tyr.  The next five rows (boxed) consider the mutations for Y32 and D158 
identified in Table 4.  The three cases denoted as ** are considered to be 
promising cases worth testing.  The last five rows consider these same five 
mutations, but with the E107T and L162P mutations observed in the 
experiments.  The case denoted as *** is the one determined experimentally. 
* Wild-type mj-TyrRS 
** Chosen designed mutant mj-TyrRS  
*** Mutant mj-TyrRS found experimentally 
 
 We also calculated the binding energy of Tyr and OMe-Tyr to the wild-type mj-
TyrRS, which is 44 kcal/mol for Tyr but –12 kcal/mol for OMe-Tyr.  The result is shown 
in the top row in Table 5.  All five mutants bind Tyr less strongly (range from 38—42 
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kcal/mol) whereas these five mutants bind OMe-Tyr by 37—49 kcal/mol.  Of the five 
mutants, three favor binding of OMe-Tyr over Tyr by at least 5 kcal/mol.  These are 
[Y32Q, D158A], [Y32M, D158A], and [Y32D, D158A], which have binding energies of 
49, 44, and 44 kcal/mol foe OMe-Tyr, and differential binding energies of 7, 5, and 6 
kcal/mol between OMe-Tyr and Tyr.  The other two cases both lead to weak binding and 
favor Tyr over OMe-Tyr, hence we will ignore them. 
 
 Figure 3 shows the predicted binding site for OMe-Tyr in the best case, [Y32Q, 
D158A].  We can see that residues Ala67, Ala158 and Leu65 form a hydrophobic pocket 
for the methyl group of OMe-Tyr.  The amide Nε2 of Gln32 has close contact with the 
oxygen atom of the OMe group (3.79 Å), whereas the Oε1 atom is stabilized by forming a 
weak hydrogen bond (3.58 Å) with the main chain NH of Leu65.  These hydrogen bonds 
might be stabilized by an intervening water.  The mutant [Y32M, D158A] is also a 
favorable candidate.  However, for [Y32D, D158A], the charged group of the Asp does 
not seem to have a favorable stabilization of the charged group, which may lead to 
folding problem. 
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Figure 3.  The predicted binding site surrounding the OMe-Tyr in the COP designed 
mutant [Y32Q, D158A] mj-TyrRS.  The mutated residues (Gln32 and Ala158) are 
labeled in yellow.  Ala67, Ala158, and Leu65 form a hydrophobic pocket for the methyl 
group.  The amide Nε2 of Gln32 has close contact with the oxygen of the OMe group, 
whereas the Oε1 of Gln32 is stabilized by forming a weak hydrogen bond with the main 
chain NH of Leu65. (Both may have intervening water molecules.) 
 
 We can then compare our prediction with experiment.  Wang et al. carried out a 
combinatorial experiment to find a mutant optimal for OMe-Tyr binding.  Because there 
was no crystal structure available, they used a sequence alignment with the 4ts1 structure.  
Their alignment suggested five residues (Y32, D158, E107, L62, and I159) are in the 
binding site.  They then screened a library containing 520 mutants.  The selection was 
carried out by first screening binding for any amino acid in the presence of OMe-Tyr in 
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the media, followed by screening against natural amino acids without OMe-Tyr in the 
media to find the one least able to bind Tyr and any other amino acid.  Their study led to 
a mutant [Y32Q, D158A, E107T, L162P].  I159 did not change in this mutant. 
 
 
Figure 4.  The predicted mj-TyrRS with explicit side chains for two residues 
Tyr32 and Asp158 involved in the design.  The Tyr ligand is also shown 
(labeled in red).  The positions of two other residues Leu162 and Glu107 are 
also shown (labeled in yellow). 
 
 Thus the experiments identified the [Y32Q, D158A] mutations designed by COP 
to be the best.  However, the experimental mutant also included E107T and L162P.  COP 
did not consider these two residues because both residues are far from the binding site in 
our predicted mj-TyrRS structure (Figure 4).  Glu107 is on the surface and is 12.9 Å from 
the binding site (from the Cα of Glu107 to the Oη of the Tyr ligand).  Leu162 is 14.5 Å 
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away from the binding site.  In Wang et al.’s alignment, Leu162 and Glu107 in mj-TyrRS 
correspond to residues Leu180 and Asn123 in the 4ts1 structure.  In 4ts1, Leu162 is in the 
middle of a β-strand on the bottom of the binding site, and a mutation Leu→Pro will 
certainly disrupt the secondary structure, thus destabilize the protein.  Asn123 is in the 
core of the protein, it thus seems unlikely that a charged Glu could fold into this structure.  
In our predicted structure, both these two residues are well outside the binding site, thus 
COP did not find these residues as mutation targets. 
 
 To understand why the combinatorial experiments led to a different selection than 
the COP design, we made mutants including the [E107T, L162P] mutations along with 
the five cases from COP design.  The L162P mutation requires a change in the main 
chain conformation, and therefore we carried out annealing MD to optimize the backbone 
structure.  The resulting best-energy structure was selected to calculate binding energies.  
These numbers are also included in Table 5. 
 
 We find that the experiment selected mutant [Y32Q, D158A, E107T, L162P] 
leads to a dramatically weak binding (17 kcal/mol) toward Tyr.  Because the experiments 
conducted several rounds of negative selection against any natural amino acids, our 
favored mutant [Y32Q, D158A] would have been screened out due to its higher affinity 
to Tyr (42.3 kcal/mol).  We also find that the experimental mutant leads to a differential 
binding energy of 9 kcal/mol for OMe-Tyr over Tyr.  This is by far the best differential 
binding among all the mutants in our design.  However, the net binding of OMe-Tyr to 
the mutant is only 27 kcal/mol.  It could explain the observation that the mutant led to an 
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incorporation rate much poorer than for the natural amino acid.  Thus, the calculations do 
seem to be consistent with the experiment and the way it carried out. 
 
 Because our predicted mutants all would have been in the mutant library in the 
experiment, it would be interesting to reexamine the three cases predicted by COP to 
determine how effective they are and how the screening can be further improved to make 
better mutants.  We suspect the predicted differentials of 5-7 kcal/mol may be sufficient 
to obtain specificity.  In addition, the total binding energies of 44-49 kcal/mol for OMe-
Tyr suggest that these new mutants would be much more active. 
 
3.4  Design of Mutant mj-TyrRS for Naphthyl-Alanine 
 
 Our next design target non-natural amino acid was L-3-(2-naphthyl)alanine 
(naph-Ala).  The same predicted mj-TyrRS was used.  Two rotamers of the naphthyl-Ala 
were built from the Tyr ligand.  Mulliken charges from QM calculation were assigned to 
naphthyl-Ala. Each of the two rotamers were matched into the binding site of Tyr, and 
clashes were calculated between the ligand and proteins.  The result was listed in Table 6. 
 
 From Table 6, Q155 has a main chain clash with rotamer 1 of naph-Ala.  This 
eliminates rotamer 1 from further consideration.  Rotamer 2 does not have any main 
chain clash, therefore the following design steps are only applied to rotamer 2.  Using a 
cutoff of 0.5 kcal/mol, two residues Y32 and D158 are selected as mutation sites.  Each 
of the 20 amino acids is tried on the two positions one at a time.  The mutated residue is 
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minimized, and the interaction energies with naph-Ala and Tyr are evaluated.  Finally a 
score is calculated for each mutation.  These results are listed in Table 7. 
 
 
Table 6.  Interaction energies of naph-Ala (both rotamers) and of Tyr with mj-TyrRS.  
The interactions are shown for all ligands with any atom within 6Å of the Tyr (referred to 
as the binding site).  All energies are in kcal/mol. 
Residue Naph-Ala  
(rotamer 1) 
Naph-Ala  
(rotamer 2) 
Tyr Difference# 
H177 -0.87 -1.49 -0.78 -0.71 
L65 -2.34 -2.36 -1.78 -0.58 
G34 -1.60 -2.00 -1.56  -0.44 
I33 -0.54 -0.78 -0.40 -0.38 
Q155 -5.48 (6.01)* -14.38 -14.06 -0.31 
Q173 -2.50 -3.08 -2.81 -0.27 
A167 0.03 -0.28 -0.08 -0.20 
V168 -0.26 -0.44 -0.25 -0.19 
A67 -1.72 -1.49 -1.36 -0.13 
G169 -0.26 -0.31 -0.19 -0.12 
A180 -0.08 -0.18 -0.12 -0.06 
H160 0.03 -0.14 -0.58 0.43 
D158 35128.41 10.99 -16.06 27.05 
Y32 1350.52 4100030.92 -15.33 4100046.24 
* Q155 has main chain clash 6.01 kcal/mol. 
# Difference is between naph-Ala rotamer 1 and Tyr. 
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Table 7.  Interaction energies of each mutation on two mutation sites (Y32 and D158).  
All 20 amino acids are tried on each site.  The final score is calculated as described in the 
method section using 95% of the nonbond interaction with ligands plus 5% of the 
constraint energy for the mutated residue with neighboring residues within protein. 
Tyr32 Tyr Naph-Ala Score Asp158 Tyr Naph-Ala Score 
I -0.47 -1.63 -1.59 G 0.02 -0.50 -0.61 
Q -0.08 -1.97 -1.29 A -0.35 -0.35 -0.24 
V -0.28 -1.03 -1.18 C -1.12 0.52 1.33 
N -0.34 -1.82 -1.15 I -1.22 0.64 2.01 
M -0.51 -1.17 -1.04 V -1.16 0.80 2.17 
T -0.07 -1.03 -0.95 H -1.50 0.68 2.26 
L -0.58 -1.71 -0.92 M -1.11 1.37 2.29 
P -0.23 -0.72 -0.86 F 1.71 3.45 3.04 
C -0.19 -0.63 -0.68 N -2.95 -0.28 3.23 
A -0.16 -0.50 -0.58 S -3.57 0.18 3.75 
G -0.12 -0.38 -0.37 Q -0.24 3.07 3.76 
S -0.15 -0.56 -0.17 T -4.55 -0.39 4.17 
E 0.52 -5.23 2.35 Y 15.60 19.64 7.21 
D -0.23 -2.07 6.21 D -5.25 -4.61 7.37 
H -0.41 5.88 6.71 K 2.21 5.91 8.88 
F -0.61 10.32 10.49 E -3.75 -0.89 9.74 
R -1.48 5.87 11.87 W 1.75 8.82 10.61 
Y -0.77 11.80 12.46 P -0.66 9.13 11.40 
K -2.52 8.43 14.86 L 3.62 28.29 25.91 
W -1.56 62.16 66.50 R 1129.31 1168.98 116.71 
 
 From Table 7, there are 12 choices for Tyr32 (I, Q, V, N, M, T, L, P, C, A, G, S), 
and two choices for Asp58 (G and A).  A cutoff value of 0 is used to choose mutations 
that favor naph-Ala over Tyr.  In the next step, 12 × 2 = 24 mutants are generated.  The 
mutants are first minimized with only the mutation residues movable and the rest of the 
protein and ligand fixed, followed by a full optimization.  Equation 1 is then used to score 
each mutants for binding with naph-Ala and Tyr.  Two possible competitors from natural 
amino acids, Trp and Phe, are also scored for binding to the mutants designed.  Normally 
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this procedure is only performed for mutants with high affinity to the designed analog, 
however, every mutants are evaluated with competitors because there are only 24 mutants 
designed.  Table 8 lists the mutants we have designed using COP. 
 
Table 8.  Designed mutant TyrRS for binding naph-Ala using COP.  The binding 
energies are in kcal/mol.  The difference is between naph-Tyr and the competitor with the 
best binding energy. 
Y32 D158 naph-Tyr Tyr Phe Trp Difference Rank Stability
M A 37.53 30.08 28.46 -15.38 7.45 1 OK 
M G 36.47 29.59 19.68 -16.55 6.88 2 OK 
Q G 34.50 28.80 22.57 -19.66 5.70 3 OK 
I G 34.54 28.95 22.25 -13.48 5.59 4 OK 
L G 33.15 27.75 24.62 -20.90 5.40 5 OK 
V G 34.01 28.90 25.43 -16.02 5.11 6 OK 
N G 34.50 29.45 28.41 -15.64 5.05 7 OK 
T G 33.83 28.86 22.08 -14.24 4.97   
P G 33.24 28.31 22.21 -7.38 4.93   
C G 32.71 27.81 19.55 -21.73 4.90   
A G 34.17 29.45 20.22 -20.36 4.72   
S G 34.14 29.42 19.35 -19.92 4.72   
G G 34.16 29.48 22.30 -16.70 4.68   
Q A 33.80 29.30 23.06 -19.38 4.50   
I A 33.76 29.43 22.51 -13.35 4.33   
L A 33.64 29.53 26.05 -19.56 4.11   
N A 33.43 29.55 21.95 -22.38 3.88   
V A 33.21 29.36 27.61 -16.01 3.85   
C A 33.71 29.94 19.81 -20.90 3.77   
T A 33.04 29.33 22.41 -13.91 3.71   
P A 32.41 28.78 22.45 -7.30 3.63   
A A 33.46 29.85 19.85 -22.43 3.61   
S A 33.46 29.89 19.87 -18.58 3.57   
G A 33.35 29.82 19.84 -18.40 3.53   
 
 From Table 8, we see that all these COP designed mutants have good binding 
energies to naph-Tyr and better binding energy than any of the competitors.  Among 
these mutants, there are seven of them having binding energies at least 5 kcal/mol better 
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than any of the competitors.  And the stability checks performed on them all indicate they 
can fold into the native state without any problem.   
 
 Further, we compare these mutants with the experimental mutant selected from a 
library of 520 mutants with five positions each replaced by one of the 20 natural amino 
acids (32).  These five positions are Y32, D158, I159, L162, and A167.  And the 
experimental mutant is Y32L-D158P-I159A-L162Q-A167V.  Compared with COP 
designed mutants, the first two mutation sites are the same as what COP found.  
However, the other three residues I159, L162 and A167 are not in contact with the analog 
naph-Ala, thus COP did not identify them as mutation residues.  The mutation Y32L also 
appears in two designed mutants with good binding affinity toward naph-Ala. On the 
other hand, P was not a choice for D158 in COP design.  The reason is that it requires 
main chain conformational change in the mutation D158P.  The phi/psi angles for D158 
in mj-TyrRS is –58o/113o, while for P it should be either –57o/-38o or –63o/139o.  We 
performed a simulation by making a mutant with all the mutations found in experiment.  
Due to the main chain conformational change in the D158P mutation, an annealing 
dynamics was carried out on the mutant to allow the back bone of the mutant to adjust to 
an optimal position.  Simulation showed the phi/psi angles were –53o/125o in the 
optimized mutant.  The mutation V159A facilitated the main chain conformational 
change by allowing the backbone move further away from the ligand (Figure 5). 
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Figure 5.  The main chain change in the mutant selected in experiment.  The phi/psi 
angle changed from –58o/113o in the wild-type mj-TyrRS (Blue) to –53o/125o in the 
mutant (Red).  The mutation V159A facilitated the change by allowing the main chain 
move further from the ligand naph-Ala. 
 
 We also calculated the binding energies of naph-Ala and its competitors (Tyr, 
Phe, Trp) and the results are listed in Table 9.  As a comparison, the wild-type mj-TyrRS 
and a few COP designed mutants are also listed. 
 
From Table 9, it is seen that the experimentally selected mutant has the worst 
binding energy to Tyr, which is also the best binding natural amino acid among the 
competitors to naph-Ala.  This is consistent with the experimental procedure, in which 
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several rounds of negative selection against natural amino acids were performed.  Our 
simulation shows that that procedure selected the mutant with the worst binding affinity 
to natural amino acids, however, neither the affinity to naph-Ala nor the differential 
binding affinity to naph-Ala was optimized in the experiment.  Such selected mutants 
usually only have moderate binding affinity to the analogs intended to design for.  In this 
case, four of COP designed mutants have better binding affinity to naph-Ala with at least 
the same differential binding affinity to naph-Ala. 
 
 
Table 9.  The binding energies (in kcal/mol) of the wild-type mj-TyrRS (first row), 
experimentally selected mutant (second row), and some COP designed mutants for 
binding naph-Ala and some natural amino acid competitors. 
Y32 D158 I159 L162 A167 Naph-
Ala 
Tyr Phe Trp Diff 
     -11.41 50.37 21.73 -21.72 -61.78 
L P A Q V 32.63 27.23 21.25 -18.17 5.40 
M A    37.53 30.08 28.46 -15.38 7.45 
M G    36.47 29.59 19.68 -16.55 6.88 
Q G    34.50 28.80 22.57 -19.66 5.70 
I G    34.54 28.95 22.25 -13.48 5.59 
L G    33.15 27.75 24.62 -20.90 5.40 
 
 
Figure 6 shows naph-Ala in the binding site of the best COP designed mutant 
Y32M-D158A.  Q155, D158A, Y32M, and A167 together form the binding site for the 
extra aromatic ring in naph-Ala.  In the experimentally selected mutant, A167V occupies 
larger space such that Y32 can only be one of the residues smaller than M, in this case it 
is V. 
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Figure 6.  naph-Ala in the binding site of the best COP designed mutant.  The extra 
aromatic ring in naph-Ala is surrounded by Q155, D158A, Y32M and A167. 
 
3.5  Design of Mutant mj-TyrRS for p-keto-Tyr 
 
 The next Tyr analog for design is p-keto-Tyr. Two low energy rotamers of keto-
Tyr were built in Biograf.  The carbonyl group is conjugate with the aromatic ring in 
these two rotamers.  Again Mulliken charges from quantum mechanics were used for 
ligands. 
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 Both rotamers of keto-Tyr were matched into the binding site of Tyr in mj-TyrRS.  
Clashes were calculated using COP.  The interactions between keto-Tyr, Tyr and residues 
in the binding site of mj-TyrRS were listed in Table 10. 
 
Table 10.  The interaction energies between two rotamers of keto-Tyr, Tyr and all 
residues in the binding site (defined as within 6 Å of keto-Tyr).  The differential is 
between rotamer 1 and Tyr.  Energies are in kcal/mol. 
Residue Keto-Tyr 
(Rotamer 1) 
Keto-Tyr 
(Rotamer 2) 
Tyr Difference 
N157 -0.61 0.18 0.27 -0.88 
L65 -2.41 -1.32 -1.78 -0.63 
G34 -1.81 -1.65 -1.56 -0.25 
H177 -0.99 -0.81 -0.78 -0.21 
V156 -0.32 -0.50 -0.17 -0.14 
I159 -0.11 -0.10 -0.01 -0.09 
A67 -1.45 -1.44 -1.36 -0.09 
H160 -0.50 -1.12 -0.58 0.07 
A180 -0.05 -0.25 -0.12 0.08 
A167 0.03 -0.22 -0.08 0.11 
Q155 -12.35 -7.88(4.82)* -14.06 1.71 
D158 441.75 7388.24 -16.06 457.81 
Y32 10734317.94 520822.01 -15.33 10734333.27 
 * note: Numbers in ( ) are main chain clashes.  
 
 From Table 10, rotamer 2 has main chain clash with Q155, and rotamer 1 has no 
main chain clash, therefore rotamer 2 was not used in further steps and only rotamer 1 
was further considered. 
 
 There are two residues having severe clash with keto-Tyr, and they are Y32 and 
D158.  A third residue, Q155, has a less favorable interaction with keto-Tyr than Tyr.  
However, this residue is not considered as a clash residue, because the interaction with 
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keto-Tyr is negative.  Further Q155 is an essential residue anchoring the amino acid 
binding by forming a hydrogen bond with the zwitterions of the amino acid ligand.  
Hence, Q155 was not included in the mutation list.  The hydrogen bond design procedure 
indicates no optimal hydrogen bond residue can be found for the carbonyl group. 
 
 Next step is to try all 20 amino acids in position Y32 and D158 one at a time.  The 
mutated residue is minimized with everything else fixed first, followed by calculating the 
interaction energy of the mutation with the ligands and the rest of the protein. A 
preferential score for each amino acid is then calculated (Table 11).   
 
Table 11.  Score for each mutation into all 20 amino acids at position Y32 and D158.  
The score was calculated as 95% of the differential interaction energy with keto-Tyr and 
with Tyr plus 5% of the constraint energy of the mutated residue with its neighbor 
residues in protein. 
Tyr32 Tyr keto-Tyr Score Asp158 Tyr keto-Tyr Score 
M -0.58 -1.27 -1.00 G 0.02 -1.75 -1.95 
Q -0.08 -1.73 -0.95 A -0.38 1.84 1.84 
N -0.34 -1.56 -0.77 N -0.87 0.90 2.02 
I -0.47 -0.90 -0.74 S -0.58 1.66 2.24 
V -0.28 -0.61 -0.64 T -1.09 3.01 4.14 
L -0.58 -1.17 -0.48 C -1.00 4.01 4.54 
T -0.07 -0.69 -0.47 I -1.28 5.59 6.83 
P -0.23 -0.45 -0.44 V -1.19 6.26 7.48 
C -0.19 -0.34 -0.29 M -1.16 6.99 7.74 
A -0.16 -0.30 -0.29 Q -0.57 7.43 8.27 
G -0.12 -0.22 -0.14 H -3.29 6.82 10.02 
S -0.15 -0.26 0.24 K 1.80 7.95 11.42 
F -0.83 0.13 0.50 Y 14.04 30.19 18.71 
H -0.63 0.04 1.06 E -3.90 8.65 18.92 
Y -0.99 0.41 1.22 D -4.59 8.38 19.06 
E 0.53 -4.94 2.60 F 4.43 22.51 19.27 
W 1.74 5.06 3.06 W 0.55 23.42 26.02 
D -0.23 -1.76 6.51 P -1.00 23.16 31.79 
R -1.47 6.39 12.60 L 4.21 83.34 81.30 
K -2.52 7.93 14.57 R 92.14 444.31 395.32 
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 From Table 11, there are 11 choices (M, Q, N, I, V, L, T, P, C, A, G) for Y32, and 
one choice (G) for D158, using a cutoff of 0 kcal/mol in score.  However, it is always 
safe to add the next choice to the list when there is only one choice.  Therefore (G, A) 
was chosen for D158.  The combined mutation generates 11×2 = 22 mutants.  The 
binding energies of each mutant for keto-Tyr and its competitors are calculated using 
Equation 1.  Table 12 lists the binding energies for all 22 mutants designed here. 
 
Table 12.  The binding energies (in kcal/mol) of COP designed mutants for binding with 
keto-Tyr and its competitors. 
Y32 D158 Keto-Tyr Phe Tyr Trp Difference Rank Stability check
N G 31.41 29.54 22.32 -23.02 1.87  No 
P G 28.34 26.48 22.25 -11.58 1.86  No 
G G 30.85 29.48 22.23 -19.79 1.37 1 OK 
M G 29.33 28.44 20.2 -21.8 0.89 2 OK 
A G 30.14 29.49 22.01 -21.73 0.65 3 OK 
Q G 28.09 28.6 19.64 -21.84 -0.51   
V G 28.18 29.44 19.44 -24.28 -1.26   
T G 28.1 29.44 19.46 -23.7 -1.34   
C G 28 29.45 19.43 -21.48 -1.45   
L A 28.56 30.09 27.69 -18.36 -1.53   
I G 27.34 29.54 19.46 -23.24 -2.2   
L G 26.78 29.6 27.54 -18.05 -2.82   
P A 23.56 26.95 22.68 -13.75 -3.39   
I A 26.6 30.06 19.73 -23.36 -3.46   
N A 23.36 30.02 22.53 -23.1 -6.66   
M A 23.41 30.24 22.73 -21.84 -6.83   
A A 22.97 29.98 22.24 -21.88 -7.01   
G A 22.72 29.96 22.44 -19.91 -7.24   
Q A 20.07 29.11 19.89 -21.89 -9.04   
V A 20.14 29.92 19.67 -24.39 -9.78   
T A 20.02 29.93 19.7 -23.8 -9.91   
C A 19.84 29.93 19.67 -21.45 -10.09   
 
 From Table 12, there are only three mutants that have better binding affinity to 
keto-Tyr than its competitors from natural amino acids and have no problem folding into 
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the native fold.  Phe seems to be the main competitor in the design here, which makes 
sense because both polar residues recognizing Tyr over Phe are being mutated to less 
polar residues.  The best mutant is Y32G-D158G with a 1.37 kcal/mol binding energy 
better than Phe, and the next two mutants Y32M-D158G and Y32A-D158G both have 
less than 1 kcal/mol binding energy better than Phe.  These deferential binding energies 
are probably not big enough to exclude the misactivation of Phe in vivo.  Therefore, no 
good mutants emerged from the design here. 
 
4. Conclusions 
 
 In this chapter, we have applied the COP protein design algorithm to design 
mutant TyrRS that would bind optimally and preferentially to new Tyr analogs over Tyr 
and all other natural amino acids. 
 
 Because there was no experimental three-dimensional structure available for mj-
TyrRS, we used STRUCFAST to predict the alignment and backbone fold.  We then used 
a series of energy minimization and annealing dynamics to optimize the predicted 
structure.  We found that this predicted structure binds Tyr much stronger than any other 
natural amino acids, which we consider a validation of the predicted structure.  In 
addition, the success in predicting mutants that compare consistently with experiment 
provides additional evidence in favor of the predicted structure. 
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Chapter 7 
 
Structure-Based Design of Mutant Phenylalanyl-tRNA 
Synthetase for Incorporation of p-Keto-Phenylalanine 
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Abstract 
 
Aminoacyl-tRNA synthetases are a class of enzymes to guard the fidelity in 
protein biosynthesis.  It has been shown that some non-natural amino acids can be 
incorporated into protein in vivo using the wild-type apparatus.  However, the number of 
such non-natural amino acids is rather limited, and the functionalities carried by these 
non-natural amino acids are minimal.  In order to incorporate non-natural amino acids 
with more interesting properties, it is necessary to manipulate the activity of the 
aminoacyl-tRNA synthetase. 
 
 In this paper we report the result of a structure-based mutant design of 
phenylalanyl-tRNA synthetase for incorporation of p-keto-phenylalanine using our 
previously published Clash Opportunity Progressive (COP) protein design tool.  There 
have been some improvements on COP since then.  The designed mutants have been 
shown experimentally to be able to incorporate p-keto-phenylalanine in vivo.  We have 
also been able to show why some of our previously designed mutants did not work 
experimentally.  The improved COP should be more accurate in mutant designs. 
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1. Introduction 
 
 The aminoacyl-tRNA synthetases (AARSs) catalyze the esterification of amino 
acids to their cognate tRNAs (1).  The accuracy of the reaction is essential due to its 
nature of protein biosynthesis fidelity.  On the other hand, protein biosynthesis is a great 
tool to make biomaterials with precise control over sequence, structure and function.  In 
natural the monomer pool is limited to the 20 natural amino acids.  It has been shown that 
the monomer pool of amino acids can be increased by incorporating some non-natural 
amino acids using the wild-type AARS apparatus (2-5).  These bioderived polymers are 
controlled by a genetic sequence, but have novel yet well controlled architectures (2, 6-
14).  However, the number of non-natural amino acids incorporated into protein using 
wild-type AARSs is small, and the functionalities carried by these non-natural amino 
acids are very limited.  Typically, these non-natural amino acids are analogs of natural 
amino acids with little difference in the side chain.  There are many non-natural amino 
acids that have desired chemical or physical properties cannot be incorporated this way.  
The most important reason is that these amino acid analogs are very different from their 
natural amino acid counterpart.  Therefore, they are rejected by the AARSs in the 
esterification to tRNAs. 
 
 In order to overcome the limitations, it is desirable to manipulate the activity of 
AARSs to make them recognize non-natural amino acids (15).  Another reason for doing 
AARS activity manipulation is the promise of expanding the genetic codes by developing 
novel tRNA:AARS pairs orthogonal to existing such pairs in cells (16).  It is typically 
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done by evolving the suppressor tRNA with nonsense codon to pair with a cross-species 
mutant AARS, which recognizes a non-natural amino acid instead of one of the natural 
amino acids.  The design of mutant AARS has been the bottleneck in this process due to 
the lack of an effective mutant screening method.  It is typically done by screening a 
library of AARS mutants, in which several positions are replaced by all 20 amino acids.  
Five such positions will generate 520 mutants.  There has been some success, but it is very 
time-consuming and cumbersome. 
 
 We have previously developed a Clash Opportunity Progressive (COP) protein 
design tool for the purpose of mutant AARS design (15).  There have been some 
improvements to COP since we last reported the procedure.  Most significantly the 
opportunity part of the design uses a protein side chain rotamer library to design possible 
hydrogen bonds for new polar atoms.  The scoring function was also updated to use a 
new Analytical Volume Generalized Born (AVGB) continuum electrostatic solvation 
model (17).  Our improved COP has been applied to design a mutant phenylalanyl-tRNA 
synthetase, and the mutant has been experimentally tested to be able to recognize the 
target analog p-keto-phenylalanine (keto-Phe).  We were also able to show why some of 
our previously designed mutant using the old COP did not work in experiment. 
 
2. Methods 
 
 The experiment of keto-Phe incorporation was done in E. coli.  However, there is 
no crystal structure available for E. coli phenylalanyl-tRNA synthetase (PheRS) in the 
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PDB.  Instead PheRS from Thermus thermophilus has been crystallized and solved under 
different conditions previously (18-21).  Because the homology between PheRSs from E. 
coli and T. Thermophilus is very high (46.2% identical residues, with only a few 
deletions), we used PheRS from T. thermophilus as the modeling system.  The structure 
of PheRS complexed with Phe (PDB ID: 1B70 resolution 2.7 Å) was downloaded from 
the Protein Data Bank, and hydrogens were added using Biograf (Accelrys, San Diego, 
CA).  The structure was minimized with conjugate gradient method to an rms force of 0.1 
kcal/mol/Å or maximum of 5000 steps.  Dreiding force field (22) was used for energy 
expression.  The protein was described using CHARMM22 (23) charges, while charges 
for the ligands were Mulliken charges derived from molecular orbitals in quantum 
mechanics using Jaguar 4.5 (Schrödinger, Portland, OR).  The minimized structure was 
used in the design. 
 
 The keto-Phe analog was built from the Phe ligand in the minimized structure.  
There are two rotamers with equally favorable energies (Figure 2).  The Clash 
Opportunity Progressive (COP) design algorithm has been described previously (15).  
There have been some new improvements to COP since it was published.  There is no 
change in identifying clashes, but for the opportunity part, we have implemented a 
rotamer library based procedure to build potential hydrogen bonds between the protein 
and the new ligand.  The library was based on the protein side chain rotamer library used 
by SCAP (24). First the new analog ligand is compared with the wild-type ligand to see if 
there is extra polar atom for the analog ligand.  If no such atom found for the analog, no 
hydrogen bond building is necessary.  Depending on the polarity of the polar atom in the 
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analog, all residues within 6 Å of the polar atom are considered to build a new hydrogen 
bond donor/acceptor residue.  Each rotamer from the side chain rotamer library is tried to 
see if there is a hydrogen bond can be formed between that residue and the polar atom in 
the analog.  Rotamers that clash with the backbone of the protein and the analog will be 
eliminated.  Once a hydrogen bond forming residue is found in this way, other residues 
that have side chain clash with it will be mutated to eliminate the clash.  These mutations 
will be added to the list of mutations from clash identification and van der Waals 
interaction opportunity optimization.  Previously this part was done by visualization and 
there is a great uncertainty which residue is a good target.  Another change we have 
implemented is that for mutations from opportunity, we now always include the original 
choice of residue type, because these mutations are not absolutely necessary. 
 
 In the scoring method, we now have an option to use Analytical Volume 
Generalized Born (AVGB) solvation to better account for the solvation effect for 
protein/ligands.  The binding energy for each protein/ligand pair is calculated as 
  )()()( ligandproteinGligandGproteinGG +∆−∆+∆=∆∆− ,         (1) 
where ∆G(protein) and ∆G(ligand) are the free energies of the protein and ligand alone, 
respectively, ∆G(protein+ligand) is the free energy for the complex. 
 
 Finally, some of our designed mutants have been proved to be unable to fold 
correctly due to unfavorable interactions caused by the mutation.  This is especially true 
when we put a charged residue in the protein core.  To solve this problem, we now use an 
individual residue interaction energy test, which was based on the statistics of the 
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interaction energy of residues in AARSs.  The interaction energy of each residue in the 
binding site with its neighbors is calculated.  A score s(n) for residue n is calculated by 
)(
)()()(
AA
AAEnEns σ
−= ,    (2) 
where E(n) is the interaction energy of residue n with its neighboring residues, E(AA) 
and σ(AA) are the interaction energy and the standard deviation of residue type AA from 
statistics.  Table 1 shows the values we used in our COP procedure.  A score higher than 
2 usually indicates a high possibility that the designed mutant has folding problem. 
 
 Table 1.  The interaction energies and standard deviations of each amino acid 
type from all the AARSs structures known so far. 
AA E(AA) (kcal/mol) σ(AA) (kcal/mol) 
Ala -1.893 3.654 
Arg -108.953 40.459 
Asn -28.324 9.948 
Asp -48.155 14.464 
Cys -4.297 3.145 
Gln -23.980 7.071 
Glu -44.910 11.809 
Gly -2.857 3.652 
His -6.088 6.505 
Ile 3.522 5.380 
Leu 1.613 5.037 
Lys -43.560 10.184 
Met -2.067 4.624 
Phe 6.536 6.326 
Pro 8.183 6.653 
Ser -6.136 5.444 
Thr -6.364 5.733 
Trp 16.568 7.371 
Tyr 0.960 5.725 
Val 1.578 4.564 
 
 
 151
3. Results and Discussions 
 
The PheRS/Phe complex was minimized as described in the methods section.  
The rmsd for the complex between and after minimization was 0.20 Å.  This showed that 
our force field was compatible with the parameters used in the original structure 
determination.  Figure 1 is the minimized PheRS in ribbon representation with Phe shown 
as ball model. 
 
 
Figure 1.  The ribbon representation of PheRS with Phe bound in the active site. 
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Figure 2.  The wild-type ligand Phe and two rotamers of the p-keto-Phe used in the 
design. 
 
The two rotamers of keto-Phe were built from the Phe ligand in the minimized 
PheRS/Phe complex structure.  Figure 2 shows the structure of Phe and two rotamers of 
p-keto-Phe used in the design.  Each rotamers of keto-Phe was matched into the binding 
site of Phe in PheRS, and clashes were calculated for each rotamer.  Table 2 shows the 
clash result for both rotamers. 
 
It is seen that rotamer 1 of keto-Phe clashes with the protein backbone with G284 
and A283, while rotamer 2 does not clash with any backbone atoms.  Therefore, only 
rotamer 2 was used in the following steps of design.  Two residues V261 and A314 were 
identified as mutation target residues.  Each of them was mutated into all 20 amino acids 
using scwrl.  A backbone-dependent rotamer library was used to place the side chain 
conformation with the lowest constraint energy in the mutation site.  Table 3 shows the 
result of the interaction of Phe and keto-Phe with these mutations. 
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Table 2.  Clashes calculated for each rotamers of keto-Phe in the binding site of 
PheRS.  The binding site is defined as within 6 Å of the keto group in the analog. 
Residue keto-Phe (r1) Phe Difference 
E220 -6.54 -2.80   -3.75 
F260 -4.31 -3.34   -0.97 
F258 -4.87 -3.90   -0.97 
G282 -2.32 -1.66   -0.66 
M285 -0.70 -0.12   -0.58 
A265 -0.56 -0.18   -0.38 
V286 -0.40 -0.07   -0.33 
L222 -0.26 -0.07   -0.18 
G264 0.11 -0.00    0.11 
G316 -1.69 -1.86    0.17 
F315 -1.33 -1.69    0.35 
G284 4.17* -0.52    4.69 
A283 25.29* -1.74   27.03 
A314 60.12 -1.31   61.43 
V261 4705.49 -1.27 4706.76 
* Indicates main chain clash.   
Residue keto-Phe (r2) Phe Difference 
E220  -8.60 -2.80  -5.80 
G282  -2.79 -1.66  -1.13 
F260  -4.19 -3.34  -0.85 
A283  -2.38 -1.74  -0.64 
G284  -1.08 -0.52  -0.56 
F315  -2.23 -1.69  -0.55 
F258  -4.39 -3.90  -0.48 
G264  -0.40 -0.00  -0.40 
S180  -8.94 -8.57  -0.36 
G221  -0.44 -0.15  -0.29 
A265  -0.39 -0.18  -0.21 
V286  -0.25 -0.07  -0.17 
M285  -0.09 -0.12   0.03 
G316  -1.77 -1.86   0.09 
E262   0.21 -0.39   0.60 
V261 161.40 -1.27 162.66 
A314 931.41 -1.31 932.72 
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Table 3.  The interactions between mutated residues with Phe and keto-Phe (r2) 
V261 Interaction with Phe Interaction with keto-Phe Difference 
G  -0.16  -0.92   -0.75 
A  -0.51   0.22    0.54 
S  -0.61   0.57    1.19 
C  -1.04   3.68    4.41 
N  -1.25   6.46    8.24 
T  -1.35   8.39    9.69 
P  -1.17   6.93   10.59 
V  -1.41  10.14   11.13 
D  -2.11   3.64   14.87 
I  -1.57  25.68   29.09 
H  -1.89  28.76   31.90 
L  -1.22 115.67  118.74 
E  -3.01 124.58  141.29 
M  62.13 228.14  166.30 
Y  57.30 289.95  249.12 
W 203.24 423.05  255.14 
K 418.60 733.53  331.06 
F  28.16 412.26  393.18 
R 204.46 2379.7 2195.66 
Q   0.72 7311.2 7312.93 
 
A314 Interaction with Phe Interaction with keto-Phe Difference 
G -0.60 -1.45 -0.85 
D -1.51 25.33 26.84 
C -1.27 30.68 31.95 
S -1.54 31.00 32.54 
A -1.07 31.75 32.82 
T -0.83 34.45 35.29 
E -1.91 37.54 39.45 
H -1.24 38.49 39.74 
L -1.50 38.29 39.79 
Q -1.47 39.26 40.73 
I -0.30 41.36 41.67 
M -1.53 40.28 41.81 
V -0.17 42.13 42.3 
N 8.40 51.23 42.83 
W -1.66 42.74 44.41 
F -1.54 51.99 53.53 
Y -1.51 52.89 54.4 
P -1.39 85.06 86.45 
R -1.60 110.25 111.85 
K -0.08 269.75 269.83 
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Using a cutoff of 0 kcal/mol, only one choice for both V261 and A314 were 
selected, and both were Gly.  There is a polar oxygen atom in the keto group.  However, 
the hydrogen bond design algorithm in COP did not find optimal hydrogen bonds for the 
keto group.  Thus COP designed a V261G-A314G mutant only.  Previously we did the 
hydrogen bond design part by visualization and decided to build a hydrogen bond donor 
residue on V286.  We also tried to make room for V286 mutation by make L222 to 
smaller residues.  Table 4 lists the binding energies to the double Gly mutant and some 
mutants we previously designed.  Both rotamers of keto-Phe and some competitors (Phe 
and Tyr in this case) were used as binding ligands.  As a test, the binding energy to the 
wild-type PheRS and an A314G mutant were also calculated.  The A314G mutant has 
been previously shown to be able to bind p-Br-Phe.  
 
Table 4.  Binding energies of both rotamers of keto-Phe and competitors (Phe 
and Tyr) to wild-type and mutant PheRS designed using COP.  The first row is 
for wild-type PheRS, the second row is the double Gly mutant PheRS designed 
by COP, and rows 3-6 are mutant PheRS designed by the old COP using 
visualization in hydrogen bond building.  The last row is a mutant known to 
bind p-Br-Phe.  Energies are in kcal/mol. A question mark in stability check 
column denotes that the mutation is questionable in stability. 
 
V261 A314 V286 L222 Phe Tyr keto-Phe  Stability check
    24.10 9.50 3.61 Y 
G G   4.35 9.61 17.06 Y 
G G R  11.47 26.51 17.91 N 
G G Q I 5.45 11.95 12.28 ? 
G G Q  8.41 13.64 15.53 ? 
G G H V 4.32 10.67 16.26 Y 
 G   6.58 9.68 4.15 Y 
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 V261G-A314G-V286R was a mutant we designed previously using visualization 
as a procedure to build hydrogen bond between the protein and the analog.  Using the 
new hydrogen bond builder with a side chain rotamer library, COP did not choose any 
residue to build hydrogen bond donors.  Also using the new scoring method, this mutant 
now shows a less favorable binding energy than Tyr, thus it will also be rejected.  The 
stability check also failed to give a stable protein fold. 
 
The V261G-A314G mutant shows a good differential binding energy between 
keto-Phe and its competitors, Phe and Tyr in this case.  It favors keto-Phe binding by 7.45 
kcal/mol better than Tyr, the closest competitor.  Figure 3 shows the binding site of keto-
Phe in the designed V261G-A314G mutant.   
 
 
Figure 3.  Keto-Phe in the binding site of the V261G-A314G mutant TrpRS.  
No hydrogen bond is found for the carbonyl group in the side chain of keto-Phe. 
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There is no specific polar interaction with the carbonyl group of the side chain of 
keto-Phe from the protein, i.e., no hydrogen bond is formed.  The two mutations V261G 
and A314G enable the binding of keto-Phe by making the binding site larger to 
accommodate the extra acetyl group in the side chain of keto-Phe.  Other interactions 
remain the same as seen in the wild-type Phe-PheRS complex.  Resides 258-261, 282-
284, and 314-316 form the binding pocket for the side chain of keto-Phe.  On the 
zwitterions part, E220, S180 and Q218 form hydrogen bonds with the N-terminus, and 
W149, H178 and R204 form hydrogen bonds with the C-terminus.  These interactions 
anchors the amino acid ligand specifically for activation with ATP to form aminoacyl 
adenylate complex. 
 
4. Conclusions 
 
We have applied the COP protein design tool to design mutant PheRS for the in 
vivo incorporation of p-keto-Phe.  A mutant V261G-A314G was designed, and showed 
good binding affinity to keto-Phe and good differential binding to keto-Phe than its 
competitors from the natural amino acids. 
 
Using a protein mutation stability check based on amino acid interaction energy 
from statistics, we have shown that some of our previously designed mutants including a 
V261G-A314G-V286R mutant cannot fold correctly due to the lack of stabilizing 
interactions from other neighboring residues. 
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Chapter 8 
 
Design of Mutant Tryptophanyl-tRNA Synthetases for  
Non-Natural Amino Acid Incorporation  
 161
Abstract 
 
 Protein biosynthesis accuracy is mainly determined by the fidelity of recognition 
of its cognate amino acid by aminoacyl-tRNA synthetase.  It has been shown that the 
wild-type aminoacyl-tRNA synthetase can be used to incorporate some non-natural 
amino acids.  To further increase the number of non-natural amino acids that can be 
incorporated, it is necessary to modify the synthetase to recognize these analogs.  We 
have previously used tyrosyl-tRNA synthetase and phenylalanyl-tRNA synthetase as 
templates to design mutant aminoacyl-tRNA synthetases to recognize non-natural amino 
acids successfully.  However, many of the amino acid analogs carrying interesting 
properties are significantly larger than tyrosine and phenylalanine, and cause our design 
algorithm to fail due to main chain clashes.  Here we used tryptophanyl-tRNA synthetase 
as a template to design mutant synthetases.  Because the size of the side chain in 
tryptophan is larger, amino acid analogs with larger side chain can be designed without 
causing main chain clash.  The results of designing for three ligands NBD-Ala, bpy-Ala, 
and DAN-Ala were presented here. 
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1. Introduction 
  
 Protein biosynthesis has excellent control over sequence and accuracy, leading to 
the enormously vast varieties of protein folds and functionalities.  This control is 
unmatched by any of the modern polymer synthesis techniques after many years of 
advance.  It is thus desirable to use protein biosynthesis as a tool to synthesize protein 
polymers with controlled sequence, stereochemistry, and molecular weight.  However, 
the monomer pool in protein biosynthesis is limited to the 20 natural occurring amino 
acids. The monomer pool needs to be increased in order to add more monomers into 
protein materials.   
 
 The in vivo incorporation of non-natural amino acids into proteins is controlled in 
large measure by the aminoacyl-tRNA synthetases (AARSs), the class of enzymes that 
safeguards the fidelity of amino acid incorporation into proteins.  It has been 
demonstrated that it is possible to use the wild-type translational apparatus to incorporate 
non-natural amino acids with fluorinated (1, 2), unsaturated (3-5), electroactive (6), and 
other side chain functions (7-10).  Nevertheless, the number of amino acids shown 
conclusively to exhibit translational activity in vivo is small, and the chemical 
functionality that has been assessed by this method remains modest.  These non-natural 
amino acids are typically the close analogs of the wild-type natural amino acid.  In order 
to expand the chemical and physical properties that can be engineered into proteins, it is 
necessary to manipulate the activity of the AARS to further expand the range of non-
natural amino acids that can be incorporated. 
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 We have previously developed a Clash Opportunity Progressive (COP) protein 
design algorithm (11) to modify an AARS to recognize an amino acid analog carrying 
different side chain and not recognized by the wild-type AARS.  The algorithm has been 
applied to design mutant TyrRS and PheRS to selectively bind OMe-Tyr, p-keto-Phe, and 
naphthyl-Ala.  However, there are other non-natural amino acids carrying more 
interesting chemical and physical functionalities cannot be designed successfully because 
the large side chain clashes with the protein backbone.  It is therefore desirable to use 
TrpRS as a template to design mutant AARSs.  The binding site of Trp is significantly 
larger than Tyr and Phe, as a result the chance of backbone clash with the protein is 
smaller.  Here we have used COP to design mutant TrpRS for recognizing 2-amino-3-(7-
nitro-benzo[1,2,5]oxadiazol-4-ylamino)-propionic acid (NBD-Ala), 2-amino-3-[2,2’] 
bipyridinyl-5-yl-propionic acid (bpy-Ala), and 2-Amino-4-(6-dimethylamino-naphthalen-
2-yl)-4-oxo-butyric acid (DAN-Ala).  Some good mutants that have good differential 
binding energy to these analogs over natural amino acids have been designed. 
 
2. Methods 
 
2.1 Structure Preparation 
 The crystal structure of TrpRS from B. stearothermophilus with Trp bound in the 
binding site (PDB: 1I6M, resolution: 1.72 Å) (12) was downloaded from the Protein Data 
Bank.  Hydrogens were added to the structure using Biograf (Accelrys, San Diego, CA), 
followed by annealing on the hydrogens to optimize the hydrogen bond network.  The 
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heavy atoms were fixed during the annealing.  The structure was subject to further 
optimization using conjugate gradient minimization with all atoms movable for 2000 
steps and with a convergence criterion of rms force reaching less than 0.1 kcal/mol/Å.  
The simulation program MPSim (13) was used along DREIDING force field (14).  
Surface Generalized Born (SGB) continuum solvation (15) was included in the 
optimization to account for the solvation effect.  The protein was described with 
CHARMM22 charges (16), while the ligand Trp was with Mulliken charges derived from 
molecular orbitals in quantum mechanics (QM).  The QM calculation was carried out at 
HF level using 6-31G** basis set in Jaguar 4.5 (Schrödinger, Portland, OR).  The 
geometry optimization was performed with forces calculated from Poisson-Boltzmann 
continuum dielectric solvent (17).  The same Mulliken charges were used for the two 
analogs and other competing natural amino acids. The rms deviation between the 
optimized complex structure and the original crystal structure was 0.32 Å.  And the 
protein TrpRS and ligand Trp were split from the complex for use in the mutant TrpRS 
design. 
 
2.2 The COP Protein Design Algorithm  
The COP protein design algorithm has been previously described (11).  The 
procedure will be described here briefly.  The first step is analog structure preparation.  
Several low energy rotamers of the analog is built from the wild-type amino acid.  The 
zwitterions part of the analog is the same as that of the ligand.  Then each of the rotamers 
of the analog is put into the binding site of the protein, and the following equation is used 
to calculate the nonbond interaction between the analog and residue k in the binding site: 
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where i and j sum over all atoms in the ligand and protein residue k, of interest, qi and qj 
are partial charges on atoms i and j, respectively. rij is the distance between atoms i and j, 
and rm and De are van der Waals distance and well depth of atoms i and j, rHB and DHB are 
hydrogen bond distance and well depth, respectively.  θ is the hydrogen bond angle 
between atoms i, j and their bridging hydrogen atom.  Please note that the hydrogen bond 
term is only evaluated for hydrogen bond pair atoms.  When there is no bridging 
hydrogen atom for i and j, the hydrogen bond term is turned off. 
 
 The same is done for the wild-type amino acid ligand, and the difference of the 
interaction energy with the analog and the wild-type amino acid is calculated for each 
residue.  Those residues that have an unfavorable binding contribution to the analog will 
show positive differential interaction energies.  These residues either clash with the 
analog or do not make enough interactions with the analog, thus they represent the 
opportunity to improve the binding to the analog.  These residues will be mutated into all 
20 natural amino acids to find choices that can wither relieve the clash or improve the 
interaction with the analog.  A score is calculated by considering the differential 
interaction energy of the mutated residue with the analog and the wild-type amino acid, 
the constraint energy of the mutated residue with the rest of the protein.  Mutations with 
positive scores are selected for use in making mutants in the combined stage. 
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 The mutant proteins are then generated by combining the choices for each 
mutation site, and optimized by minimization.  The binding energy of the analog to the 
mutant is calculated as 
)()()( ligandproteinGligandGproteinGGbinding +∆−∆+∆=∆∆− ,  (2) 
where ∆G(protein), ∆G(ligand) and ∆G(protein+ligand) are the free energies of the 
protein, the ligand, and the protein ligand complex, respectively. 
 
 The binding energies of competitors from natural amino acids are also calculated, 
and the differential binding energy between the analog and the best competitor is used as 
a criterion to select mutants.  These mutants will be checked by stability of each mutated 
residues to make sure that they make enough interactions with the rest of the protein so 
that the fold is stable. 
 
3. Results and Discussions 
 
3.1 Design for NBD-Ala 
 Two rotamers of NBD-Ala with low energy were built in Biograf using the same 
coordinates for zwitterions as in wild-type Trp ligand.  These two rotamers along with 
Trp are shown in Figure 1.  There are other rotamers for NBD-Ala, however, they have 
less overlap with the binding site of Trp and almost certainly they will clash with the 
protein backbone in the design using COP.  Hence, only the two rotamers shown here 
were used. 
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Figure 1.  Tryptophan and NBD-Ala (two rotamers) used in the design of mutant TrpRS. 
 
 
 The two rotamers of NBD-Ala were placed into the binding site of TrpRS, and the 
interaction energies of each residue with NBD-Ala and Trp ligand were calculated using 
Equation 1.  The difference of the interaction between NBD-Ala and Trp was then 
calculated.  Table 1 shows the result of these calculations. 
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Table 1.  Interaction energies (in kcal/mol) of each residue in the 
binding site with NBD-Ala and Trp.  The binding site is defined as with 
6 Å of the side chain of NBD-Ala.  Residues labeled with * have at least 
1 kcal/mol less favorable interactions with NBD-Ala compared to Trp. 
 
 Residue NBD-Ala (r1) Trp Difference
G7 -4.53 1.18 -5.70 
Q147 -20.16 -18.07 -2.09 
S6 -3.81 -2.11 -1.70 
C38 -1.07 0.13 -1.20 
Q80 -0.35 0.65 -1.00 
P142 -0.03 0.69 -0.72 
Y125 -17.34 -16.72 -0.61 
T138 -0.44 0.03 -0.47 
Q9 -12.56 -12.19 -0.37 
G144 -0.40 -0.11 -0.29 
V40 -1.49 -1.36 -0.13 
A174 -0.28 -0.27 -0.01 
I151 -0.83 -0.85 0.02 
I8 -2.34 -2.38 0.04 
H43 -2.60 -2.81 0.21 
I140 0.13 -0.16 0.29 
F26 -0.17 -0.57 0.40 
A22 0.04 -0.58 0.62 
I133 -0.65 -1.29 0.63 
A130 0.50 -0.38 0.87 
L128 0.76 -0.13 0.88 
F5 -0.37 -1.46 1.09* 
M129 -4.37 -7.03 2.65* 
D132 -2.65 -26.57 23.93* 
V143 127.41 -2.09 129.51* 
V141 982.50 -1.02 983.52* 
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  Table 1.  (continued) 
Residue NBD-Ala (r2) Trp Difference
Q147 -22.84 -18.07 -4.76 
G7 -1.73 1.18 -2.90 
S6 -3.50 -2.11 -1.40 
D146 7.43 8.67 -1.23 
Y125 -17.88 -16.72 -1.16 
Q9 -13.01 -12.19 -0.82 
I8 -3.18 -2.38 -0.80 
I151 -1.24 -0.85 -0.39 
A174 -0.51 -0.27 -0.24 
G144 -0.35 -0.11 -0.24 
C38 -0.08 0.13 -0.21 
T138 -0.16 0.03 -0.19 
Q80 0.59 0.65 -0.06 
F26 -0.63 -0.57 -0.06 
I133 -1.29 -1.29 -0.00 
I140 -0.13 -0.16 0.03 
A22 -0.53 -0.58 0.04 
P142 0.86 0.69 0.16 
L128 0.06 -0.13 0.19 
V40 -1.07 -1.36 0.29 
H43 -2.24 -2.81 0.57 
M129 -5.48 -7.03 1.55* 
F5 0.84 -1.46 2.30* 
D132 -12.96 -26.57 13.61* 
V143 115.18 -2.09 117.28* 
V141 333.89 -1.02 334.91* 
 
 
 From Table 1, five residues (V141, V143, D132, M129 and F5) were found to 
have less favorable interactions with rotamer 1 of NBD-Ala compared to Trp.  The same 
five residues had less favorable interactions with rotamer 2 of NBD-Ala.  Here a cutoff 
value of 1 kcal/mol was used to select residues to mutate.  We have been using the cutoff 
value of 0.5 kcal/mol, however, it would give us more than five residues to mutate.  In 
our design, we limit the number of residues for mutation to 5.  There were no main chain 
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clash between either rotamer of NBD-Ala and the protein.  Therefore, both rotamers were 
used in further design steps. 
 
 Each residue was mutated into 20 natural amino acids one by one, and the 
interaction energies between the mutated residue and ligands (NBD-Ala and Trp) again 
were calculated using Equation 1.  A score was assigned to each mutation by combining 
95% of the differential interaction energy with the mutated residue between NBD-Ala 
and Trp, plus 5% of the constraint energy of the mutated residue with the rest of the 
protein.  A score cutoff of 0 kcal/mol was used to select good mutations favoring NBD-
Ala binding over Trp.  Note that the interaction energy between the mutated residue and 
NBD-Ala had to be favorable for the mutation to be chosen.  Table 2 lists the mutations 
that were chosen for each rotamers of NBD-Ala.  Because the interaction energy of these 
residues with NBD-Ala were all positive except F5 as seen in Table 1, the original choice 
of each residue was also included in the mutation lists.  The reason for doing this is that 
some mutants might need only three or less mutations to achieve optimal selection. 
 
 Table 2.  Selected mutations for residues identified in clash calculation 
Residues Mutations for rotamer 1  Mutations for rotamer 2 
V141 G A Q A G Q 
V143 A T N G C  T N C A S G 
D132 I M N G S A H C T P V Q W L I M G 
M129 M L I  M L I N S 
F5 F W N Y F 
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 Finally these mutations were combined to make mutant TrpRS.  A total number of 
3 × 5 × 11 × 3 × 3 = 1485 mutants were generated for rotamer 1 of NBD-Ala, and for 
rotamer 2 the number is 3 × 6 × 6 × 5 × 2 = 1080.  These mutants were each scored by its 
binding energy to NBD-Ala calculated using Equation 2.  A cutoff binding energy of 25 
kcal/mol was used to select mutants with good binding energy to NBD-Ala.  These 
selected mutants were further scored with binding energy to Trp, Tyr and Phe, because 
they were thought to be the main competitors from natural amino acids due to their 
similarity to NBD-Ala.  The mutants were ranked by the differential binding energy 
between NBD-Ala and the best competitor among Trp, Tyr and Phe.  Finally a stability 
check for each mutation was performed for each mutant.  Those mutants with mutations 
making unfavorable protein-protein interactions were discarded due to their possible 
problem with folding.  Table 3 lists the top mutants designed by COP for NBD-Ala. 
 
Table 3.  Binding energies of designed mutants with better binding energy to NBD-Ala 
than any competitors. The difference is between NBD-Ala and the best competitor.  
Binding energies are in kcal/mol. (a) Rotamer 1 of NBD-Ala, (b) Rotamer 2 of NBD-Ala. 
(a)  
V141 V143 D132 M129 F5 NBD-Ala Phe Tyr Trp Difference 
G T M M F 41.27 32.30 30.32 -159.00 8.97 
G C M M F 52.40 44.10 41.75 -97.39 8.30 
A T M M F 53.27 45.21 43.13 -103.92 8.06 
A G M M F 52.14 44.18 41.93 -81.31 7.96 
G C I I F 33.56 25.61 22.66 -78.39 7.95 
G T I I F 35.07 27.16 24.82 -179.72 7.91 
A A M M F 51.62 44.08 41.95 -116.13 7.54 
A G I I F 33.11 25.74 23.28 -58.68 7.37 
A T I I F 34.02 26.88 24.59 -186.32 7.14 
A C I I F 32.50 25.54 22.77 -199.37 6.96 
A A I I F 32.59 25.69 23.20 -58.50 6.90 
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Table 3. (continued) 
(b) 
V141 V143 D132 M129 F5 NBD-Ala Phe Tyr Trp Difference 
G T I L F 45.79 32.74 29.59 -238.22 13.05 
G T I N F 46.44 32.13 33.71 -80.73 12.73 
G T L S F 40.79 32.11 26.48 -230.24 8.68 
A T L S F 40.01 31.93 26.51 -313.87 8.08 
G T M I F 39.69 31.70 29.93 -119.66 7.99 
A T M I F 38.89 31.68 29.93 -114.50 7.21 
G T M L F 35.50 28.69 22.28 -124.12 6.81 
G C L N F 29.11 22.33 15.97 -264.66 6.78 
G T I M F 40.84 34.18 29.90 -78.08 6.66 
G S I I F 32.17 25.93 23.90 -59.58 6.24 
A T M L F 34.65 28.61 22.32 -166.98 6.04 
G C I I F 31.58 25.61 22.66 -78.39 5.97 
A S I I F 31.44 25.83 23.60 -130.75 5.61 
 
 Most of the mutants generated have been shown to not have enough favorable 
interactions between the mutated residues and the rest of the protein; therefore they might 
not fold correctly.  These mutants were eliminated from further consideration.   
 
Among the mutants designed based on rotamer 1 of NBD-Ala, F5 remained F for 
all of them. Interestingly V141 and M129 were always mutated to the same residue.  The 
V141 mutation, which had severe clash with NBD-Ala before mutation, can be either G 
or A.  This mutation is presumably for relieving the clash between the nitro group of 
NBD-Ala and the protein.  M129 seemed to be less critical as it could be either M or I. 
Both seem to have the same size. The V143T mutation formed a hydrogen bond with the 
nitro group (Figure 2).  D132 recognizes the side chain NH of the Trp ligand in wild-type 
TrpRS, and mutation D132I blocks the normal binding of Trp.  As a result, Trp is hardly 
a competitor in the competitive binding (Table 3). 
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 Figure 2.  The binding site of NBD-Ala in one of the mutants designed by COP. 
  V143T forms a hydrogen bond with the nitro group. 
 
 Thirteen mutants were designed based on rotamer 2 of NBD-Ala.  Similar to the 
case of rotamer 1, mutation V141 to G or A allows the nitro group to go in further in the 
binding site, and V143T forms a hydrogen bond with the five-member ring of the NBD.  
The choice for D132 was among M, L and I.  Again, this mutation blocks the binding of 
Trp, and Trp indeed binds poorly to these mutants.  The position M129 seems to be less 
discriminative, and can be any of L, M, S, I or N.  F5 did not change in these mutants. 
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 Figure 3.  The mutations in mutant V141G-V143T-D132I-M129L-F5F 
designed by COP based on rotamer 2 of NBD-Ala. 
 
 
3.2 Design for bpy-Ala 
 
 The second design case was for bpy-Ala.  Quantum mechanics calculation using 
Jaguar showed that the trans-conformation was 8.39 kcal/mol lower in energy than the 
cis-conformation.  Bpy-Ala is a good binding agent to transitional metal ions.  In free 
solution it is usually in trans-conformation, and upon binding it switches to cis- 
conformation to form coordinated binding from both nitrogen atoms.  Hence only the 
trans-conformation was used in preparing the rotamers.  Two low energy rotamers in 
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trans-conformation were built in Biograf.  These two rotamers were shown in Figure 4.  
To ensure that the binding mode was the same as for Trp, the coordinates of the 
zwitterions were borrowed from Trp. 
 
 
 
Figure 4.  Two rotamers of bpy-Ala used in COP design of mutant TrpRS. 
 
 
 When these rotamers were simply placed in the binding site of TrpRS, they had 
very bad clash with the backbone of TrpRS.  The reason was that these rotamers were not 
aligned optimally with the binding site for Trp.  Figure 5 showed the alignment of bpy-
Ala and Trp before and after optimization, and it is seen that the alignment is 
significantly better after optimization. 
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Figure 5.  Alignment between Trp and bpy-Ala before and after optimization.  Trp is in 
green, bpy-Ala is in blue (before optimization) and red (after optimization). 
 
 In order to optimize the orientation of the side chain of bpy-Ala, the following 
procedure was adopted to get the conformation with lowest backbone clash energy.  First 
a mutant TrpRS with all Gly was generated, i.e., all the side chains of the protein were 
taken out.  A grid of conformations for bpy-Ala was then generated by changing the χ1 
and χ2 angles (χ1 was defined as the dihedral angle of N-Cα-Cβ-Cγ, and χ2 was defined 
as the dihedral angle of Cα-Cβ-Cγ-Cδ, see Figure 4).  Finally the bpy-Ala analog was put 
into the binding site of the all Gly TrpRS, and the energy of the complex was calculated 
after 10 steps of steepest descents minimization of the analog with the protein fixed.  The 
energy was plotted in a two-dimensional energy surface plot (Figure 6). 
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Figure 6.  The energy surface of interaction between the all Gly TrpRS (backbone) with 
bpy-Ala by changing the χ1 and χ2 angles of bpy-Ala for (a) rotamer 1 and (b) rotamer 2.  
Ten steps of steepest descents minimization were performed before the energy 
evaluation. 
 
 The minimum in the energy surface plot for rotamer 1 of bpy-Ala had χ1 = -78.5o 
and χ2 = 150o, and for rotamer 2 the minimum was at χ1 = -76o and χ2 = 160o.  The 
conformation of the two rotamers was adjusted to these values. 
 
 These two rotamers were then placed in the binding site of the wild-type TrpRS, 
and the binding contribution from each residue in the binding site was calculated using 
Equation 1.  The same was done for the Trp ligand, and the difference was calculated 
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between bpy-Ala (both rotamers) and Trp for each residue.  These results were listed in 
Table 4. 
 
Table 4.  The interaction energies (in kcal/mol) of each residue in the binding site of 
TrpRS with bpy-Ala (both rotamers) and Trp.  The residues were sorted by the 
interaction energy difference with bpy-Ala and Trp.  The numbers in ( ) indicate clash 
with the backbone of TrpRS.  
Residue bpy-Ala (rotamer 1) Trp Difference 
Q9 -12.76 -11.48 -1.28 
Q147 -17.74 -16.61 -1.13 
C38 -0.77 0.02 -0.79 
G7 -0.22 0.29 -0.51 
S6 -2.26 -2.06 -0.19 
I8 -2.20 -2.19 -0.01 
I151 -0.50 -0.76 0.26 
V143 -1.07 -1.88 0.81 
M129 -5.60 -6.75 1.15 
H150 1.21 -0.44 1.65 
V40 3.24 -1.48 4.71 
D132 -5.29 -22.82 17.53 
V141 30.36 -1.03 31.40 
I133 241.02(12.84) -1.36 242.39 
F5 6251.94 -1.55 6253.48 
 
Residue bpy-Ala (rotamer 2) Trp Difference 
S6 -3.93 -2.06 -1.87 
G7 -1.05 0.29 -1.34 
Q9 -12.78 -11.48 -1.30 
Q147 -17.67 -16.61 -1.06 
C38 -1.00 0.02 -1.02 
Q80 -0.30 0.45 -0.75 
H43 -2.78 -2.65 -0.13 
I8 -2.15 -2.19 0.04 
M129 -4.98 -6.75 1.77 
V40 8.79 -1.48 10.27 
I133 35.93(9.76) -1.36 37.30 
D132 29.24 -22.82 52.06 
F5 468827.98 -1.55 468829.53 
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 From Table 4, it is obviously that both rotamers still had clash with the backbone 
of the protein.  However, the backbone clash was not very severe, and usually several 
steps of minimization could relieve these clashes significantly.  However, rotamer 1 had 
8 residues that need to be mutated, if we use our normal cutoff of 0.5 kcal/mol.  When 
there is more than 5 resides involved in the mutation, it usually means too much change 
for the binding site.  Therefore, we chose to design for rotamer 2, which had less main 
chain clash and only 5 mutations to do.  The 5 mutation residues were F5, D132, I133, 
V40, and M129.  A cutoff of 0.5 kcal/mol was used here. 
 
 We then tried to mutate each of the five residues to all 20 natural amino acids one 
by one.  The mutated residue conformation was chosen from a rotamer library with the 
lowest energy rotamer being selected.  A score was calculated as 95% of the differential 
interaction energy of the mutated residue with bpy-Ala and Trp, plus 5% of the constraint 
energy between the mutated residue and the rest of the protein.  Mutations with positive 
score were chosen, and the choices were listed in Table 5. 
 
Table 5.  Selected mutations for residues identified in clash calculation 
Residues Mutations 
F5 G 
D132 G A 
I133 T S M A G C 
V40 A G 
M129 M L I F H C V 
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 The mutants were generated by combining the mutations from each residue, and a 
total number of 1 × 2 × 6 × 2 × 7 = 168 mutants were generated.  Each mutant was scored 
by the binding energy to bpy-Ala using Equation 2.  A cutoff of 25 kcal/mol was used to 
select good binding mutants to calculate binding energies to competitors from natural 
amino acids.  Here we assumed Trp, Tyr and Phe as competitors because their similar 
size.  The difference of the binding energy between bpy-Ala and the competitor with the 
best binding energy was calculated and used to select best mutants.  Finally a stability 
check for each mutation was performed for each mutant.  Those mutants with mutations 
making unfavorable protein-protein interactions were discarded due to their possible 
problem with folding.  Table 6 listed all 14 of those mutants with binding energy to bpy-
Ala at least 5 kcal/mol better than any of the competitors. 
 
Table 6.  Binding energies of designed mutants with better binding energy to bpy-Ala 
than any competitors. The difference is between bpy-Ala and the best competitor.  
Binding energies are in kcal/mol. 
F5 D132 I133 V40 M129 bpy-Ala Phe Tyr Trp Difference
G A T A C 38.81 30.28 27.10 27.11 8.53 
G A A A C 37.94 30.28 27.03 26.59 7.66 
G A S A C 37.92 30.31 27.02 27.21 7.61 
G G T A C 36.53 29.74 27.75 29.60 6.79 
G G A A C 35.98 29.69 27.75 23.28 6.29 
G G S A C 35.71 29.76 27.70 29.77 5.94 
G A M A C 37.37 31.67 28.37 28.15 5.70 
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Among these seven mutants designed by COP, three residues have the same 
mutation in all of them.  These mutations are F5G, V40A and M129C.  D132 is mutated 
to either G or A.  I133, which has slight clash with bpy-Ala in main chain, can be 
mutated into A, S, T, or M.  Figure 7 shows the binding site of bpy-Ala formed by these 
mutations in mutant F5G-D132A-I133T-V40A-M129C.  It is seen in Figure 7 that the 
extra six-member ring takes the space opened by mutation F5G. D132A also opens some 
space for the extra six-member ring in bpy-Ala.  Other mutations contribute to the 
binding of bpy-Ala by shaping the binding site according to the orientation assumed by 
bpy-Ala upon its binding.  V40A makes the orientation of the Cβ-Cγ bond possible.  
I133T seems to form a weak hydrogen bond with the nitrogen atom in the second six-
member ring in bpy-Ala.  The distance between the nitrogen atom and the Oγ1 in T133 is 
3.2 Å. 
 
Figure 7.  The mutations in the binding site of bpy-Ala in mutant F5G-
D132A-I133T-V40A-M129C.   
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3.3 Efforts in designing for DAN-Ala 
 
 2-Amino-4-(6-dimethylamino-naphthalen-2-yl)-4-oxo-butyric acid (DAN-Ala) is 
a synthetic fluorescent amino acid, and it was reported earlier this year that it could be 
used as an internal probe for protein electrostatics (18).  The fluorophore it carries is 6-
dimethylamino-2-naphthalene (DAN), and DAN undergoes large charge redistribution 
upon excitation and has nearly ideal environment sensor property (19). DAN-Ala has 
been incorporated into the B1 domain of streptococcal protein G and the Kir2.1 and 
Shaker potassium ion channels using chemical synthesis method (18).  Due to its 
potential as a protein electrostatic probe, it would be very interesting to see if COP can be 
used to design a mutant AARS to recognize DAN-Ala. 
 
 Figure 8 shows the structure of DAN-Ala along with Trp.  Compared with Trp, 
DAN-Ala side chain is about 3 to 4 CC bond length longer than Trp.  And indeed we 
saw very bad main chain clash with DAN-Ala on residues V141, V143 and P142 (Table 
7).  Therefore, our effect on design for DAN-Ala failed. 
 
Table 7. Clash calculation with DAN-Ala in the binding site of TrpRS 
Residue DAN-Ala Trp Difference 
S6 -0.36 -2.05 1.69 
M129 -5.20 -7.26 2.06 
Q147 -14.62 -19.03 4.41 
F5 4.68 (6.31)* -1.42 6.10 
D132 2.55 -28.41 30.97 
V143 113649.80 (339.54)* -1.92 113651.72 
V141 668295.71 (211526.31)* -1.03 668296.74 
P142 1463046.56 (1463044.84)* 0.59 1463045.97 
Note: * indicates main chain clash 
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Figure 8. The structure of DAN-Ala along with Trp 
 
Conclusions 
 
 We have used the COP protein design tool to design mutant AARSs for 
recognizing NBD-Ala, bpy-Ala using TrpRS.  Some mutants showing good preferential 
binding energy to these non-natural amino acids were designed.  Currently mutant 
TrpRS:tRNA pairs are being evolved experimentally, and it would be interesting to test 
the efficiency of these mutants designed here. 
 
 A third non-natural amino acid, DAN-Ala, has large main chain clash with several 
residues in the binding site, therefore COP failed to design any mutant. 
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Appendix I 
 
Protein Dynamics in a Family of Laboratory Evolved 
Thermophilic Enzymes* 
 
 
 
 
 
 
 
                                                          
* This appendix is adapted from a paper  to JMB (in press) and coauthored with Patrick L. Wintrode, 
Nagarajan Vaidehi, Frances H. Arnold and William A. Goddard, III 
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Summary 
 
 Molecular dynamics simulations were employed to study how protein solution 
structure and dynamics are affected by adaptation to high temperature. Simulations were 
carried out on a para-nitrobenzyl esterase (~450 residues) and two thermostable variants 
that were generated by laboratory evolution. Although these variants display much higher 
melting temperatures than wild-type (up to 18 oC higher) they are both >97% identical in 
sequence to the wild-type. In simulations at 300 K the thermostable variants remain 
closer to their crystal structures than wild-type. However, they also display increased 
fluctuations about their time-averaged structures. Additionally, both variants show a 
small but significant increase in radius of gyration relative to wild-type. The vibrational 
density of states was calculated for each of the esterases. While the density of states 
profiles are similar overall, both thermostable mutants show increased populations of the 
very lowest frequency modes (< 10 cm-1), with the more stable mutant showing the larger 
increase. This indicates that the thermally stable variants experience increased concerted 
motions relative to wild-type. Taken together, these data suggest that adaptation for high 
temperature stability has resulted in a restriction of large deviations from the native state 
and a corresponding increase in smaller scale fluctuations about the native state. These 
fluctuations contribute to entropy and hence to the stability of the native state. The largest 
changes in localized dynamics occur in surface loops, while other regions, particularly 
the active site residues, remain essentially unchanged.  Several mutations, most notably 
L313F and H322Y in variant 8G8, are in the region showing the largest increase in 
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fluctuations, suggesting that these mutations confer more flexibility to the loops.  As a 
validation of our simulations, the fluctuations of Trp102 were examined in detail, and 
compared with Trp102 phosphorescence lifetimes that were previously measured. 
Consistent with expectations from the theory of phosphorescence, an inverse correlation 
between out of plane fluctuations on the picosecond time scale and phosphorescence 
lifetime was observed.  
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Introduction 
 
 The physical basis for the remarkable stability of enzymes isolated from 
thermophilic organisms has been the subject of intensive research 1; 2.  There are now 
numerous studies comparing the sequences and structures of thermophilic enzymes with 
those of homologous enzymes from mesophilic organisms (ibid). These studies have 
found many types of stabilizing interactions in thermophilic enzymes, and there does not 
appear to be a single preferred mechanism for stabilization. In general, it appears that 
thermophilic enzymes have adapted to high temperature through the accumulation of 
numerous mildly stabilizing interactions, including salt bridges, hydrogen bonds, and van 
der Waals contacts. 
 
 Researchers have also focused on the dynamic properties of thermophilic 
enzymes.  The conformational flexibility of homologous thermophilic and mesophilic 
enzymes has been probed using different techniques, such as fluorescence quenching 3, 
hydrogen/deuterium exchange 4; 5; 6, molecular dynamics (MD) simulations 7, and neutron 
scattering 8; 9. Many of these studies have found that the conformational flexibility of 
thermophilic enzymes at room temperature is considerably reduced compared to 
mesophilic enzymes. At the same time, the flexibility of thermophilic enzymes near their 
physiological (high) temperatures is often comparable to that of mesophilic enzymes at 
their physiological (moderate) temperatures 3; 4. These findings concluded that reduced 
flexibility is a necessary consequence of thermostabilization, i.e., more stable proteins are 
less prone to have their structures perturbed by thermal fluctuations and therefore appear 
less flexible. Some researchers have further concluded that these differences in 
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conformational flexibility have functional consequences and can explain observed 
differences in the temperature-activity profiles of thermophilic and mesophilic enzymes 
(for example, the fact that thermophilic enzymes generally display poor activity at 
moderate temperatures) 1. Briefly, the argument states that conformational fluctuations in 
enzymes play an important role in their function as catalysts, but these fluctuations can 
also lead to the loss of structure and function if they become too large. Since the 
magnitude of the fluctuations experienced by an enzyme will depend on the available 
thermal energy, kBT, evolution has modified the strength and number of stabilizing 
interactions in enzymes to achieve the optimal balance of stability and flexibility at a 
given temperature. As a result, large changes in temperature will disrupt this balance, 
causing cold adapted enzymes to become unstable (at high temperatures), and 
thermophilic enzymes to become too rigid to function effectively (at low temperatures). 
 
 The results of several recent studies, however, are in marked contrast to those 
cited above. From the millisecond timescale dynamics of the hyperthermophilic 
rubredoxin from Pyrococcus furiosus investigated by NMR-monitored 
hydrogen/deuterium exchange, it was concluded that the protein’s conformational 
flexibility at room temperature is indistinguishable from that of mesophilic proteins on 
this time scale 6.   The room temperature dynamics of a pair of mesophilic and 
thermophilic α-amylases were probed using both hydrogen exchange and inelastic 
neutron scattering 8. This study also found no discernable difference in dynamics as 
monitored by hydrogen exchange, and found increased mobility on the picosecond time 
scale in the thermophilic protein, as measured by neutron scattering. 
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 The confusion regarding the relationship of conformational dynamics to stability 
and function in proteins stems from several sources. Firstly, different studies have 
monitored flexibility using different techniques. While all of these techniques are 
sensitive to protein conformational fluctuations, they often monitor very different aspects 
of these fluctuations. Fluorescence quenching relies on the quenching of fluorescing 
tryptophan residues by acrylamide, and is therefore only sensitive to those motions that 
allow acrylamide molecules to penetrate into the core of proteins and interact with buried 
tryptophans. Hydrogen/deuterium (H/D) exchange is sensitive to both local and global 
unfolding motions that expose buried amide hydrogens to water. However, under EX2 
conditions, where most studies have been performed, H/D exchange rates are 
proportional to the equilibrium constant for the conformational change(s) that result in 
the exposure of a given hydrogen 10. H/D exchange under these conditions is therefore a 
static measure of flexibility: it reflects the equilibrium populations of different 
conformations 11; 12. Inelastic neutron scattering is sensitive to the motions of individual 
hydrogens on the picosecond time scale 9, but it provides no spatial resolution. One can 
only measure the distribution of amplitudes for an entire protein and thus cannot assign a 
given amplitude of motion or relaxation time to a particular hydrogen atom.  
 
 In addition to the fact that protein mobility was probed using different techniques, 
the various studies of dynamics in thermally stable enzymes have employed different 
proteins, often with quite distinct native topologies. It is possible that different protein 
structures have had their dynamics altered in different ways by adaptation to high 
temperature. Finally, a single pair of homologous thermophilic and mesophilic enzymes 
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will typically differ at many (often >100) amino acid positions13. While some of these 
amino acid differences will be related to high temperature adaptation, many others will be 
neutral 14—the result of genetic drift—or will reflect adaptation of other enzyme 
properties. Although not all amino acid differences between a mesophilic enzyme and its 
thermophilic cousin will be directly related to temperature adaptation, they all have the 
potential to affect dynamics. It is therefore not straightforward to determine which 
observed differences in protein dynamics are related to high temperature adaptation and 
which are the result of neutral drift or adaptation to unrelated properties, a difficulty 
analogous to that of interpreting differences in amino acid sequences 15. 
 
 The ambiguities introduced by the presence of non-adaptive mutations can be 
avoided by studying a family of extremophilic enzymes evolved in the laboratory 15; 16.  A 
para-nitrobenzyl esterase (~450 residues) from B. subtilus was evolved for increased 
thermostability while its activity at room temperature was retained 17; 18. The final, eighth 
generation mutant 8G8 had a melting temperature 18oC higher than wild-type and had 
room temperature activity twice that of wild-type. In spite of these large functional 
differences, 8G8 differs from wild-type at only 13 out of 490 amino acid positions. 
Subsequently, the structures of wild-type, an intermediate mutant in the evolutionary 
pathway (referred to as 56C8) and the thermophilic mutant, 8G8, were determined by x-
ray crystallography19. The three-dimensional structure of the thermostable esterase 8G8, 
including the locations of the thermostabilizing mutations, is shown in Figure 1. 
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Figure 1. Three-dimensional structure of the pNB esterase mutant 8G8. The 
catalytic triad is shown in red and the 13 mutations from wild-type are shown in 
blue. Trp 102 is shown is yellow.   
 
 In order to investigate the relationship between stability, dynamics, and evolution, 
we have used the crystal structures of wild-type, 56C8, and 8G8 as the starting point for 
MD simulations including solvation. These MD simulations show the differences in 
dynamics between a set of proteins with a wide range of thermal stabilities, evolved 
under known selection pressures and differing by only a small number of functional 
mutations. 
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Results 
 
Validation of the simulations 
The overall calculated root-mean-square deviation (CRMS) of all atoms of the 
minimized wild-type, 8G8 and 56C8 structures from their respective crystal structures are 
0.39 Å, 0.72 Å and 0.79 Å. This shows that the forcefield and the surface generalized 
Born solvation method 20 are suitable for describing the dynamics of the system. Figure 2 
a shows the overall CRMS from the crystal structure for all atoms during the MD 
simulations. The large CRMS change in the initial several picoseconds is the result of 
heating the system from 0K to 300 K, and a simulation of the wild-type at 77 K shows a 
much smaller CRMS of 1.3 Å after equilibrium (data not shown).  From Figure 2 b, it is 
clear that the system has equilibrated after 100 ps of simulations (within ~0.1 Å CRMS of 
the average).   The overall fluctuations from the crystal structure are smaller for the 
thermostabilized mutants 8G8 and 56C8 than for wild-type. Figure 3 a, b and c compare 
the calculated CRMS for all the residues to the temperature factor (B factor) reported in 
the crystal structure for wild-type, 56C8 and 8G8, respectively. The fluctuations in 
CRMS by residue correlate well with the temperature factors from crystallographic data. 
For example in Figure 3c, residues 148 to 153 and 312 to 322 in 8G8 have high CRMS 
and also show large temperature factors. Both the high B factors and the large 
fluctuations during the simulations are expected for these regions, as they are composed 
of surface loops. This correlation between experimental and calculated fluctuations 
provides validation that our simulations accurately describe the dynamics of the system. 
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(a)
 
(b) 
 
Figure 2. Overall all-atom CRMS from (a) the minimized crystal structure, and (b) 
the time-averaged dynamic structure for wild-type pNBE and the two mutants as 
functions of time.  (Color coding: WT-blue, 56C8-cyan, 8G8-red) 
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(a) 
 
(b) 
 
(c) 
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(d) 
 
 
Figure 3. Averaged CRMS from the time-averaged  structure during the last 400 
picoseconds of the simulation vs. residue compared with experimental temperature 
factors for (a) wild-type, (b) 56C8 and (c) 8G8. All mutations in the two variants 
were labeled in (b) and (c).  Figure 3 d shows the difference in CRMS from the 
time-averaged structure between wild-type and 56C8 (cyan) and between wild-type 
and 8G8 (red). 
 
Differences in flexibility  
The CRMS from (a) the crystal structure and (b) the time-averaged structure for 
wild-type and both mutants as a function of time are shown in Figures 2 a and b, 
respectively. These CRMS values are averaged over all the residues.  The time-averaged 
structure is based on coordinates constructed from the average of all snapshots from MD 
simulations from 100 ps to 500 ps at interval of 1 ps. The time-averaged structure 
represents the average solution structure for a given protein. Relative to wild-type, the 
time-averaged structures of the thermostable mutants (particularly the most stable mutant 
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8G8) are closer to the crystal structures. However, the thermostable mutants actually 
show increased fluctuations about their time-averaged structures relative to wild-type.  
 
 
 
Figure 4. (a) Radius of gyration calculated using Equation 2 and (b) Total solvent 
accessible surface areas for wild-type (blue), 56C8 (cyan) and 8G8 (red) as 
functions of time.  
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Figure 4a shows the calculated radius of gyration for each of the esterases as a 
function of time. Both 56C8 and 8G8 show a small but statistically significant increase 
(about 1%) in radius of gyration relative to wild-type. This indicates a more expanded 
average structure, possibly as a result of larger or more frequent conformational 
“breathing” motions. Figure 4b shows the total solvent accessible surface area as a 
function of time for each of the three esterases.  Here, 8G8 shows a small but significant 
increase (about 5%) relative to wild-type. This again indicates a more “open” average 
structure for 8G8. In contrast, 56C8 shows only a very small difference from wild-type.  
 
Density of states 
For each of the three esterases, the vibrational density of states was calculated 
from the velocity autocorrelation function generated from the simulations. While the 
densities of states for the three structures are quite similar, there are discernible 
differences. Figure 5a shows the power spectra (vibrational density of states) of wild-
type, 56C8 and 8G8. The overall shape of the spectra are similar to the power spectra of 
other proteins, including those calculated from MD simulations (as was done in this 
work) and from normal mode analysis21. It is also similar to neutron scattering spectra 
obtained for globular proteins 21.  This demonstrates that our sampling rate is sufficient to 
capture the salient features of the dynamics, including the peak at ~3000 cm-1 which 
corresponds to hydrogen vibrations. Significant differences can be discerned in the DOS 
profiles at the lower wavenumbers. Figure 5b shows an expanded view of the DOS 
profiles from 2.0 to 25 cm-1.  Relative to wild-type, thermostable variants have 
substantially increased their populations of the lowest frequency modes (below 10 cm-1).  
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 (a) 
 
 (b) 
 
Figure 5. (a) Vibrational density of states (DOS) calculated using Equation 1 for 
wild-type (black line), 56C8 (blue line), and 8G8 (red line). (b) Expanded view of 
the DOS from 2.0 to 25 cm-1.  Intensity of DOS has the unit of number of modes 
per cm-1. 
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Theoretical studies 22 have established that the modes in this region correspond to 
collective motions, in which many atoms in a given protein region move in a concerted 
manner. The thermostable esterases thus appear to undergo concerted motions more often 
than wild-type, in contrast to what would be expected if higher stability were always 
accompanied by reduced mobility. The degree to which these low frequency modes have 
been increased varies among the mutants, with 8G8 showing a larger increase than 56C8. 
The rank order of the degree of increase in the low frequency modes thus matches the 
rank order of thermostability for the 8G8 and 56C8 variants, with the more stabilized 
mutant showing larger increase. That 56C8 and 8G8 experience concerted motions more 
frequently than wild-type is very consistent with the observation that both of these 
mutants have a larger radius of gyration than wild-type. 
 
Localized changes in mobility 
As thermostability is increased, both the N and C terminal domains of pNBE 
show significant reductions in CRMS from the crystal structure. At the same time, CRMS 
from the time-averaged structure is found to increase in many regions. Figure 3d shows 
the difference in CRMS fluctuations about the time-averaged structure between wild-type 
and the two mutants calculated for each residue. This is calculated by subtracting the 
CRMS given for wild-type in Figure 3 a from the CRMS given for each of the two 
mutants in Figures 3 b and c.  Some important mutations are labeled in the plot.  It is seen 
that 8G8 shows larger fluctuations about the time-averaged structure than wild-type, 
especially for those residues around the mutations. Also these fluctuations are over longer 
stretches of consecutive residues in 8G8 than wild-type. The most dramatic changes 
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between the thermophilic mutant 8G8 and wild-type are seen in the regions comprised of 
residues 240-290, 312-360, and 410-420 (Figure 3 d). Coincidentally, there are several 
mutations in this region, most notably L313F and H322Y, which suggests that these 
mutations confer more flexibility in thermophilic 8G8. Residues 310-320 form a part of 
the active site, and Glu310 itself is part of the catalytic triad. For all three residues that 
make up the catalytic triad—Ser189, Glu310, and His399—the CRMS from the average 
structure are very close for wild-type and 8G8 (Table 1). This indicates that the dynamic 
properties of the critical active site residues have been conserved in spite of significant 
changes in other regions. 56C8 shows larger differences from wild-type at the active site. 
This may be a reflection of the fact that, experimentally, 56C8 is less catalytically active 
than wild-type in aqueous solution (56C8 was originally evolved for activity for 
catalyzing hydrolysis of para-nitrobenzyl ester in aqueous organic solvents, see 17 for 
details). A region that shows negative differences in CRMS between wild-type and the 
mutants is comprised of residues 414-420. This is interesting because in most other 
regions 8G8 shows large CRMS than wild-type.  These residues form a short turn of α-
helix in 56C8 and 8G8. In wild-type, however, they do not appear in the electron density, 
indicating that this regions is highly dynamic or disordered 19. For purposes of the 
simulation, these residues were built into the wild-type structure based on the coordinates 
of 8G8. The fact that this region has high mobility during our simulation of wild-type is 
consistent with the observation that this region does not appear in the electron density of 
the wild-type crystal structure, and further confirms that our simulations have correctly 
described the structural dynamics of the system. 
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Table 1. Fluctuations of the catalytic triad (Å) during the last 400 ps of MD simulation 
Residue Wild-type 56C8 8G8 
Ser 189 0.35 0.32 0.34 
His 399 0.39 0.60 0.42 
Glu 310 0.32 0.44 0.39 
 
 
It is of interest to identify the nature of the low frequency modes of motion whose 
populations are increased in the thermophilic mutants relative to wild-type (see the 
discussion of the vibrational density of states above). Aligning structures taken at various 
times during the simulation allows us to identify those regions that show the largest 
differences in mobility between wild-type and the mutants. The aligned snapshots of 8G8 
show larger average RMS deviations than those of wild-type; consistent with the fact that 
8G8 shows larger fluctuations about its time-averaged structure. From the alignment, the 
largest displacements are located in the regions comprised of residues ~240-295 and 
~310-360 (Figure 6 a, b). These regions contain several helices (residues 252-266, 287-
294, 326-333, 337-345, and 350-362) whose positions fluctuate up to 6Å in 8G8, while 
they remain essentially superimposable in wild-type. It is interesting to note that these 
helices shift their positions essentially as rigid bodies, with little evidence of unraveling 
or deformation. Such motions involve a large number of atoms moving in a concerted 
manner, and are thus good candidates for the low frequency motions that are increased in 
the thermostable mutants.  Further, the surface loop comprised of residues ~315-323 
undergoes fluctuations of up to 6Å in 8G8, while it shows little movement in wild-type. 
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These motions each involve up to 14 residues moving in a concerted manner, and may 
thus contribute to the increased density of states seen at wavenumbers below ~10 cm-1.  
We note that in this same region the wild-type structure exhibits large deviations from the 
crystal structure (Figure 7 a, b). In particular, the helices from residues 326-333 and 337-
345 in wild-type shift significantly from their initial positions, while they remain close in 
8G8. 
 
Figure 6. Superimposed snapshots of (a) 8G8 and (b) wild-type taken at 100 
(blue), 300 (green), and 500 ps (yellow). Residues 240-300 and 310-360 are 
shown. 
 
The largest difference in RMSD about the time-averaged structure between wild-
type and 8G8 is seen in the loop comprised of residues 315-323 (Figure 3d). This region 
is flanked by two stabilizing mutations, L313F and H322Y. L313F forms an edge-face 
interaction with Phe 314, while H322Y forms interactions with a number of residues  
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Figure 7. Superimposed energy minimized crystal structure (blue) and structure at 
300 ps (green) for (a) 8G8 and (b) wild-type. 
 
including Ile 270 and Val 358 (resulting from the stabilizing mutation M358V). These 
contacts are maintained during the simulation, and appear to prevent the 315-323 loop 
from shifting substantially away from its position in the crystal structure (as occurs in 
wild-type). While the two ends of the loop are thus fixed in place, the region between 
them experiences larger fluctuations during the simulation than in wild-type. The RMSD 
from the time-averaged structure for 8G8 (Figure 3 c) reveals several “spikes”, i.e., 
stretches of residues in which the RMSD is markedly greater than in the surrounding 
regions. Examining the distribution of mutations in Figure 3 c, it can be seen that 
mutations are found in the “valleys” immediately adjacent to these areas. These 
observations suggest that the stabilizing mutations in 8G8 act as local anchors, locking 
down specific regions and preventing them from deviating far from their conformation in 
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the crystal structure. Regions adjacent to these anchor points experience increased 
fluctuations, though these fluctuations occur about a mean conformation that is closer to 
the crystal structure than would be the case if the stabilizing mutations were absent. The 
case of the 215-223 loop flanked by mutations L313F and H322Y illustrate this 
particularly well, and provides a clearer physical picture of what is meant by the 
statement that the thermophilic mutants remain closer to their crystal structures while 
exhibiting increased fluctuations about their time-averaged structures.  
 
Mobility of Trp 102 
The primary mechanism for non-radiative decay in phosphorescing Trp residues 
is vibrational coupling between the triplet state and the ground state due to out-of-plane 
distortions of the aromatic ring 23; 24. Thus, longer phosphorescence lifetimes indicate 
reduced local fluctuations. Tryptophan phosphorescence lifetimes have been used to 
probe local mobility/rigidity in proteins 25. The phosphorescence lifetimes of Trp102 
were measured previously for wild-type and several thermostable mutants, including 8G8 
18. Lifetimes were not experimentally measured for 56C8, but were determined for the 
closely related mutant 1A5D1 (56C8 has all of the stabilizing mutations present in 
1A5D1 plus two additional mutations, L334S and P317S, which do not lie near Trp102). 
It was found that all mutants show increased phosphorescence lifetimes relative to wild-
type, with 8G8 showing the largest increase (1.9 times that of wild-type). The lifetime 
measurements for Trp102 provide an ideal means for assessing the quality of our 
simulations, since the motions responsible for phosphorescence decay are believed to 
occur on the picosecond timescale. Figure 8 a shows the all-atom CRMS from the time- 
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Figure 8. (a) All-atom CRMS from the time-averaged dynamic structure for Trp102 as a 
function of time. (b) Out-of-plane bending motions (see text) for Trp102 as a function of 
time. (c) Time-averaged sin2θ versus the inverse of phosphorescence lifetime.  
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averaged structure of Trp102 for wild-type, 56C8, and 8G8.  The average CRMS in all 
three enzymes is ~ 0.5Å. However, the frequency and magnitude of larger deviations is 
clearly greater for wild-type than for 8G8. Figure 8 b shows the out-of-plane bending 
motion angle for Trp102 as a function of time. From Figure 8a and 8b it is clear that 
Trp102 in WT shows larger instantaneous fluctuations in CRMS from the crystal 
structure and also higher values for sin2θ in the out-of-plane bending motion than either 
56C8 or 8G8. If the time-averaged sin2θ value is plotted versus the inverse 
phosphorescence lifetime, the data can be fit into a straight line (Figure 8 c).  This is 
consistent with the theory that phosphorescence lifetime inversely correlates with sin2θ 
23. These motions occur at the picosecond timescale and thus are in accordance with the 
experimental findings. The degree of larger deviations for 56C8 falls between wild-type 
and 8G8. Thus the degree of Trp102 motion on the picosecond timescale ranks as wild-
type > 56C8 > 8G8. This is in excellent correspondence with what is expected from the 
observed phosphorescence lifetimes. As expected, an inverse correlation is seen between 
the degree of Trp102 motions during the simulation and the measured phosphorescence 
lifetimes. 
 
Discussions 
 
The most striking result from this study is the apparent discrepancy between 
different measures of flexibility. Based the CRMS from the crystal structure it appears 
that the thermophilic mutant 8G8 is indeed more rigid than its mesophilic parent. 
However, the CRMS from the time-averaged structure, the radius of gyration, and the 
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population of low frequency modes all indicate that 8G8 is in fact more mobile than wild-
type. These observations are not necessarily contradictory. Proteins experience a wide 
array of motions spanning a vast range of amplitudes and timescales. There is no reason 
to expect that all of these different modes of motion will change in the same way as a 
given protein evolves to become more stable.  
 
Our results indicate a need to refine the term “flexibility” as it is currently used in 
discussions of temperature adaptation in proteins. The timescales, amplitudes, and 
locations of the motions presumed to contribute to flexibility must be specified. Clearly 
certain modes of motion, particularly those that may initiate unfolding, must be reduced 
if a protein is to achieve increased stability at elevated temperatures. In the case of pNBE, 
this is perhaps being reflected in the reduced deviations of surface loops from their 
positions in the crystal structure. 
 
For many other types of motions, however, there is little evidence that they are 
detrimental to global stability. In fact, there is increasing evidence that various modes of 
motion contribute to the stability of the native state. In general, work has focused on 
small amplitude local fluctuations. Recent neutron scattering studies of a mesophilic and 
thermophilic α-amylase found that the thermostable enzyme displayed increased mobility 
relative to the mesophilic one on the 0.3 to 6.0 picosecond timescale 8; 9. These same 
studies, however, found no difference in mobility between the two proteins in the 
unfolded state, suggesting that increased conformational entropy in the native state may 
contribute to the stability of the thermophilic enzyme. Recent NMR relaxation studies of 
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bond vector motion in proteins have led to estimates of the contribution of native-state 
conformational entropy to stability 26. These studies conclude that local internal protein 
motions may increase stability by increasing the entropy of the native state. Such motions 
can also raise the melting temperature of a protein by increasing the heat capacity of the 
native state and thus decreasing the heat capacity difference between the native and 
denatured states (∆Cpunfold) 27. Such a decrease in ∆Cp will expand the temperature range 
in which a protein remains folded by both raising the melting temperature and decreasing 
the cold-denaturation temperature. The idea that protein motions contribute to stability is 
supported by the opposing trends we observed for the CRMS deviations from the esterase 
crystal structures and the CRMS fluctuations about the time-averaged structures during 
the simulations. Relative to wild-type, the thermophilic esterase 8G8 maintains its 
average structure closer to the crystal structure even while it experiences greater 
fluctuations about this average. This idea is also supported by the fact that the 
thermophilic variants show increases in the population of the low frequency modes. 
Further, calculation of thermodynamic parameters from the velocity autocorrelation 
function does indicate that thermostabilization is accompanied by increases in the 
absolute native state entropy and heat capacity. Due to the limited simulation time it is 
unlikely that these calculated values would agree exactly with measured values 
(excepting the heat capacity, these absolute values are not practically amenable to 
experimental measurement in any case). However, they do indicate that, on this 
timescale, the thermostable mutants explore more degrees of freedom than wild-type.  
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 The dynamics of folded proteins are often described in terms of a high 
dimensional energy landscape consisting of many conformational substates (local energy 
minima) separated by energy barriers 28. In this picture, transitions may be expected to 
occur frequently between conformations of similar energy separated by low barriers. In 
contrast, transitions between conformations separated by large energy barriers will be 
observed only rarely. Our results indicate that different aspects of the energy landscape 
can respond to the demands of high temperature adaptation in different ways. On a global 
scale, the fact that 56C8 and 8G8 are more stable than wild-type indicates that the 
distance between the native state ensemble and the denatured state ensemble has 
increased. Both mutants remain closer to their minimum energy structures during the 
simulation. An equivalent statement is that conformational substates, which depart 
substantially from the minimum energy structure, are being sampled less frequently. This 
suggests that the energetic barriers separating such substates from the minimum energy 
state have been increased. At the same time, the increased fluctuations about the time-
averaged structure indicate that the barriers between some conformational substates have 
been reduced.   
 
In addition to these differences in overall mobility, it is also clear that different 
regions of the protein have manifested different changes in mobility in response to 
temperature adaptation. In general, surface loops show the largest differences in mobility 
(as measured by both CRMS from the crystal structure and the time-averaged structure) 
in going from wild-type to 8G8.  Large displacement of surface loops from their native 
conformation has been identified in other studies as an important factor in thermostability 
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29; 30. Such large loop displacements may expose the hydrophobic core of a protein to 
water penetration, leading to unfolding.  It is not unexpected, therefore, to find that 
alterations in loop mobility accompany the thermostabilization of pNBE. At the same 
time other regions of the protein display much smaller changes in mobility as a result of 
temperature adaptation. In particular, the RMS fluctuations of the three catalytic residues 
are remarkably conserved between wild-type and 8G8 (Table 1). While fluctuations about 
the time-averaged structure increased in many regions of the thermostabilized pNBE 
variants, they decreased in the immediate vicinity of Trp 102, consistent with the 
experimental observation that its phosphorescence lifetime is longer in more stable 
mutants.  
 
 It is useful to compare our results with two recent simulation studies of 
thermophilic and mesophilic proteins. Colombo and Merz 30 performed extensive 
simulations of wild-type subtilisin E and a homology model of its thermophilic 
counterpart 5-3H5, which was generated by directed evolution.  They also found a 
difference in the flexibilities as measured by CRMS from the crystal structure and by 
CRMS from the time-averaged structure. While the thermostable enzyme showed smaller 
deviations from the crystal structure, it showed larger fluctuations about the time-
averaged structure.  The simulations reported here allow for comparisons with 
experimental data in the form of crystallographic temperature factors and tryptophan 
phosphorescence lifetimes. The observed correlation of our results with the available 
experimental data increases our confidence that the increased flexibility seen in the 
thermostable mutants is real and not simply an artifact of the simulation. 
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 In another study, Lazaridis et al. 7 performed simulations on mesophilic and 
hyperthermophilic rubredoxins. In contrast to the results of this study and that of 
Colombo and Merz, Lazaridis et al. found that, by all measures, the hyperthermophile 
showed slightly reduced mobility relative to the mesophile at room temperature. The 
hyperthermophilic rubredoxin was natural rather than laboratory evolved, and the results 
of Lazaridis et al. may indicate that natural thermophilic enzymes are altered in their 
conformational mobility in fundamentally different ways than laboratory evolved 
thermophilic enzymes (the experimental results from the α-amylases argue against this, 
however). It is also possible that the low mobility of the hyperthermophilic rubredoxin is 
the result of functional considerations. In contrast to enzymes, which are thought to 
require a considerable degree of mobility in order to catalyze reactions efficiently, the 
rubredoxins are thought to undergo only very minor conformational changes during 
oxidation/reduction 31. 
 
Given the variety of protein topologies and functions, it is not surprising to find 
that different proteins have responded to the challenge of high temperature adaptation in 
different ways. The family of laboratory-evolved pNB esterases has provided us with a 
unique opportunity to examine how protein dynamics change in response to adaptive 
evolution without the complications and ambiguities introduced by neutral mutations and 
unknown selective pressures. Our study has found that adaptation to high temperature 
results in a rich variety of alterations in dynamic behavior, including reductions in certain 
types of motions and increases in others. This may help explain the apparently 
 213
contradictory experimental results that have been reported in studies of thermophilic 
enzymes. Some techniques, such as H/D exchange of the slowly exchanging hydrogens, 
will be sensitive primarily to motions that involve significant departures from the native 
state. We have seen a reduction of such displacements from the minimum energy 
structure in our simulation of the thermophilic esterases. Other techniques, such as 
neutron scattering and nuclear magnetic relaxation, can detect small amplitude local 
fluctuations, which we have seen increased in the thermophilic esterases. Our study 
suggests that the apparently contradictory results reported from these diverse 
experimental techniques might reflect different aspects of dynamic adaptation to high 
temperatures. 
 
Materials and Methods 
 
 The three crystal structures WT, 8G8 and 56C8 were used as the starting structure 
for all the molecular dynamics (MD) simulations (PDB entries 1QE3, 1C7J and 1C7I). 
All the hydrogen atoms were added explicitly using Polygraf, and counterions Na+ and 
Cl- were added to neutralize the side chains of Asp, Glu, Arg and Lys 32. These 
counterions are allowed full freedom to move in the dynamics, but stay close to the 
original positions. 
 
We used Dreiding forcefield 33 with the charges from CHARMM22. 34 The 
nonbond (Coulomb and van der Waals) interactions were calculated using the Cell 
Multipole Method 35 (CMM) for fast and accurate calculations of nonbond interactions. 
CMM scales linearly with the number of atoms, so that no cutoffs are required.   
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Since inclusion of explicit water in the MD simulations is computationally 
intensive, we have used the Surface Generalized Born (SGB) continuum solvation model 
20 to calculate both the energy and the forces due to the solvent acting on the protein 
structure. SGB accounts for the response in the protein conformation due to electrostatic 
interactions with the solvent, which is assumed to extend beyond the solvent accessible 
surface of the protein. The only properties of solvent required are the dielectric constant 
(78.32) and the solvent radius (1.4 Å).  We assume an ionic strength of 0.1.  We assumed 
that the internal dielectric constant of the protein is 2.0. The SGB method is an 
approximation to the Poisson-Boltzmann continuum solvation model 36 for calculating 
energies and forces but is much faster.  Of course both are faster than explicitly including 
the water solvent.  
 
The total potential energy of each of the three structures was minimized using 
conjugate gradients. The minimization was performed for 1000 steps with a termination 
criterion that the RMS force is less than 0.1 kcal/mol/Å.   
 
Constant temperature Hoover MD simulations 37 were carried out on all three 
structures for 500 ps. The temperature of the simulations was set to 300 K. The parallel 
MPSIM MD program 38; 39 was used for all simulations. 
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Calculation of RMS difference in coordinates:   
As a simple measure of similarity between two structures we calculate the root 
mean square of the differences in coordinates between all corresponding atoms in the two 
structures. First an optimal translation and rotation is performed to superpose the center 
of mass and the moments of inertia and then the coordinates of equivalent positions are 
compared.  This is referred to as the CRMS (coordinates root mean square) difference.  In 
calculating the CRMS (and radius of gyration) we do not include the counterions. 
 
We first validated our forcefield by calculating the CRMS differences between 
the experimental crystal structure and the energy-minimized structure.  Generally a 
CRMS lower than 0.6 A is considered to indicates that the forcefield is sufficiently 
accuracy.  
 
We also report CRMS differences between the snapshots of the MD structures at 
various time intervals and the starting minimized energy structure. The CRMS with 
respect to the minimized structure shows the temperature factors for various regions of 
the protein indicating which parts are more flexible than others (in solution).  
 
The average MD structure was calculated by averaging the coordinates of the 
various MD snapshots from 100 ps to 500 ps at 1 ps time intervals. This average structure 
represents the structure of the protein equilibrated in salt and solvent. 
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Calculation of density of states:  
The vibrational density of states (power spectrum) was calculated from the 
Fourier transform of the velocity auto-correlation function: 
                                        ∑
=
=
N
j
vvjCmS
3
1
)(~2)( νβν ,      (1) 
where )(~ νvvC  is the Fourier transform of the velocity auto-correlation function Cvv(t),  mj 
is the mass of atom j, β = 1/(kBT) and kB is Boltzmann’s constant, T is the absolute 
temperature of the system.  Sampling of the velocities was done as low as every 1 fs to 
obtain the high frequency and less often to obtain the low frequency modes.  
 
Calculation of solvent accessible surface area:  
The solvent accessible surface area is calculated using Connolly’s molecular 
surface calculation program in which a probe is rolled along the surface of the protein 40.  
The probe size used was 1.4 Å.  
 
Calculation of radius of gyration:  
The radius of gyration is calculated using the following definition: 
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ii
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rm
R ,     (2) 
in which ri is the distance of the atom i from the center of mass of the protein molecule, 
and mi is the mass of the  ith atom. 
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Calculation of Trp out-of-plane bending modes:  
In the absence of oxygen, the phosphorescence lifetime of a buried Trp is 
primarily determined by the out-of-plane motion. In the present calculations we have 
defined out-of-plane bending as involving the nitrogen atom in the indole ring 23; 24. The 
out-of-plane bending is measured as the angle, θ, between the p orbital of the N atom and 
the normal of the six-member ring.  The phosphorescence lifetime of the indole ring 
decreases with increasing sin2θ value 23.   
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Appendix II 
 
 
Guanidine Hydrochloride-Induced Unfolding of Rubredoxin 
from Pyrococcus furiosus: Evidence for “Unfolding” 
Intermediates* 
 
 
 
                                                          
* This appendix is based on a manuscript for Biochemistry coauthored with Michael W. W. Adams, and 
Sunney I. Chan 
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Abbreviations 
 
 
 
RdPf, rubredoxin from Pyrococcus furiosus; GuHCl, guanidine hydrochloride; DTT, 
dithiothreitol; ANS, 1-anilino-naphthalene-8-sulfonate; CD, circular dichroism; F, folded 
state; U, unfolded state; I1, the first intermediate state; I2, the second intermediate state; K, 
equilibrium constant; fF, fraction of folded; fI1, fraction of the first intermediate; fI2, 
fraction of the second intermediate; fU, fraction of unfolded; zi, the fractional change in 
the spectral property from the folded state to the i-th intermediate state; ∆GDH2O, global 
unfolding free energy; ∆GI,i, the free energy difference between the folded state and the i-
th intermediate state; mD, the dependence between free energy change and denaturant 
concentration; R, universal gas constant; T, absolute temperature. 
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Abstract 
 
 
Rubredoxin from Pyrococcus furiosus (RdPf) is a hyperthermophilic protein that 
does not undergo thermal melting even at temperatures well above 100 oC at neutral pH. 
However, it is possible to denature the protein at pH 2 by disrupting all the salt bridges. 
We report here denaturant-induced unfolding of RdPf in the presence of guanidine 
hydrochloride at pH 2 as followed by UV-visible absorption, fluorescence and CD 
spectroscopic techniques. The results obtained suggest that at least two different 
intermediates are present in the equilibrium unfolding pathway. The two intermediates 
have maximum population at 2.4 and 3.3 M guanidine hydrochloride, respectively. The 
global unfolding free energy (∆GDH2O) for RdPf at pH 2 is estimated to be 13.6 kcal/mol. 
However, if the disrupted salt bridges are taken into account, this value will be larger for 
RdPf at neutral pH, suggesting that RdPf is thermodynamically more stable than most 
other single-domain proteins. The factors contributing to the stability of RdPf are 
estimated, and the results suggest that the enhanced protein stability does not require 
strong stabilizing forces, merely tuning of the forces to accomplish a redistribution of 
thermally accessible conformational states. 
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Introduction 
 
 
Hyperthermophiles are microorganisms that have optimal growth temperatures of 
at least 80 oC. Several of them have optimal temperatures over 100 oC, which is the 
highest temperature that life is known to exist to date. Most of the proteins isolated from 
such organisms exhibit correspondingly enhanced thermostability. This property is useful 
both for the investigation of fundamental biological questions of protein stability, and for 
the development of biotechnological applications that require protein stability at high 
temperatures. Examples of such applications are detergent manufacturing, production of 
high-fructose corn syrup, the polymerase chain reaction (PCR), etc. (1).  
 
The origin of the thermostability of enzymes from hyperthermophiles has not 
been fully understood, despite that many primary sequences of hyperthermophilic 
proteins and their mesophilic counterparts are available for comparison, and high-
resolution structures of hyperthermophilic proteins have become available for many 
proteins, e.g., rubredoxin (2, 3), GAPDH (4), aldehyde ferredoxin oxidoreductase (5), 
histone HMfB (6) and glutamate dehydrogenase (7). Surprisingly, the structures of 
homologous proteins from hyperthermophilic sources are strikingly very similar to their 
mesophilic counterparts. For example, the RMS difference between rubredoxin from the 
hyperthermophile Pyrococcus furiosus (RdPf) and the mesophile Clostridium 
pasteurianum (RdCp) is only 0.47 Å for the main chain (3), presumably because of the 
high sequence identity and very few additions or deletions of amino acid residues. It is 
not clear that hyperthermophilic proteins are intrinsically more stable thermodynamically. 
Preliminary investigations with RdPf have suggested that such proteins could be 
  
224
kinetically trapped in some local energy minimum (Cavagnero et al., unpublished result). 
To resolve this issue, thermodynamic studies on hyperthermophilic proteins are greatly 
needed.  
 
 An ideal model system to address the issue of protein hyperthermostability is the 
rubredoxin from Pyrococcus furiosus (RdPf), a non-heme iron-protein with 53 amino 
acids. Its biological function is not known, although it is believed to take part in electron 
transfer processes in the cytoplasm (8). Both X-ray crystallographic and NMR solution 
structures of RdPf are available (2, 3). Its amino acid sequence and three-dimensional 
structure made from Molscript (9) are shown in Figure 1. Calorimetric studies on RdPf 
suggest that the protein has a melting temperature of 113 oC (10). Results of hydrogen-
exchange studies on the native protein have been used to infer that the melting 
temperature of this protein could be as high as 170 oC (11). The role of salt bridges and 
the β-sheets in determining the hyperthermostability of RdPf has been evaluated (12, 13).  
Recently a RdPf variant without the Fe-(Cys)4 center has been designed and used as a 
model to evaluate the contribution of surface salt bridges to protein stability (14, 15). The 
conformational flexibility of RdPf has been discovered to be in millisecond time scale 
using hydrogen exchange technique (16). In addition, several theoretical studies have 
appeared on the protein dynamics and thermal unfolding simulation of RdPf (17-19). 
 
 In the present study, we report the results of guanidine hydrochloride-induced 
RdPf unfolding experiments and the unfolding transition determined by UV-visible 
absorption, fluorescence and circular dichroism spectroscopic measurements.  Evidence 
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is obtained for unfolding intermediates in the denaturant-induced unfolding process.  The 
implications of these findings will be discussed.   
 
 
Figure 1.  Molscript representation of RdPf structure.  The iron-4cys coordination is 
shown in ball-and-stick model.  The amino acid sequence is shown below the 
structure. 
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Materials and Methods 
 
 
Materials.     
RdPf was isolated and purified from Pyrococcus furiosus as described 
previously(20).  The purity of the protein was adjudged by the ratio of extinction 
coefficients between 280 nm and 380 nm. This ratio was 0.40 for the samples used in this 
study compared to 0.42 reported in literature(20). Protein concentrations were determined 
by measuring their absorption at 280 nm.  The protein was stored in 50 mM Tris buffer 
(pH 8.0) with 0.3 M NaCl at –20 oC.  It was concentrated and buffer-exchanged with a 
Microcon 3 device (Amicon) before use.  
 
Ultra-pure guanidine hydrochloride (GuHCl) was purchased from Baker and used 
without further purification.  Dithiothreitol (DTT, electrophoresis grade) was purchased 
from ICN Biomedical.  
 
Spectroscopic measurements of the unfolding transition.     
8 M GuHCl stock solution was prepared before the denaturation experiments.  
The stock solution was then diluted to different concentrations in attempts to denature the 
protein.  20 mM phosphate buffer was added to the protein solution to maintain the pH at 
either 2.0 or 7.0.  A pHM93 pH meter from Radiometer Copenhagen with a general-
purpose pHC2406 electrode was used to measure the pH values.  The samples were 
incubated typically for 60 hours at room temperature to reach equilibrium. 
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 UV-visible absorption spectra were recorded with a Hewlett-Packard 8452A 
single-beam diode array spectrophotometer.  A 1 cm quartz cuvette was used in spectra 
acquisition.  All the experiments were performed at room temperature.  Buffers 
containing appropriate concentrations of GuHCl were used as the blank.  Published 
values for the extinction coefficients of RdPf at the wavelengths of maximum absorption 
were used (20).  The UV-visible absorption spectra were recorded and the absorbance at 
380 nm was used to follow the unfolding process.  
 
 The tryptophan fluorescence was recorded on a Hitachi F-5000 Fluorescence 
Spectrophotometer.  The excitation wavelength was set at 280 nm and the emission 
spectrum was recorded at the wavelength range from 290 nm to 450 nm.  Since the buffer 
and GuHCl do not fluoresce at this region, no blank was subtracted.  The spectra were 
plotted against wavenumber or the reciprocal of wavelength and then simulated by a 
three-peak Gaussian function centered at 310 nm, 335 nm and 355 nm, respectively.  The 
fluorescence intensity at 353.8 nm was used to analyze the data, because the ratio of the 
fluorescence intensity of the unfolded protein to the folded protein shows a maximum 
value of about 5 at this wavelength.    
 
Far-UV circular dichroism spectra were acquired with a JASCO 600 
spectropolarimeter using a 0.1 cm path quartz cell from Hellma.  RdPf concentrations 
were typically from 5 to 10 µM.  The CD spectra were recorded over the range of 200-
300 nm.  The scan step was set at 0.2 nm and the scan speed was 50 nm per min.  The 
sensitivity of the CD signal was 50 mdeg.  Each spectrum was an average of three scans 
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to improve the signal-to-noise ratio.  The ellipticity at 225 nm was used as a measure of 
the secondary structure (β-sheet).  The buffer and GuHCl show no CD in this region.  
 
Analysis of the unfolding curves.   
Since more than one technique has been used to follow the unfolding process, we 
shall refer to the various physical or spectroscopic parameters as “y” in the present 
generic analysis of the data. 
 
For a two-state folding process, we may write (21) 
 
 
      Folded (F) ⇔  Unfolded (U).            (1) 
 
 
Here, it is assumed that only the folded and unfolded conformations are present at 
significant concentrations.  Consequently, fF + fU =1, where fF and fU are the fraction of 
protein present in the folded and unfolded conformations, respectively.  Thus, the 
observed value of the spectroscopic parameter y at any denaturant concentration will be y 
= yFfF + yUfU, where yF and yU represent the values of y characteristic of the folded and 
unfolded states, respectively, under the conditions where y is being measured.  
Combining these equations yields 
             (2)                                                          .   
UF
F
U yy
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 The equilibrium constant, K, and the free energy change, ∆G, can be calculated 
using 
(3)                                                  
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and 
     (4)                                             ,lnln
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yyRTKRTG −
−−=−=∆  
where R is the gas constant (1.987 cal/mol/K) and T is the absolute temperature.  Values 
of yF and yU in the transition region are obtained by extrapolating from the pre- and post-
transition regions.  When y remains unchanged in the pre- or post-transition region, yF 
and yU can be simply the value of y at 0 M and 6 M denaturant concentration, 
respectively.  Values of K can be measured most accurately near the midpoints of the 
denaturation curves, the errors become substantial for K values outside the range 0.1  
10.  Consequently, only ∆G values within ±1.5 kcal/mol are generally used. 
 
 In a scenario where more than one step is observed in the unfolding transition, 
intermediates have to be included in the equilibrium(21): 
  Folded (F)   ⇔     Intermediate 1 (I1) ⇔     •••••• 
⇔     Intermediate n (In)  ⇔     Unfolded (U)      (5) 
Whether or not the intermediates are present directly on the unfolding pathway from F to 
U is not important, because the distribution is the same in the equilibrium.  When stable 
intermediate states, Ii are present, and each characterized by the property yi and fraction fi, 
the observed extent of unfolding, e.g. Equation (2), becomes 
 ∑+=
i
iiUobs zfff ,     (6) 
where 
FU
Fi
i yy
yyz −
−= .      (7) 
  
230
Thus, fobs will differ from fU by an amount that depends on the concentration of the 
intermediates weighted by their zi values.   The zi value for an intermediate is the 
fractional change in y in going from F to Ii and is likely to be between 0 and 1, because yi 
will generally fall between yF and yU (21). 
 
 The linear extrapolation model is used in the free energy analysis.  The 
relationship between ∆GD and the denaturant concentration is (21): 
    (8)                                               ][2 denaturantmGG OHDD −∆=∆  
It is assumed that both ∆GD and ∆GI,i obey this model independently, i.e., they have 
different m values, where ∆GI,i is the free energy difference between the fully folded state 
and the i-th intermediate state.  Combining Equations (2)-(4) and (6)-(8), we can obtain 
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where [D] is the concentration of denaturant, mD and mi are the m values for the fully 
unfolded state and the i-th intermediate state, respectively.  All the other parameters are 
the same as defined before.  Equation (9) has been used to fit the experimental data in all 
cases.  
 
 The data analysis was done using Microcal Origin (version 5.0).  The built-in 
multi-Gaussian function was used to simulate the fluorescence spectra.  User-defined 
functions were constructed for the two-state, three-state and four-state transitions and 
used to simulate the unfolding transition curve. 
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Results 
 
 
GuHCl-induced unfolding of RdPf at pH 2  
UV-visible absorption.     
The guanidine hydrochloride-induced unfolding of RdPf in 20 mM potassium 
phosphate buffer at pH 2 and 25 oC, was monitored by UV-visible absorption 
spectroscopy.  RdPf exhibits four absorption bands in the UV-visible region.  The 
absorption band at 280 nm is contributed by tryptophan and tyrosine residues (22).  The 
other three bands at 380 nm, 490 nm and 570 nm are due to the charge-transfer 
transitions between the iron and the four sulfurs (23).  The UV-visible absorption 
spectrum of RdPf revealed no changes upon lowering the pH from 7.0 to 2.0 (12).  The 
380 nm band was chosen to follow the unfolding process because the differential 
absorption between the fully unfolded protein and the folded native protein is the largest. 
 
The observed fraction of unfolded protein was obtained from Equation (2) by 
substituting A380 for y and plotted as a function of GuHCl concentration (Fig. 2).  The 
absorbance of the fully folded RdPf was simply taken from the spectrum at 0 M GuHCl 
because A380 shows no change with GuHCl concentration in the pre-transition region (0 
 1 M).  The protein was fully unfolded under 6.0 M GuHCl so that the absorbance is 
zero.  
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Figure 2.   GuHCl-induced unfolding of RdPf at pH 2 as followed by UV-
visible absorption spectra.  The samples have been incubated at room 
temperature for 40 hours before recording.  The unfolding curve is analyzed 
by taking the absorbance at 380 nm.  Two-state and three-state models have 
been used to fit the transition curve. 
 
It is clear that at least one intermediate exists in the unfolding transition, because 
there is a shoulder at about 3.2M GuHCl (Figure 2).  A two-state transition has a smooth 
curve.  The presence of intermediates in the unfolding is very important in determining 
the unfolding parameters.  The presence of intermediates can greatly increase the 
unfolding free energy of a protein.  For example, a two-state analysis of the α-subunit of 
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tryptophan synthase led to ∆GD = 3.6 kcal/mol, but when the intermediate is taken into 
account, ∆GD =11.0 kcal/mol (24).  
Here, in the case of RdPf, the ∆GD was 2.98 kcal/mol with a m value of 0.89 
kcal/mol/M for a two-state model, while for a three-state model, the parameters were 
∆GD = 10.60 kcal/mol, mD = 3.17 kcal/mol/M, ∆GI = 3.27 kcal/mol, mI = 1.37 
kcal/mol/M, zI = 0.46.  The simulated two-state and three-state transition curves are also 
shown in Figure 2.  It is very clear that the fit to a three-state model is much better than 
that to a two-state model.  The results of fitting the data to a four-state model are included 
in Table 1. 
 
Table 1.  Parameters for two- and multi-state fits to the observed transition curves 
( units: ∆G/ kcal/mol, m/ kcal/mol/M ) 
 
Model Spec ∆GI1H2O ∆GI2H2O ∆GDH2O mI1 mI2 m z1 z2 
 
Two-
state 
UV 
Fluo 
CD 
  2.98 
3.82 
3.24 
  0.89 
1.18 
1.08 
  
 
Three-
state 
UV 
Fluo 
CD 
3.27 
3.14 
2.63 
 10.60 
10.61 
9.39 
1.37 
0.97 
0.76 
 3.18 
2.86 
2.43 
0.46 
0.88 
1.26 
 
 
Four-
state 
UV 
Fluo 
CD 
2.10 
2.73 
1.72 
5.33 
5.58 
4.16 
13.16 
13.55 
13.09 
1.19 
0.69 
0.15 
2.45 
1.94 
1.64 
4.35 
4.05 
4.05 
0.10 
0.48 
0.56 
0.51 
0.83 
0.78 
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Tryptophan fluorescence.   
Figure 3 shows the GuHCl-induced unfolding of RdPf at pH 2.0 at room 
temperature as followed by tryptophan fluorescence spectroscopy.  The fluorescence 
maximum shifts from about 335 nm at lower GuHCl concentration to about 355 nm at 
higher GuHCl concentration.  The fluorescence intensity at 353.8 nm was used to analyze 
the data, because the ratio of the fluorescence intensity of the unfolded protein to the 
folded protein has a maximum value of about 5 at this wavelength.  In determining the 
intensity of the folded and unfolded protein, again we found little dependence on the  
 
Figure 3.  GuHCl-induced unfolding of RdPf at pH 2 and room temperature 
derived from tryptophan fluorescence spectra.  The fluorescence intensity at 
353.8 nm was used to calculate the fraction unfolded.  Three-state and four-
state models have been applied to fit the unfolding curve. 
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denaturant concentration.  Surprisingly, another intermediate appears at 1.8 M GuHCl, 
and it is apparent that this intermediate is different from the one identified by UV-visible 
absorption spectroscopy.  One possible reason that we could not observe this intermediate 
by the UV-visible absorption spectroscopy might be its similar extinction coefficient as 
the native state.  In fact, the non-coincidence of different techniques can reassure the 
presence of intermediates (25).  The data from tryptophan fluorescence were fitted to 
two-state, three-state and four-state models using equation (9) and the parameters are 
presented in Table 1. 
 
Figure 4.  The unfolding transition curve of RdPf at pH 2 and room 
temperature as followed by circular dichroism.  The fraction unfolded is 
calculated by taking the intensity at 225 nm.  The curve has been fitted to 
a two-state and a three-state model. 
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Circular dichroism.          
The secondary structure of RdPf includes a three-stranded β-sheet and several 
short α-helical turns (3).  It is believed that the negative band at 225 nm represents the β-
sheet content of RdPf(12).  The ellipticity at 225 nm has been transformed to fraction 
unfolded by using equation (2).  The fraction unfolded is shown in Figure 4.  The fraction 
of unfolded changes irregularly at lower concentrations of GuHCl.  However, in the 
transition region where the ellipticity is actually decreasing, the pattern is much 
smoother.  To complicate matters, the CD band at 225 nm shows double negative peaks 
in several RdPf samples.  This suggests that the change of the secondary structure of 
RdPf with GuHCl concentration is highly complex.  Our attempts to fit the unfolding data 
to two-, three- and four-state models are summarized in Table 1. 
 
Populational distribution of species at pH 2.    
From the parameters in Table 1, the fractions of the folded forms( fF ), two 
intermediates (fI1 and fI2) and the totally unfolded forms (fU) can be calculated as a 
function of GuHCl concentration.  The appropriate equations are 
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Figure 5 shows the fraction distribution of these states for a four-state model with 
the parameter set deduced from the tryptophan fluorescence experiment.  According to 
this model, the first intermediate state is already 5% populated at very low GuHCl 
concentration and accumulated to a maximum of 30% at 2.4 M GuHCl.  The second 
intermediate reaches a maximum population of 70% at 3.3 M GuHCl.  The fully unfolded 
form does not appear until about 2.5 M GuHCl.  
 
Figure 5.  The population distribution of the fully folded, the two 
intermediates and the fully unfolded state as a function of GuHCl 
concentration.  The parameters are from the four-state model fit with the 
tryptophan fluorescence experiment. 
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GuHCl-induced unfolding of RdPf at pH 7.0 
GuHCl-induced unfolding of RdPf at pH 7.0 revealed that RdPf was partially 
denatured in 8 M GuHCl at pH 7.   In Figure 6 a, b, c, we show the UV-visible, 
tryptophan fluorescence and UV-visible CD spectra of RdPf in 8 M GuHCl at 25 oC after 
60 hrs.  
 
Figure 6. (a) GuHCl-induced unfolding of RdPf at pH 7.0 as monitored by UV-
visible absorption spectra. The protein was incubated at 0 and 8M GuHCl at room 
temperature for 60 hours. 
 
UV-visible absorption.     
 First, the visible absorption of RdPf shows a very little change. This indicates 
that iron-sulfur ligation is not perturbed in the presence of 8 M GuHCl. However, the 
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intensity of the peak at 280 nm decreases about 10%.  The absorption band at 280 nm is 
mainly due to the absorption by tryptophan residues (22).  RdPf has two tryptophan 
residues (residue 3 and residue 36).  One possibility is that one of the tryptophan residues 
becomes exposed to the solvent at 8 M GuHCl.  
 
Tryptophan fluorescence.  
Tryptophan fluorescence is more sensitive than UV absorption as an indicator of 
its environment.  As expected, the fluorescence of the two tryptophans reveals both an 
intensity increase and a shift of the maximum to the red.  The fluorescence maximum of 
RdPf appears at 335 nm in 0 M GuHCl and 350 nm in 8 M GuHCl.  335 nm is the 
wavelength maximum for a buried tryptophan (22). On the other hand, 350 nm is not 
exactly the fluorescence wavelength maximum for an exposed tryptophan.  However, the 
data are consistent with one buried tryptophan residue, and one exposed and solvated at 8 
M GuHCl.  Given that the fluorescence of native RdPf arises from two buried tryptophan 
residues, half of the fluorescence of RdPf in 0 M GuHCl can be subtracted from the 
fluorescence of RdPf in 8 M GuHCl.  The residue spectrum was then fitted as a function 
of wavenumber by a single Gaussian function centering at 355 nm (Figure 7).  The 
resultant fluorescence spectrum is consistent with an exposed tryptophan.  Molecular 
dynamics simulation studies on the unfolding pathway of RdPf has predicted that Trp 36 
is among the most labile residues along the unfolding pathway (19).  A site-directed 
mutation Trp 36 →  Phe could resolve this question. 
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Figure 6. (b) GuHCl-induced unfolding of RdPf at pH 7.0 as monitored by 
tryptophan fluorescence spectra. The protein was incubated at 0 and 8M GuHCl at 
room temperature for 60 hours. 
 
 
Circular dichroism.      
From the CD spectra (Figure 6 c), we conclude that the secondary structure content 
decreases about 15% at 8 M GuHCl compared to 0 M GuHCl.  This could be due to the 
partial disruption of the β-sheet.  Another change noted occurs in the aromatic group 
region around 500 nm.  The negative bands are contributed by some rigid aromatic 
groups (22).  The decrease in the 470 nm peak indicates that a number of aromatic groups 
have become more flexible, possibly exposed and solvated, in the presence of 8 M 
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GuHCl, which is in accordance with the observations by UV and fluorescence 
spectroscopy. 
 
Figure 6. (c) GuHCl-induced unfolding of RdPf at pH 7.0 as monitored by 
UV-visible CD.  The protein was incubated at 0 and 8M GuHCl at room 
temperature for 60 hours. 
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Figure 7. The difference fluorescence spectra of RdPf at 8M GuHCl (F8M) 
and 0M GuHCl (F0M).  The spectra are plotted vs. wavenumber µm-1.  The 
whole and half of F0M were subtracted from F8M in F8M-F0M and F8M-½F0M, 
respectively.  The two spectra have been simulated by a single Gaussian 
function (peak wavelength shown in curves). 
 
Discussions 
The equilibrium has been reached before measurement 
An important issue in the equilibrium unfolding experiments here is that we have 
allowed the protein to reach equilibrium before measurements are taken.  Thermal 
denaturation of RdPf has been reported to be irreversible (10, 26).  The denaturant-
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induced unfolding studied here indicates that we are observing the unfolding under 
reversible conditions.  On the other hand, we must remind ourselves that RdPf is strongly 
resistant toward denaturation.  The protein does not denature at 6 M GuHCl at neutral pH 
and room temperature even after 24 hours of incubation (20).  In our experiments, we 
have incubated the solutions for 40 to 80 hours to ensure that the equilibrium has been 
reached.  We took pains to ascertain that there were no spectroscopic changes between 40 
and 80 hours of incubation (data not shown).  Finally, we have observed the kinetics of 
the unfolding of RdPf by monitoring the absorption at 380 nm.  Several transient phases 
were observed, with the final phase occurring on a time constant of about an hour.  The 
absorption value matched the observed equilibrium value when the kinetic curve was 
extrapolated to infinite time.  When we tried to reverse the process by diluting the 
solution to lower the concentration of GuHCl from 6 M to 3 M, only a small part of the 
absorbance at 380 nm was restored after 40 hours.  This suggests that either the reversed 
reaction is extremely slow, or the incorporation of iron into the apo-protein requires 
additional factors.  
 
The properties of the intermediate states 
It is possible to derive some characteristics of the unfolding intermediates and the 
unfolded state from the spectroscopic properties that we have observed here.  First, the 
fully unfolded state of RdPf has no iron-sulfur coordination as the visible absorption 
bands are absent in 6 M GuHCl at pH 2.  The secondary structure is disrupted as 
monitored by CD spectroscopy.  The hydrophobic core is exposed because the tryptophan 
fluorescence has an intensity maximum at 355 nm, which is the characteristic feature of 
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solvated tryptophan residues (22).  The fluorescence intensity is 5 times stronger than that 
of the folded RdPf, which is an indication of the loss of iron.  Iron strongly quenches the 
tryptophan fluorescence but does not shift the wavelength (the fluorescence of apo-RdPf 
has a maximum at 335 nm).  On the other hand, solvation decreases tryptophan 
fluorescence and shifts the maximum intensity from 335 nm to 355 nm.  The ratio of the 
intensity is about 20 for the former effect, but only 4 for the latter.  These factors account 
for the observed 5-fold increase in the fluorescence intensity of RdPf from the folded to 
unfold state.   
 
Second, there remains the question as to whether or not in the unfolded RdPf 
disulfide bonds are formed when the iron atom has been displaced.  We have attempted to 
address this issue by adding 50 mM DTT to the solution in the unfolding experiments of 
RdPf at pH 2.  If disulfide bonds were formed in the unfolded protein, the free energy 
difference between the native state and the unfolded state should be different.  In our 
experiments, no difference was observed in ∆GD.  Also, the expected CD bands around 
250 nm for the disulfide bond did not appear.  We thus conclude that there is no oxidation 
of the sulfhydryls upon unfolding of the RdPf.  The reason may be the low pH value used 
in the present study.  When the iron-sulfur bonds are broken, there are two possible 
reactions: (i) oxidation by di-oxygen; and (ii) the protonation. The reactions compete 
with each other.  The high concentration of protons at pH 2 would favor the latter.  At 
neutral pH, there is at least one disulfide bond formed upon displacement of the iron from 
the protein (Zhang et al., unpublished results). 
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 Generally a z value close to 0 implies that the intermediate is more similar to the 
folded form than the unfolded form, while a z value close to 1 implies a structure that is 
closer to the unfolded form.  The z values of the first intermediate of RdPf observed at pH 
2 are 0.10, 0.48 and 0.56 as monitored by UV-visible absorption, fluorescence and CD, 
respectively.  These properties are expected from the partially unfolded form of RdPf at 
pH 7, and thus the same intermediate may have been formed.  The partially unfolded 
form at pH 7 has native-like iron-sulfur ligation.  When the visible absorption by the iron-
sulfur cluster is used as a criterion, this partially unfolded state is very close to the folded 
state.  That is, a small z value close to 0 is noted.  One of the tryptophan residues is 
exposed in the partially unfolded form of RdPf.  The fluorescence gains some intensity 
because the tryptophan residue is further away from the iron.  On the other hand, it loses 
some intensity because of solvation.  A z value of 0.48 for fluorescence is a reasonable 
value for such a structure.  A z value of 0.56 is higher than expected for the CD property 
of the intermediate, because only 15% of the CD change was observed at 8 M GuHCl at 
pH 7.  However, this may be peculiar to the irregular CD change in the low GuHCl 
concentration region. 
 
 A z value of 0.83 for the second intermediate at pH 2 from the fluorescence is 
almost twice the z value of the first intermediate.  Thus, the two tryptophan residues are 
both exposed in the case of the second intermediate.  A z value of 0.51 for the absorption 
at 380 nm suggests that the intermediate has a distorted iron-sulfur coordination.  A z 
value of 0.78 from CD means that the intermediate is almost devoid of secondary 
structure. 
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 From Figure 5, the first intermediate has a population about 5% in H2O with no 
denaturant at pH 2.  This result is in agreement with the previous observation that RdPf 
can bind ANS at lower ionic strengths (12).  Since the intermediate has a tryptophan 
residue exposed, ANS binding is expected and can shift the equilibrium to the ANS-
bound form.  The other tryptophan residue is still buried, thus only a portion of the 
hydrophobic core is open, and the observed 1:1 binding is reasonable.  At higher ionic 
strengths, the fully unfolded state is stabilized and ANS binding is impossible.  This 
suggests that the fully folded state is destabilized by electrostatic interactions at pH 2.  
This conclusion is borne out by the distribution of surface charges under these conditions; 
at pH 2, the protein surface of RdPf is positively charged, especially in the region of the 
closely spaced A1, K2, K28 and K50 (12).   
 
Comparison with other studies on RdPf unfolding 
 It is interesting to compare this unfolding pathway with that deduced from earlier 
studies.   The unfolding pathway has been suggested from thermal unfolding (27): The 
native protein first loses some secondary structure, then releases the iron; more secondary 
structure is then lost, and this is finally followed by the formation of unfolded state.  
While our CD data do support the loss of the secondary structure, we observe the release 
of the iron only in the final step of the GuHCl denaturation examined here.  Another 
theoretical study (19) on the thermal unfolding pathways of RdPf concluded that RdPf 
unfolds first by opening of the loop region to expose the hydrophobic core, followed by 
the unzipping of the β-sheet.  Although the disruption of the iron is not reported by this 
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study, the simulation time was probably too short to account for the iron loss.  Because 
the fully unfolded state exists in a high free energy state, it will require rather long time to 
observe the event in simulation.   
 
 The unfolding free energy has been given in the native state hydrogen exchange 
experiment on RdPf (11).  A value of about 17 kcal/mol was obtained from the free 
energy  temperature curve.  This is in very good agreement with our current study if 
we consider the difference in our experiment conditions. The unfolding free energy 
obtained in our study is 3.4 kcal/mol less.  It is presumably due to the disruption of the 
salt bridges in RdPf by the low pH condition.   
 
 We conclude this study with some thoughts on the contributions of different 
factors to the hyperthermostability of RdPf.  These factors include the secondary 
structures, electrostatic interactions, hydrophobic core and the iron-sulfur ligation.  The 
contribution of the iron-sulfur ligation can be obtained from the free energy difference of 
the fully unfolded state and the partially unfolded state in 3.3 M GuHCl at pH 2, which is 
supposed to be essentially devoid of tertiary packing.  The result is 13.6 - 5.6 = 8.0 
kcal/mol.  Thus, we can conclude that this is the most important factor that contributes to 
the hyperthermostability of RdPf.  However, this factor alone cannot account for the 
hyperthermostability of RdPf, presumably because it makes a similar contribution to the 
stability of mesophilic rubredoxins. The unfolding study on of a RdPf variant without the 
Fe-(Cys)4 center gives an unfolding free energy 3.2 kcal/mol at 1 oC (14).  It seems that 
the only difference between this variant and native RdPf is the Fe-(Cys)4 center. 
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However, this gives a total unfolding free energy of 11.2 kcal/mol for native RdPf. The 
difference might be partly due to the temperature difference in these studies. It is also 
possible that the small change in the structure of the variant actually has a bigger impact 
on the overall stability of the protein than we expect. The contributions from secondary 
structures and hydrophobic packing can be estimated from the free energy difference 
between the two intermediates, which is 5.6-2.7 = 2.9 kcal/mol. The contribution from 
the electrostatic interactions can be estimated by comparing the stability of RdPf at pH 2 
and pH 7.  At pH 7, only the first unfolded state is reached under 8M GuHCl, while at pH 
2 the protein is fully unfolded.  If the free energy difference between the folded state and 
the partially unfolded state at pH 7 is known, we can estimate the contribution of the salt 
bridges by comparing it to the free energy difference between the folded state and the 
first partially unfolded state at pH 2.  On the other hand, the 3.4 kcal/mol unfolding free 
energy difference between the hydrogen exchange experiment (11) and our study here 
gives a first-order approximation for the contribution of the electrostatic interactions.  In 
any case, we know that these salt bridges play an important role in stabilizing RdPf.  The 
salt bridges might be an even more important stabilizing factor at high temperatures, if 
we take into account the fact that the dielectric constant of water decreases from 82.20 at 
20oC to 55.51 at 100 oC. 
 
 To summarize, even though the contributions from the different factors to the 
hyperthermostability cannot be dissected clearly, we conclude that the folding and 
unfolding of this protein is not highly co-operative.  Single-domain proteins are normally 
only marginally stable, and the distribution of protein conformational states is such that 
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the protein folds or unfolds essentially cooperatively.  It is evident that proteins can be 
produced more stable thermodynamically, though the judicious addition of salt bridges 
and hydrophobic bonds, and this increased stability must necessarily come at the expense 
of decreased overall conformational flexibility, which is reflected in the cooperativity of 
the folding and unfolding of the protein.  The presence of intermediates is consistent with 
a dispersion of conformational states, each set responding differentially to denaturing 
forces, either thermal or chemical denaturants.  The protein merely shifts its structure 
among these different subsets of accessible states under varying environmental 
conditions.  Thus, enhanced protein stability does not require strong stabilizing forces, 
merely tuning of the forces to accomplish a redistribution of thermally accessible 
conformational states.   
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Femtosecond dynamics of rubredoxin: Tryptophan
solvation and resonance energy transfer in
the protein
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Laboratory for Molecular Sciences, Arthur Amos Noyes Laboratory of Chemical Physics, California Institute of Technology, Pasadena, CA 91125
Contributed by Ahmed H. Zewail, October 31, 2001
We report here studies of tryptophan (Trp) solvation dynamics in
water and in the Pyrococcus furiosus rubredoxin protein, including
the native and its apo and denatured forms. We also report results
on energy transfer from Trp to the iron-sulfur [Fe-S] cluster. Trp
fluorescence decay with the onset of solvation dynamics of the
chromophore in water was observed with femtosecond resolution
(160 fs; 65% component), but the emission extended to the
picosecond range (1.1 ps; 35% component). In contrast, the decay
ismuch slower in the native rubredoxin; the Trp fluorescence decay
extends to 10 ps and longer, reflecting the local rigidity imposed by
residues and by the surfacewater layer. The dynamics of resonance
energy transfer from the two Trps to the [Fe-S] cluster in the
protein was observed to follow a temporal behavior characterized
by a single exponential (15–20 ps) decay. This unusual observation
in a protein indicates that the resonance transfer is to an acceptor
of a well-defined orientation and separation. From studies of the
mutant protein, we show that the two Trp residues have similar
energy-transfer rates. The critical distance for transfer (R0) was
determined, by using the known x-ray data, to be 19.5 Å for Trp-36
and 25.2 Å for Trp-3, respectively. The orientation factor (2) was
deduced to be 0.13 for Trp-36, clearly indicating that molecular
orientation of chromophores in the protein cannot be isotropic
with2 value of 23. These studies of solvation and energy-transfer
dynamics, and of the rotational anisotropy, of the wild-type
protein, the (W3Y, I23V, L32I) mutant, and the fmetPfRd variant at
various pH values reveal a dynamically rigid protein structure,
which is probably related to the hyperthermophilicity of the
protein.
Tryptophan (Trp) is the most important fluorophore amongamino acid residues for optical probing of proteins. However,
Trp fluorescence is complex because of different rotamers in the
ground state and the two nearly degenerate electronic states
(1La, 1Lb) with perpendicular transition moments. Accordingly,
numerous studies (1–10) have focused on the lifetime, quantum
yield, Stokes shift, and fluorescence anisotropy. Most of these
studies were made with picosecond or nanosecond time resolu-
tion (3, 6–10). To probe the local protein dynamics, Trp solvation
by neighboring softrigid water molecules, or by other polar
amino acid residues, must be resolved on the femtosecond time
scale. Moreover, such studies are important for examining the
nature of resonance energy transfer (RET) that is used for
deducing distances and orientations between the Trp and
quenchers in the protein (e.g., see refs. 3 and 10, and references
therein).
We choose the hyperthermophilic iron-sulfur protein, Pyro-
coccus furiosus rubredoxin (PfRd), as a prototype system (Fig.
1). The high-resolution x-ray crystallographic structures of PfRd
at 0.95 Å and its formylmethionine variant (fmetPfRd) at 1.2 Å,
have been recently reported (11). PfRd is a small protein of 53
amino acid residues with an iron atom coordinated by the sulfur
atoms of four cysteine side chains and functions as an electron-
transfer protein (12). It is approximately ellipsoidal in overall
shape with a hydrophilic tail protruding into the solvent at the
C terminus region. The structure consists of a three-stranded
antiparallel -sheet with a hydrophobic core containing six
aromatic residues (Fig. 1); two of them are Trp-3 and Trp-36.
The [Fe-S] cluster has a strong charge-transfer absorption band
at 380 nm (13, 14), which overlaps with the Trp emission. Thus,
RET between Trp and the cluster is expected and has been
observed in other iron-sulfur proteins (15).
Experimental Methods
All experimental measurements were carried out by using the
femtosecond-resolved fluorescence up-conversion technique
(16). All protein samples were generously provided by the group
of Michael W. W. Adams at the University of Georgia. L-Trp,
N-acetyl-L-tryptophanamide (NATA) and N-acetyl-L-Trp ethyl
ester (NATEE) were purchased from Sigma. Ultrapure guani-
dine hydrochloride (GdnHCl) was obtained from Baker, and
trichloroacetic acid from Fisher. All chemicals were used as
received.
The iron-sulfur protein rubredoxin we obtained was isolated
and purified from Pyrococcus furiosus. The protein was concen-
trated and stored in 50 mM Tris buffer (pH 8) with 0.3 M NaCl
at20°C. Its purity was checked routinely by measuring the ratio
of the extinction coefficient at 280 nm and 380 nm (17). For most
experiments, the formylmethionine variant of PfRd (fmetPfRd)
was used with a concentration of 0.3 mM in a 20 mM phosphate
buffer at pH 7. Aside from the wild-type PfRd, we also examined
the (W3Y, I23V, L32I) mutant of fmetPfRd in which the Trp-3
was replaced by Tyr, leaving only one Trp (Trp-36) in the
protein.
Apo-fmetPfRd was prepared (17) first by denaturing the
holo-protein in 10% trichloroacetic acid. After a few hours, the
precipitated apo-fmetPfRd was suspended twice in 6% trichlo-
roacetic acid and then dissolved in 3 M GdnHCl. After rena-
turation of the protein by dialysis against 50 mM Tris buffer at
pH 8, the apo-PfRd solution was clear. Circular dichroism
showed that the apo protein has a similar secondary structure to
the holo form.
The steady–state absorption and f luorescence spectra
(265-nm excitation) are shown in Fig. 2. The distinctive absorp-
tion spectrum has an intense band at 280 nm (Trp absorption).
Other bands at 380 nm, 490 nm, and 570 nm (not shown) arise
from charge transfer within the [Fe-S] cluster, from the cysteinyl
thiolates to Fe(III) (13, 14). The mutant and the variant of PfRd
show the same absorption as the wild-type PfRd, but their
thermostabilities are slightly different (18). The fluorescence
emission of apo-fmetPfRd peaks at 337 nm. For the native
protein, the Trp emission at the red side strongly overlaps with
the iron-sulfur charge-transfer absorption and thus it is
Abbreviations: Trp, tryptophan; fmetPfRd, formylmethionine variant of Pyrococcus furio-
sus rubredoxin; RET, resonance energy transfer; NATA, N-acetyl-L-tryptophanamide;
NATEE, N-acetyl-L-Trp ethyl ester.
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quenched through RET by several orders of magnitude. Ac-
cordingly, the resulting spectrum is blue-shifted, peaking at 325
nm (Fig. 2) because of the comparable time scales of energy
transfer and solvation (see below).
The fluorescence emission of Trp in buffer solution shifts to
the red, 352 nm, because of solvation. Clearly, the Trp residues
buried in apo-fmetPfRd (337 nm) are in a more hydrophobic
environment than in the buffer solution. The denatured form of
fmetPfRd has a similar emission spectrum to that of Trp in buffer
solution, except for a tail at the blue side because of the tyrosine
emission of the protein. To mimic the peptide bond in protein,
we also studied the model systems: NATA in a phosphate buffer
solution (30 mM) at pH 2 and NATEE in a solvent of p-dioxane.
The emission spectrum of NATA is similar to that of Trp with
a slight shift to the red side, by 5 nm; for NATEE it shifts to the
blue side and peaks at 330 nm.
Results and Discussion
Excited States of Trp. The two electronic excited states, 1La and
1Lb, are both involved in the absorption and fluorescence
emission. Two transition dipoles are nearly perpendicular to
each other, and the direction of the 1Lb transition dipole is along
the side chain (19). The 1La state has a larger static dipole
moment than its ground state so it is more sensitive to solvation.
In polar solvents, the 1La state is red-shifted and becomes lower
in energy than the 1Lb state. The observed steady–state fluo-
rescence, especially at wavelengths longer than 340 nm, is mainly
from the 1La state (8). For each electronic state, there are three
rotamers of the alanyl side chain of Trp (1). The reported two
principal lifetimes, 500 ps and 3 ns in bulk solution, were
attributed to different conformers, and, as discussed below, our
observed long-time component (500 ps) at different wave-
lengths is an average value of the two lifetimes.
Solvation Dynamics of Trp. Fig. 3A shows femtosecond-resolved
fluorescence transients of Trp in phosphate buffer at pH 2 with
a systematic series of detection wavelengths. All transients have
three distinct time scales. At the blue end of 310 nm, the signal
decays with time constants of 700 fs (78%), 3.13 ps (8.6%), and
518 ps (13.4%); at 340 nm, it first rises in 200 fs and then decays
in 1.8 ps (20%) and 865 ps (80%); at 370 nm, it rises in 330 fs
(86%) and 1.9 ps (14%) and then decays in 1.12 ns; and at the
red end of 440 nm, the transient rises in 410 fs (57%) and 2.21
ps (43%) and finally decays in 1.45 ns. We also studied NATA
in the same buffer and similar transients were observed. For
NATEE in p-dioxane, we observed slower temporal behaviors,
e.g., at 310 nm the signal decays in 4.7 ps (58%) and 500 ps
(42%) and at 340 nm it rises in 420 fs (72%) and 11 ps (28%) and
then decays in 3.2 ns. These results are indicative of solvation.
The initial femtosecond decay at the blue side and the rise at
the red side dominantly result from solvation processes, and are
not due to the electronic relaxation (1La and 1Lb coupling) and
vibrational cooling. This conclusion was based on the following
observations: First, the internal conversion between 1La and 1Lb
occurs in100 fs as measured by ultrafast anisotropy decay (see
below). Recent studies deduced a time constant of 10–40 fs for
the internal conversion of 5-methoxyindole in hexadecane (20).
Second, Trp emission strongly depends on solvent polarity. From
p-dioxane (or in the protein) to buffer solution, the emission
peak shifts from 330 nm (337 nm) to 357 nm. Third, the initial
Trp dynamics also show different temporal behaviors in different
solvents. In p-dioxane it occurs in several picoseconds (21)
whereas in water it is on the femtosecond time scale, as expected
for water solvation (22, 23). Finally, all transients gated at various
emission wavelengths are nearly independent of excitation wave-
length (265 nm and 288 nm), ruling out a large contribution from
vibrational cooling.
By following the time-resolved emission (Stokes shift with
time), we constructed the correlation function (solvent response
function) to obtain the solvation time: c(t)  [(t)  ()]
[(0)  ()], where (t), (0), and () are time-resolved
emission maxima in cm1, respectively. The c(t) function, shown
in Fig. 3A Inset gives an apparent biexponential behavior: 160 fs
(65%) and 1.1 ps (35%). These two solvation times are close to
the reported values (126 fs and 880 fs) in bulk water (23). The
former reflects the librational motion of water molecules and the
latter represents their diffusive motion.
After establishing the Trp solvation dynamics in bulk water, we
studied Trp solvation in the apo-fmetPfRd and the denatured
form of the protein. The results are given in Fig. 3 B and C,
respectively. In apo-fmetPfRd, the transient at 310 nm decays in
1.2 ps (17%), 12 ps (26%), and320 ps (57%); for 340 nm, it first
rises in 200 fs and then decays 530 ps and for 370 nm, it rises
in 200 fs (89%), 5.6 ps (11%) and then decays 640 ps. Clearly,
Trp buried in apo-fmetPfRd shows multiexponential temporal
behavior and the solvation processes become slower. According
to the x-ray structure (11), both Trp-3 and Trp-36 face the
Fig. 1. Ribbon presentation of high-resolution x-ray structure of hyperther-
mophilicPyrococcus furiosus rubredoxin (11). Six aromatic aminoacid residues
in thehydrophobic coreare, along theprimary sequence, Trp-3, Tyr-10, Tyr-12,
Phe-29, Trp-36, and Phe-48. A tail at the C terminus protrudes into the solvent.
Fig. 2. Absorptionof thePfRdproteinandnormalizedfluorescenceemission
for different systems. Note that the spectral overlap between the Trp emission
in apo-PfRd and the [Fe-S] cluster absorption in PfRd. The fluorescence inten-
sity in PfRd is actually much weaker than that in apo-PfRd. The arrows mark
two excitation wavelengths used in this study, 265 nm and 288 nm.
14  www.pnas.orgcgidoi10.1073pnas.012582399 Zhong et al.  
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hydrophobic core, but they are partially exposed to the protein
surface and also interact with neighboring polar (Tyr) and
negatively charged (Asp and Glu) residues. Thus, the observed
multiple time scales represent dynamical motions of both water
molecules in the rigid water layer around the protein surface and
the interacting residues.
Very recently, Vivian and Callis (24) have carried out exten-
sive theoretical studies of the interactions of Trp with water and
other amino acid residues in proteins for interpretation of the
fluorescence shifts. The simulation of a single Trp in proteins
under the partial exposure to water gave a time scale of several
picoseconds for the decay of the shifted spectral components
because of the large-amplitude motions of the protein backbone
and side chains andor wholesale rearrangement of nearby
hydrogen-bonded water clusters, consistent with our observation
of solvation occurring up to 10 ps or longer. By placing an
extrinsic dye probe in a protein pocket, solvation dynamics of
polar amino acid residues or rigid water molecules on slower time
scales also have been recently reported (25, 26). Ultrafast
solvation dynamics in protein by using the intrinsic probe, Trp,
were not reported before.
Fig. 3C shows the dynamics of Trp residues in the denatured
fmetPfRd obtained by addition of 6 M GdnHCl into the protein
solution at pH 2. At 310 nm, the transient decays in 1.2 ps (56%),
19 ps (22%), and 818 ps (22%); at 340 nm, it first rises in 280
fs and then decays 2.83 ps (25%), 40 ps (25%), and1 ns (50%);
and at 370 nm, it initially rises in 300 fs (91%), 1.52 ps (9%) and
then decays with long components (1 ns). These results show
a faster solvation process in the denatured fmetPfRd than in its
apo form, consistent with the fact that both Trp-3 and Trp-36 are
exposed to more water molecules in its denatured state. This is
also evident from the emission spectra shifting from 337 nm in
the apo form to 352 nm in the denatured form; see Fig. 2.
However, the solvation process in the denatured state is much
slower than that of Trp in water. Under 6 M GdnHCl, the ratio
of water molecules to GdnHCl is 5:1. Thus, the observed slow
dynamics results from the increased ‘‘viscosity’’ because of the
high cationic and anionic concentrations (27) as well as the
random-coiled polypeptide chain. But, the polarity of water
molecules leads predominantly to the same steady–state emis-
sion spectra of Trp both in water and in the denatured protein.
Resonance Energy Transfer. Fig. 4 shows the fluorescence tran-
sients of Trps in fmetPfRd for a series of fluorescence detection
wavelengths after 288-nm excitation. Four striking results were
observed: (i) The transient decay time systematically increases,
from the blue side to the red side, and the decay because of RET
follows a single-exponential behavior at all wavelengths (Fig.
4A) (ii); all transients decay to zero in 100 ps and no longer
components are observed; (iii) an initial constant signal within
3 ps is observed at wavelengths longer than 340 nm (Fig. 4B); and
(iv) transients obtained at 265-nm excitation (not shown) show
similar temporal behavior. In the transients in which we ob-
served the energy transfer, the effect of solvation is reflected on
the shorter time scale: femtosecond rise at the red side and a
small picosecond decay component (2 ps and 13%) at the blue
side (310 nm) as observed in the apoprotein.
Specifically, at 310 nm the transient dominantly decays in 15.6
ps. At 320 nm, the transient follows a single-exponential decay
in 16.4 ps. From 340 nm, we start to observe a constant signal in
2–3 ps and then it decays in 20.3 ps at 340 nm and 22.6 ps at 360
nm, respectively. The observed gradual increase of time con-
stants (15–23 ps) toward longer wavelengths is from the influ-
ence of picosecond solvation of Trp in the protein. Thus, the
decay time of 20 ps obtained at 340 nm best represents the
dynamics of RET between Trps and the [Fe-S] cluster because
we only observed a long component (500 ps) of the solvated
state in apo-fmetPfRd at this wavelength (Fig. 3B).
Fig. 3. (A) Normalized, femtosecond-resolvedfluorescence decay of Trp in buffer solution at pH2with a series ofwavelength detection. (Inset) The constructed
solvent response c(t). Normalized fluorescence decay of Trp in the apo-fmetPfRd protein (B) and in its denatured state (C). Note that the transient at 340-nm
emission in B decays only with a long lifetime of 530 ps.
Zhong et al. PNAS  January 8, 2002  vol. 99  no. 1  15
 256
According to the theory of Fo¨rster energy transfer (28), the
RET rate from Trp to the [Fe-S] cluster depends on the relative
position (r) and orientations of donor (Trp) and acceptor ([Fe-S]
cluster), and the rate of transfer kRET can be expressed as
follows: kRET  (R0r)6D, R0  9.78  102(2n4QDJ)1/6. R0
(in nm), the critical transfer distance, is defined as the donor-
acceptor distance at which the transfer efficiency is 50%. 2 is the
orientation factor, n is the refractive index of themedium (1.4),
D andQD are the donor excited-state lifetime and quantum yield
in the absence of the acceptor (here in apoprotein), respectively,
and J is the spectral overlap integral (in unit of cm3M) between
donor-emission and acceptor-absorption.
It is striking that for RET each transient decays to zero with
only a single exponential temporal behavior although the fmet-
PfRd protein has two Trps (Trp-3 and Trp-36). According to the
x-ray structure, the distance between Trp-36 (the middle point
of the C–C bridge in the indole ring) and the center of [Fe-S]
cluster is 9.6 Å and it is 13.2 Å for Trp-3. Both Trps in
apo-fmetPfRd have a similar lifetime D and quantum yield QD,
and if they have the same R0 we should observe two distinct RET
rates differing by a factor of 6.8, obviously inconsistent with our
result of a single exponential decay. Thus, our observations
indicate that either the two Trps have similar energy-transfer
rates, but with different R0 (or 2), or one of Trps has 2  0;
i.e., no energy transfer.
During RET, Trps in the protein do not undergo significant
tumbling motions (see below); the anisotropy studies indicate
that they are actually rigid. In such a short time of 20 ps, each Trp
has a certain value of the orientation factor 2. Here, we must
also consider Trp–Trp RET. The critical distance for Trp–Trp is
in the range of 5–12 Å (29, 30), and the distance between Trp-3
and Trp-36 is 10.6 Å. The energy transfer between Trp-3 and
Trp-36 takes 100 ps. If one Trp doesn’t transfer energy to the
[Fe-S] cluster (2  0), but it transfers energy to the other Trp,
we would observe a longer component (100 ps) in the tran-
sients, again inconsistent with our observation. Thus, the case for
2  0 is excluded.
The observed single-exponential decay in 20 ps indicates that
the two Trps have similar RET rates but with different 2 values.
We further carried out site-directed mutagenesis studies by
replacing Trp-3 with tyrosine. At 265-nm excitation, we observed
for RET a single exponential decay time of 13 ps for the mutant
with only one energy donor Trp-36, and 17.5 ps for fmetPfRd
with two energy donors Trp-36 and Trp-3 at 340-nm detection
(Fig. 5). Therefore, the decay time for Trp-3 because of RET is
estimated to be 20 ps by simulations of our transients.
The lifetimes of Trps in apo-fmetPfRd were measured to be
290 ps (53%), 1.44 ns (37%), and 4.03 ns (10%). The average
lifetime (D) is 1.1 ns. Thus, the deduced average critical
distance R0 for RET between Trp-36 and the [Fe-S] cluster is
19.5 Å and25.2 Å for Trp-3. The overall quantum yield (QD)
was estimated to be 0.15, and the spectral overlap integral was
evaluated as 1.2  1014 cm3M. We obtained the orientation
factor 2 to be 0.13 for Trp-36 and 0.62 for Trp-3. The orientation
Fig. 4. Normalized, femtosecond-resolved fluorescence decay of Trp in the fmetPfRd protein at 288-nm excitation with a series of wavelength detection at
long time scale (A) and for the initial part (B). Note that at wavelengths longer than 340 nm, a constant signal was observed up to 3 ps.
Fig. 5. (A) Normalized, femtosecond-resolved fluorescence transients of Trp in various systems and under different conditions for 340-nm detection at 265-nm
excitation. The corresponding initial parts are shown in B. Note that only the wild-type PfRd and the variant fmetPfRd at pH 7 have an initial constant signal for
2–3 ps; see text for detail.
16  www.pnas.orgcgidoi10.1073pnas.012582399 Zhong et al.  
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factor for Trp-36 former is far away from 0.67, the value for
assumption of isotropic orientation distributions for both donor
and acceptor molecules.
On the other hand, if we use the isotropic 2 value in our case
of PfRd, we would obtain a critical distance (R0) of 25.5 Å for
Trp. The resulting distance, r, from Trp-36 to the cluster center
is deduced to be 12.5 Å. Compared to the x-ray structural
distance of 9.6 Å for Trp-36, a 30% error in this case is
introduced for use of the isotropic value of 0.67 for 2. Thus, care
must be taken when the isotropic value is used to calculate the
distance in protein. The consequence of the new 2 values of Trp
for more theoretical studies of electron transfer in the [Fe-S]
cluster of the rubredoxin is clear.
The distinct initial f latness for a time of 2–3 ps, observed at
wavelengths longer than 340 nm before the decay by RET, may
indicate the presence of an early build-up process. One possi-
bility is RET between Tyr and Trp and this process must take
place in several picoseconds. In the hydrophobic core of the
protein, there are another four aromatic residues, Tyr-10 and
Tyr-12, Phe-29, and Phe-48. At 265-nm excitation, the absorp-
tion is distributed by75% for Trp,22% for Tyr and3% for
Phe, and the distribution becomes 90% for Trp and 10% for
Tyr at 288-nm excitation (31). RET may occur between these
aromatic residues, as observed in other proteins (32, 33), espe-
cially from Tyr to Trp. The calculated 2 values for different
energy-transfer pairs based on the x-ray structure are given in
Table 1. The estimated RET time constants are in the range of
2–6 ps for Tyr-12–Trp-36 (1Lb) and 12–27 ps for Tyr-12–Trp-36
(1La) with a separation of 5.9 Å by using a critical distance of
14–17 Å (29, 34) and a lifetime (D) of 1.7 ns for Tyr residues
(35). The energy transfer of all other pairs takes much longer
time. Further studies can be made by tuning the excitation
wavelength to the red side at 295–300 nm to excite Trp only and
eliminate the Tyr contribution.
To examine the influence of the structure on the observed
rates of RET, we compared the transients for all different forms.
Fig. 5 shows fluorescence transients gated at 340-nm emission,
under 265-nm excitation, for the different systems and condi-
tions reported here. Except for the partial denatured protein at
3.3 M GdnHCl, all transients show for RET a single exponential
decay time: 20 ps for the wild-type PfRd, 13 ps for the mutant,
17.5 ps for the variant (fmetPfRd) at pH 7, and 18 ps for the
variant at pH 2. We also observed a long component (250 ps;
15%) in the case of the variant PfRd under the condition of pH
2, indicating that Trp residues in some protein conformers with
unique orientations escape the quenching by RET. This obser-
vation shows a more flexible structure at pH 2 than those at pH
7 and in the wild-type form.
PfRd is a hyperthermophilic protein and its melting temper-
ature is as high as 200°C (36). It is not fully denatured at pH
7, but it easily unfolds at pH 2 when using denaturants to disrupt
all of the salt bridges (37, 38). Experimental results (38) at pH
2 have shown two different intermediates occurring in the
unfolding pathway at 2.4 M and 3.3 M GdnHCl. Our studies of
fmetPfRd at the latter concentration show a triple-exponential
temporal behavior: 2.6 ps (25%), 25 ps (32%) and 432 ps
(43%); the initial decay reflects solvation processes as observed
in the denatured protein (Fig. 3C). The decay time of 25 ps is for
RET between Trp residues and the [Fe-S] cluster. The last long
component is the lifetime of unquenched Trp residues of the
denatured protein. Thus, the ratio of the folded to the unfolded
species is about 1:1.3.
The initial temporal behaviors are shown in Fig. 5B. Only the
wild-type and the variant proteins at pH 7 show a constant signal
for3 ps. This observation indicates that both the wild-type and
the variant (at pH 7) have a more rigid structure and favorable
RET between Trp-36 and Tyr-12. On the other hand, the variant
at pH 2 and the mutant must have a more flexible structure,
consistent with their lower thermostability (11).
Fig. 6. (A) Femtosecond-resolved fluorescence transients of Trp in water at parallel and perpendicular conditions (Upper) for 340-nm emission at 265-nm
excitation and the corresponding anisotropy decay (Lower). (Inset) The anisotropy decay for the long time scale. (B) Femtosecond-resolved fluorescence
transients of Trps in the fmetPfRd protein at parallel and perpendicular conditions (Upper) for 310-nm emission at 288-nm excitation and the corresponding
anisotropy decay. The anisotropy at 340-nm emission shows an identical temporal behavior (not shown). Note that the anisotropy of Trps in the protein stays
constant on the picosecond time scale.
Table 1. Orientation factors based on the high-resolution x-ray crystallographic structure
Trp-3–Trp-36 Tyr-12–Trp-36 Tyr-10–Trp-36 Tyr-12–Trp-3 Tyr-10–Trp-3
La–La La–Lb Lb–La Lb–Lb Lb–La Lb–Lb Lb–La Lb–Lb Lb–La Lb–Lb Lb–La Lb–Lb
2 0.50 0.22 0.66 0.61 0.35 1.62 0.32 1.23 0.14 0.17 0.25 2.41
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Anisotropy and Internal Conversion. The initial anisotropy of Trp,
‘‘r0’’, has been extensively studied and discussed (3, 4, 8, 39, 40).
In brief, it shows strong dependence on excitation wavelength.
Even under subpicosecond resolution, the measured value is still
far from the ideal value of 0.4. For example, it is0.2 at 330-nm
emission under 295-nm excitation (4). The observed smaller
value r0 is due to ultrafast internal conversion between two
nearly degenerate electronic states of 1La and 1Lb with mutually
perpendicular transition dipole moments, and is the average one
after the internal mixing. The dependence of r0 on excitation
wavelength is attributed to the different contributions of the two
states at different wavelength.
Fig. 6 shows our measured anisotropy of Trp in buffer solution
and in the fmetPfRd protein. At 265-nm excitation (Fig. 6A), the
anisotropy gated at 340 nm promptly drops to 0.19 in200 fs and
then decays with a time constant of 46 ps because of the
orientation relaxation. Thus, internal conversion is ultrafast and
the time constant is estimated to be 80 fs. Here, we observed
high initial anisotropy (0.37) at negative time (t  0) because
of the broad experimental response function (300 fs) (41, 42).
The observed apparent r0 (0.19) here is consistent with the
reported value of 0.2 (4).
The anisotropy of Trp in the protein at 288-nm excitation
shows a similar behavior. It initially drops to 0.1 in 450 fs but
then stays at this value during RET. The measured anisotropy of
r0 (0.1) is also close to the reported value of 0.12 (4). The
deduced time constant for internal conversion is 150 fs. In
contrast with Trp in water, the Trp residue is rigid in the protein
(43, 44). Thus, during RET from Trp to the [Fe-S] cluster, their
orientations are relatively frozen and the orientation factor 2 is
uniquely determined, consistent with the single-exponential
decay observed in RET. This result also reveals a rigid structure
of the hydrophobic core in PfRd.
Conclusions
The reported studies with femtosecond time resolution of Trp
elucidate its solvation dynamics in different environments and its
resonance energy transfer in Pyrococcus furiosus rubredoxin.
The solvation process of Trp in water was observed to be
ultrafast, 160 fs and 1.1 ps, but in the protein it covers a wide
range of a much longer time scale. This slow solvation process,
which is evident in the time-dependent spectral relaxation, is the
origin for nonexponential subnanosecond decays of Trp fluo-
rescence in proteins. The internal conversion between 1La and
1Lb states occurs in100 fs, and the frequently reported r0 value
is actually the average anisotropy after the internal state mixing.
These results are significant for future studies of local protein
structures and dynamics by using Trp as an intrinsic probe.
Resonance energy transfer between Trps and the [Fe-S] cluster
in the protein was observed to follow a single-exponential
temporal behavior on the picosecond time scale. The two Trp
residues have similar rates. The critical distance and the corre-
sponding orientation factor for each Trp are uniquely deter-
mined. Studies involving measurements of both the population
decay and the anisotropy for the wild-type, the mutant and the
variant at different pH values reveal a dynamically rigid protein
structure. This inflexible structure is probably related to its
thermostability (45).
The reported studies indicate that energy transfer occurs on a
much faster time scale than the local orientation relaxation
(RETorien) and that the transfer efficiency is as high as 100%.
This finding contrasts the other limit where orienRET; in this
limit, a mobile energy donor results in multiple energy-transfer
rates with relatively low efficiency, contrary to our observation.
Solvation in the protein occurs on a similar time scale to that of
energy transfer (solvRET), resulting in wavelength-dependent
transfer rates, as observed in this study. With oriensolvRET,
energy transfer is separated from solvation by femtosecond-
resolved fluorescence gating of the relaxed state as observed
here. If oriensolvRET, energy transfer is convoluted with
both orientational relaxation and solvation. Thus, the elucida-
tion of the time scales, in this case orien, solv, and RET, is crucial
to the understanding of protein dynamics.
Note. In the process of writing this work, we learned of a study
of Trp solvation in water (46). The ultrafast solvation in 160 fs
was not resolved and the reported 1.2 ps solvation time is
consistent with our observed long-time component (1.1 ps)
reported here.
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